|  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- |
| SNo | Wno | Year | Formulas | Claims | Diseases | Compunds |
| 166 | **BR112019013192** | 2019 |  |  | treatment of chronic pain, oral, buccal, rectal, topical, transdermal, transmucosal, lozenge, spray, intravenous, oral solution, oral mucosal layer tablet, administration, parenteral, syrup or injection site is formulated. These compositions can be used for the treatment of chronic pain. |  |
| 167 | **MX2019003912** | 2019 |  |  | formulated for oral, buccal, rectal, topical, transdermal, transmucosal, lozenge, spray, intravenous, oral solution, buccal mucosal layer tablet, parenteral administration, syrup, or injection. Such compositions may be used to treatment of oral mucosal inflammatory, dry mouth or oral dry mouth mediated infectious diseases. |  |
| 168 | **NZ732044** | 2019 |  |  | formulated for oral, buccal, rectal, topical, transdermal, transmucosal, intravenous, parenteral administration, syrup, or injection. Such compositions may be used to treatment of neurodegenerative diseases and psoriasis. |  |
| 169 | **MX2019006164** | 2019 |  |  | treatment of fungal infections may be formulated for oral, buccal, rectal, topical, transdermal, transmucosal, lozenge, spray, intravenous, oral solution, buccal mucosal layer tablet, parenteral administration, syrup, or injection. Such compositions may be used to treatment of fungal infections. |  |
| 170 | **MX2019006163** | 2019 |  |  | formulated for oral, buccal, rectal, topical, transdermal, transmucosal, lozenge, spray, intravenous, oral solution, buccal mucosal layer tablet, parenteral administration, syrup, or injection. Such compositions may be used to treatment of oral infectious diseases. |  |
| 171 | **US20190350877** | 2019 |  | A compound of Formula VI    and a pharmaceutically acceptable hydrate, solvate, enantiomer, and stereoisomer thereof, wherein RH independently represents  menthol, retinoic acid, vitamin A, retinol, retinal, isotretinoin, curcumin, tretinoin, α-carotene, β-carotene retinol, d2 ergosterol, ergocalciferol, 7-dehydrocholesterol, cholecalciferol, 25-hydroxycholecalciferol, calcitriol (1,25-dihydroxycholecalciferol), calcitroic acid, d4 dihydroergocalciferol, alfacalcidol, dihydrotachysterol, calcipotriol, tacalcitol, paricalcitol, tocopherol, naphthoquinone, phylloquinone, menaquinone, menadione, menadiol, thiamine, acefurtiamine, allithiamine, benfotiamine, fursultiamine, octotiamine, prosultiamine, sulbutiamine, riboflavin, niacin, nicotinamide, pantothenic acid, dexpanthenol, pantethine, pyridoxine, pyridoxal phosphate, pyridoxamine, pyritinol, biotin, folic acid, dihydrofolic acid, folinic acid, levomefolic acid, adenosylcobalamin, cyanocobalamin, hydroxocobalamin, methylcobalamin, choline, ascorbic acid, dehydroascorbic acid, 1-docosanol or        2. The compound of [**claim 1**](https://patentscope.wipo.int/search/en/detail.jsf?docId=US276883309&_cid=P12-L9NXM7-29584-18#CLM-00001), selected from the group consisting of:      3. A pharmaceutical composition comprising a compound of claim 1 and a pharmaceutically acceptable carrier.  4. The pharmaceutical composition of claim 3, wherein said pharmaceutical composition is formulated to treat a patient in need with an effective amount of said pharmaceutical composition by oral administration, delayed release or sustained release, transmucosal administration, syrup, topical administration, parenteral administration, injection, subdermal, administration, oral solution, rectal administration, buccal administration or transdermal administration.  5. The pharmaceutical composition of claim 4, wherein said pharmaceutical composition is formulated for the treatment of chronic pain, surgery pain, wound pain, ulcer pain, neuropathic pain, central and peripheral nerve damage pain. | treatment of chronic pain may be formulated for oral, buccal, rectal, topical, transdermal, transmucosal, lozenge, spray, intravenous, oral solution, buccal mucosal layer tablet, parenteral administration, syrup, or injection. Such compositions may be used to treatment of chronic pain. |  |
| 172 | **NZ731396** | 2019 |  |  | The compositions may be formulated for oral, buccal, rectal, topical, transdermal, transmucosal, intravenous or parenteral administration, as a syrup, or for injection. Such compositions may be used in the treatment of neurodegenerative diseases and other inflammatory diseases. |  |
| 173 | **MX2019007713** | 2019 |  |  | treatment of chronic pain may be formulated for oral, buccal, rectal, topical, transdermal, transmucosal, lozenge, spray, intravenous, oral solution, buccal mucosal layer tablet, parenteral administration, syrup, or injection. Such compositions may be used to treatment of chronic pain. |  |
| 174 | **EP3558279** | 2019 |  |  | oral, buccal, rectal, topical, transdermal, transmucosal, lozenge, spray, intravenous, oral solution, buccal mucosal layer tablet, parenteral administration, syrup, or injection. Such compositions may be used to treatment of chronic pain. |  |
| 175 | **EP3554494** | 2019 |  |  | formulated for oral administration, intravenous, spray, parenteral, lozenge, solution, syrup, sachet, transdermal administration, or injection. Such compositions may be used to treatment of inflammation or its associated complications. |  |
| 176 | **CN110325179** | 2019 |  |  | treatment of chronic pain may be formulated for oral, buccal, rectal, topical, transdermal, transmucosal, lozenge, spray, intravenous, oral solution, buccal mucosal layer tablet, parenteral administration, syrup, or injection. Such compositions may be used to treatment of chronic pain. |  |
| 177 | **WO2019186357** | 2019 |  |  | treatment of neurological diseases may be formulated for oral, buccal, rectal, topical, transdermal, transmucosal, lozenge, spray, intravenous, oral solution, nasal spray, oral solution, suspension, oral spray, buccal mucosal layer tablet, parenteral administration, syrup, or injection. Such compositions may be used to treatment of neurological diseases. |  |
| 178 | **BR112019010816** | 2019 |  |  | treatment of fungal infections may be formulated for oral, buccal, rectal, topical, transdermal, transmucosal administration​, lozenge, spraying, intravenous, oral solution, mucosal layer tablet, parenteral administration, syrup, or injection. Such compositions can be used for treating fungal infections. |  |
| 179 | **BR112019010809** | 2019 |  |  | treatment of oral infectious diseases can be formulated for oral, buccal, rectal, topical administration​, transdermal, transmucosal, dragee, intravenous, oral, oral solution, buccal, parenteral, syrup, or injection layer tablets. Such compositions can be used for the treatment of oral infectious diseases. |  |
| 180 | **MX2019005568** | 2019 |  |  | formulated for oral, buccal, rectal, topical, transdermal, transmucosal, lozenge, spray, intravenous, oral solution, buccal mucosal layer tablet, parenteral administration, syrup, or injection. Such compositions may be used to treatment of gastrointestinal polyps or its associated complications. |  |
| 181 | **SG10201906474Q** | 2019 |  | 1. A CQmpOund of formula I:    Formula I  or pharmaceutically acceptable hydrates, solvates, enantiomers, or stereoisomers thereof;  Wherein,  RH independently represents '  l-hydroxy-2-naphth~ic acid, 2,2-dichloroacetic acid, 2-hydroxyethanesulfonic acid, ,2-, oxoglutaric acid, 4-acetamidobenzoic acid,' 4-aminosalicylic acid, acetic acid, adipic acid, ascorbic acid, aspartic acid, benzertesulfonic acid, benzoi~ acid, camphoric acid, camphor-lO-sulfonic acid, capric acid (decanoic acid), caproic acid (hexanoic aCid), caprylic acid (octanoic acid), carbonic acid, cinnamic acid, citric aci~ cyclamic acid, caproic acid, caprilic acid, capric acid. lauric acid. myristic acid, myristoleic acid. palmitic acid, palmitoleic acid, stearic acid, oleic acid, elaidic acid, linoleic acid, linolenic acid, linolelaidic acid, arachidonic acid. dodecylsulfuric acid, ethane-l,2-disulfonic acid, ethanesulfonic acid, fonnic acid, fumaric acid, galactaric acid, gentisic acid, glucQneptonic acid, gluconic acid, glucuronic acid, glutamic acid, glutaric acid, glycerophosphoric ,acid, glycolic acid, hippuric acid, hydrobromic acid, hydrochloric acid, isobutyric acid, lactic acid, lactobionic acid, lauric acid, maleic acid, malic acid, malonic acid, mandelic acid, methanesulfonic acid, naphthalene-l,5-disulfonic acid; naphthalene-2-sulfonic acid, nicotinic acid, R-Lipoic acid, nitric acid, oleic acid, oxalic acid, palmitic acid, pamoic acid, phosphoric acid, proprionic acid, pyroglutamic acid, salicylic acid, sebacic acid, stearic acid, succinic acid, sulfuric acid~ tartaric acid, thiocyanic acid, . toluenesulfonic acid, undecylenic acid, n-acetyl cysteine, furoate, methyl furoate, ethyl furoate or aminocaproic acid.  2. A compound of formula V:    Formula V  or pharmaceutically acceptable hydrates, solvates, enantiomers, or stereoisomers thereof;  .Wherein,  RH independently represents  I-hydroxy-2-naphthoic ~id, 2,2-dichloroacetic acid, 2-hydroxyethanesulfonic' acid, 2-oxoglutaric acid, 4-acetamidobenzoic acid, 4-aminosalicylic acid, . acetic acid, adipic acid, ascorbic acid, aspartic. acid, benzenesulfonic acid, benzoic acid, camphoric acid, camphor-l 0-sulfonic acid, capric acid (decanoic acid), caproic acid (hexanoic aCi:id), caprylic acid (octanoic acid), carbonic acid, cinnamic acid, citric acid, cyclamic acid, caproic acid, caprilic acid, capric acid, lauric acid, myristic acid, myristoleic acid, palmitic acid, palmitoleic acid, stearic acid, oleic acid, elaidic acid, linoleic acid, linolenic acid, linolelaidic acid, arachidonic acid, dodecylsulfuric acid, ethane-I,2-disulfonic acid, ethanesulfonic acid, formic acid, fumaric acid, galactaric acid. gentisic acid, glucoheptonic acid, gluconic acid, glucuronic acid, glutamic acid, glutaric acid,. glycerophosphoric acid, glycolic acid, hippuric acid,. hydrobromic acid, hydrochloric acid, isobutyric acid, lactic acid, lactobionic acid, lauric acid, maleic acid, malic acid, malonic acid, mandelic acid, methanesulfonic acid, naphthalene-I,5-disulfonic acid, . naphthalene-2-sulforiic acid, nicotinic acid, R-Lipoic acid, nitric acid, oleic acid, oxalic acid, palmitic acid. pamoic acid, phosphoric acid, proprionic acid, pyroglutamic acid. salicylic acid, sebacic acid. stearic acid, succinic acid. sulfuric acid, tartaric acid, thiocyanic acid, toluenesulfonic acid, undecylenic acid, n-acetyl cysteine, furoate, methyl furoate, ethyl furoate or aminocaproic acid.  3. A pharmaceutical composition comprising a compound of claim 1 and a pharmaceutically acceptable carrier.  4. A pharmaceutical composition comprising a compound of claim 2 and a pharmaceutically . acceptable carrier.  5. A method of treating pain, mucositis, odontostomatology: gingivitis, stomatitis, glossitis, aphthous ulcers, dental surgery, oral ulceration, pharyngitis, tonsillitis, post-tonsillectomy, radiation or intubation mucositis, wherein the method comprises adniinistering to a patient in need thereof a therapeutically effective amount of the pharmaceutical composition of claim 3, and wherein said pharmaceutical composition is administered to the patient in need ,by oral administration, delayed release or sustained release, transmucosal, syrup, mucoadhesive, spray, buccal formulation, mucoadhesive tablet, topical, parenteral administration, injection, subdermal, oral solution, rectal adminis~on, buccal administration or transdermal administration.  6. A method of treating mucositis, pain, pain associated with oral mucositis, depression, anxiety disorders, pruritus, insomnia, chronic idiopathic urticariai, atopic dennatitis, lichen simplex chronicus and new-opathy, wherein the method comprises administering to a patient in need thereof a therapeutically effective amount of the pharmaceutic8l composition of claim 4, and wherein said pharmaceutical composition is administered to the patient in need by oral administration, delayed release or sustained release, transmucosal, syrup, mucoadhesive, spray, buccal formulation, mucoadhesive tablet, topical,. parenteral administration, injection, subdermal, oral solution, rectal administration, buccal administration or transdermal administration.  7. A compound of claim 1, wherein the compound is:    8. A compound of claim 2, wherein the compound is: | formulated for oral, mouth wash, buccal, rectal, topical, transdermal, transmucosal, intravenous, oral solution, buccal mucosal layer tablet, parenteral administration, syrup, or injection. Such compositions may be used to treatment of oral and gastrointestinal mucositis, mucosal inflammatory and oral infectious diseases |  |
| 182 | **US20190292171** | 2019 |  | A compound of formula VI:    and pharmaceutically acceptable enantiomers and stereoisomers thereof;  wherein,  R 1, R 3, R 5represents CD 2, NUL            within the proviso, wherein  n represents 0 to 12;  R 6is not H when R 5is NULL;  R 7and R 8independently represent    2. A pharmaceutical composition comprising a compound of claim 1 and a pharmaceutically acceptable carrier.  3. The pharmaceutical composition of claim 2, wherein said pharmaceutical composition is formulated to treat an underlying etiology in a patient with an effective amount by oral administration, delayed release or sustained release, transmucosal administration, syrup, topical administration, parenteral administration, injection, subdermal administration, oral solution, rectal administration, buccal administration, or transdermal administration.  4. A method of using of the pharmaceutical composition of claim 3 for the treatment of colorectal cancer, breast cancer, gastric cancer, oesophageal cancer, anal cancer, colorectal cancer, oesophageal cancer, stomach cancer, pancreatic cancer, and skin cancer, actinic keratoses, Bowen's disease, fungal infections, candidiasis and oral infectious diseases. | treatment of cancer and infectious diseases may be formulated for oral, buccal, rectal, topical, transdermal, transmucosal, lozenge, spray, intravenous, oral solution, buccal mucosal layer tablet, parenteral administration, syrup, or injection. Such compositions may be used to treatment of cancer, neoplasm, infections and skin diseases. |  |
| 183 | **EP3538086** | 2019 |  |  | oral, buccal, rectal, topical, transdermal, transmucosal, lozenge, spray, intravenous, oral solution, buccal mucosal layer tablet, parenteral administration, syrup, or injection. Such compositions may be used to treatment of gastrointestinal polyps or its associated complications. |  |
| 184 | **EP3538514** | 2019 |  |  | treatment of fungal infections may be formulated for oral, buccal, rectal, topical, transdermal, transmucosal, lozenge, spray, intravenous, oral solution, buccal mucosal layer tablet, parenteral administration, syrup, or injection. Such compositions may be used to treatment of fungal infections. |  |
| 185 | **EP3538079** | 2019 |  |  | treatment of oral infectious diseases may be formulated for oral, buccal, rectal, topical, transdermal, transmucosal, lozenge, spray, intravenous, oral solution, buccal mucosal layer tablet, parenteral administration, syrup, or injection. Such compositions may be used to treatment of oral infectious diseases. |  |
| 186 | **CN110198929** | 2019 |  | 1. ​A compound as shown in Formula I:    ​and a pharmaceutically acceptable hydrate, solvate, enantiomer, and stereoisomer thereof;  ​wherein:  ​RH is selected from the group consisting of 1-hydroxy-2-naphthoic acid, 2,2-dichloroacetic acid, 2-hydroxyethylsulfonic acid, 2-oxoglutarate, 4-acetaminobenzoic acid, 4-aminosalicylic acid, acetic acid, adipic acid, ascorbic acid, aspartic acid, benzenesulfonic acid, adipic acid, ascorbic acid, aspartic acid, benzenesulfonic acid, citric acid, glutamic acid, glutaric acid, glycerophosphoric acid, glycolic acid, fumaric acid, hydrobromic acid, isobutyric acid, lactic acid, lactobionic acid, lauric acid, maleic acid, malic acid, malonic acid, mandelic acid, methanesulfonic acid.​Naphthalene -1, 5-disulfonic acid, naphthalene-2-sulfonic acid, nicotinic acid, nitric acid, oleic acid, oxalic acid, palmitic acid, nitric acid, oleic acid, oxalic acid, palmitic acid, palmitic acid, phosphoric acid, propionic acid, pyroglutamic acid, salicylic acid, tartaric acid, stearic acid, toic acid, lauric acid, alpha-lipoic acid, R-lipoic acid, myristic acid, myristic oleic acid, palmitic acid, palmitoleic acid, stearic acid, oleic acid, fumaric acid, linoleic acid, linolenic acid, trans-linoleic acid, arachidonic acid.  ​Alternatively,    ​wherein:  ​Each R1, R2, and R3 independently represent:      2. ​A compound as shown in Formula II:    ​and a pharmaceutically acceptable hydrate, solvate, prodrug, enantiomer, and stereoisomer thereof;  ​wherein:  ​RH is selected from the group consisting of 1-hydroxy-2-naphthoic acid, 2,2-dichloroacetic acid, 2-hydroxyethylsulfonic acid, 2-oxoglutarate, 4-acetaminobenzoic acid, 4-aminosalicylic acid, acetic acid, adipic acid, ascorbic acid, aspartic acid, benzenesulfonic acid, adipic acid, ascorbic acid, aspartic acid, benzenesulfonic acid, citric acid, glutamic acid, glutaric acid, glycerophosphoric acid, glycolic acid, fumaric acid, hydrobromic acid, isobutyric acid, lactic acid, lactobionic acid, lauric acid, maleic acid, malic acid, malonic acid, mandelic acid, methanesulfonic acid.​Naphthalene -1, 5-disulfonic acid, naphthalene-2-sulfonic acid, nicotinic acid, nitric acid, oleic acid, oxalic acid, palmitic acid, nitric acid, oleic acid, oxalic acid, palmitic acid, palmitic acid, phosphoric acid, propionic acid, pyroglutamic acid, salicylic acid, tartaric acid, stearic acid, toic acid, lauric acid, alpha-lipoic acid, R-lipoic acid, myristic acid, myristic oleic acid, palmitic acid, palmitoleic acid, stearic acid, oleic acid, fumaric acid, linoleic acid, linolenic acid, trans-linoleic acid, arachidonic acid.  ​Alternatively,    ​wherein:  ​Each R1, R2, and R3 independently represent:      3. ​A compound represented by formula III:    ​and a pharmaceutically acceptable hydrate, solvate, prodrug, enantiomer, and stereoisomer thereof;  ​wherein:  ​RH is selected from the group consisting of 1-hydroxy-2-naphthoic acid, 2,2-dichloroacetic acid, 2-hydroxyethylsulfonic acid, 2-oxoglutarate, 4-acetaminobenzoic acid, 4-aminosalicylic acid, acetic acid, adipic acid, ascorbic acid, aspartic acid, benzenesulfonic acid, adipic acid, ascorbic acid, aspartic acid, benzenesulfonic acid, citric acid, glutamic acid, glutaric acid, glycerophosphoric acid, glycolic acid, fumaric acid, hydrobromic acid, isobutyric acid, lactic acid, lactobionic acid, lauric acid, maleic acid, malic acid, malonic acid, mandelic acid, methanesulfonic acid.​Naphthalene -1, 5-disulfonic acid, naphthalene-2-sulfonic acid, nicotinic acid, nitric acid, oleic acid, oxalic acid, palmitic acid, nitric acid, oleic acid, oxalic acid, palmitic acid, palmitic acid, phosphoric acid, propionic acid, pyroglutamic acid, salicylic acid, tartaric acid, stearic acid, toic acid, lauric acid, alpha-lipoic acid, R-lipoic acid, myristic acid, myristic oleic acid, palmitic acid, palmitoleic acid, stearic acid, oleic acid, fumaric acid, linoleic acid, linolenic acid, trans-linoleic acid, arachidonic acid.  ​Alternatively,    ​wherein:  ​Each R1, R2, and R3 independently represent:      4. ​A compound represented by formula IV:    ​and a pharmaceutically acceptable hydrate, solvate, prodrug, enantiomer, and stereoisomer thereof;  ​wherein:  ​RH is selected from the group consisting of 1-hydroxy-2-naphthoic acid, 2,2-dichloroacetic acid, 2-hydroxyethylsulfonic acid, 2-oxoglutarate, 4-acetaminobenzoic acid, 4-aminosalicylic acid, acetic acid, adipic acid, ascorbic acid, aspartic acid, benzenesulfonic acid, adipic acid, ascorbic acid, aspartic acid, benzenesulfonic acid, citric acid, glutamic acid, glutaric acid, glycerophosphoric acid, glycolic acid, fumaric acid, hydrobromic acid, isobutyric acid, lactic acid, lactobionic acid, lauric acid, maleic acid, malic acid, malonic acid, mandelic acid, methanesulfonic acid.​Naphthalene -1, 5-disulfonic acid, naphthalene-2-sulfonic acid, nicotinic acid, nitric acid, oleic acid, oxalic acid, palmitic acid, nitric acid, oleic acid, oxalic acid, palmitic acid, palmitic acid, phosphoric acid, propionic acid, pyroglutamic acid, salicylic acid, tartaric acid, stearic acid, toic acid, lauric acid, alpha-lipoic acid, R-lipoic acid, myristic acid, myristic oleic acid, palmitic acid, palmitoleic acid, stearic acid, oleic acid, fumaric acid, linoleic acid, linolenic acid, trans-linoleic acid, arachidonic acid.  ​Alternatively,    ​wherein:  ​Each R1, R2, and R3 independently represent:      5. ​A compound of formula V:    ​and a pharmaceutically acceptable hydrate, solvate, prodrug, enantiomer, and stereoisomer thereof;  ​wherein:  ​RH is selected from the group consisting of 1-hydroxy-2-naphthoic acid, 2,2-dichloroacetic acid, 2-hydroxyethylsulfonic acid, 2-oxoglutarate, 4-acetaminobenzoic acid, 4-aminosalicylic acid, acetic acid, adipic acid, ascorbic acid, aspartic acid, benzenesulfonic acid, adipic acid, ascorbic acid, aspartic acid, benzenesulfonic acid, citric acid, glutamic acid, glutaric acid, glycerophosphoric acid, glycolic acid, fumaric acid, hydrobromic acid, isobutyric acid, lactic acid, lactobionic acid, lauric acid, maleic acid, malic acid, malonic acid, mandelic acid, methanesulfonic acid.​Naphthalene -1, 5-disulfonic acid, naphthalene-2-sulfonic acid, nicotinic acid, nitric acid, oleic acid, oxalic acid, palmitic acid, nitric acid, oleic acid, oxalic acid, palmitic acid, palmitic acid, phosphoric acid, propionic acid, pyroglutamic acid, salicylic acid, tartaric acid, stearic acid, toic acid, lauric acid, alpha-lipoic acid, R-lipoic acid, myristic acid, myristic oleic acid, palmitic acid, palmitoleic acid, stearic acid, oleic acid, fumaric acid, linoleic acid, linolenic acid, trans-linoleic acid, arachidonic acid.  ​Alternatively,    ​wherein:  ​Each R1, R2, and R3 independently represent:        6. ​A pharmaceutical composition comprising the compound of claim 1 and a pharmaceutically acceptable carrier.  7. ​A pharmaceutical composition comprising the compound of claim 2 and a pharmaceutically acceptable carrier.  8. ​A pharmaceutical composition comprising the compound of claim 3 and a pharmaceutically acceptable carrier.  9. ​A pharmaceutical composition comprising the compound of claim 4 and a pharmaceutically acceptable carrier.  10. ​A pharmaceutical composition comprising the compound of claim 5 and a pharmaceutically acceptable carrier.  11. ​The pharmaceutical composition of claim 6, wherein the pharmaceutical composition is formulated from an effective amount of the compound of claim 1 for oral administration, transmucosal administration, parenteral administration, intravenous administration, subcutaneous administration, rectal administration, oral administration, or transdermal administration.  12. ​The pharmaceutical composition of claim 7, wherein the pharmaceutical composition is formulated from an effective amount of the compound of claim 2 for oral administration, transmucosal administration, topical administration, parenteral administration, intravenous administration, subcutaneous administration, rectal administration, oral administration, or transdermal administration.  13. ​The pharmaceutical composition of claim 8, wherein the pharmaceutical composition is formulated from an effective amount of the compound of claim 3 for oral administration, transmucosal administration, topical administration, parenteral administration, intravenous administration, subcutaneous administration, rectal administration, oral administration, or transdermal administration.  14. ​The pharmaceutical composition of claim 9, wherein the pharmaceutical composition is formulated from an effective amount of the compound of claim 4 for oral administration, transmucosal administration, topical administration, parenteral administration, intravenous administration, subcutaneous administration, rectal administration, oral administration, or transdermal administration.  15. ​The pharmaceutical composition of claim 10, wherein the pharmaceutical composition is formulated from an effective amount of the compound of claim 5 for oral administration, transmucosal administration, topical administration, parenteral administration, intravenous administration, subcutaneous administration, rectal administration, oral administration, or transdermal administration.  16. ​The compound of claim 1 or the composition according to claim 11, formulated for the treatment of fungal infections, candidiasis, and oral infectious diseases.  17. ​The compound of claim 2 or the composition according to claim 12, formulated for the treatment of fungal infections, candidiasis, and oral infectious diseases.  18. ​The compound of claim 3 or the composition according to claim 13, formulated for the treatment of fungal infections, candidiasis, and oral infectious diseases.  19. ​The compound of claim 4 or the composition according to claim 14, formulated for the treatment of fungal infections, candidiasis, and oral infectious diseases.  20. ​The compound of claim 5 or the composition according to claim 15, formulated for the treatment of fungal infections, candidiasis, and oral infectious diseases.  21. ​The compound of claim 1, wherein the compound has the following chemical structure:    22. ​The compound of claim 2, wherein the compound has the following chemical structure:    23. ​The compound of claim 3, wherein the compound has the following chemical structure:    24. ​The compound of claim 4, wherein the compound has the following chemical structure:    25. ​The compound of claim 5, wherein the compound has the following chemical structure:    26. ​A compound as shown in Formula VIII:    ​and a pharmaceutically acceptable hydrate, solvate, prodrug, enantiomer, and stereoisomer thereof;  ​wherein:  ​RH is selected from the group consisting of 1-hydroxy-2-naphthoic acid, 2,2-dichloroacetic acid, 2-hydroxyethylsulfonic acid, 2-oxoglutarate, 4-acetaminobenzoic acid, 4-aminosalicylic acid, acetic acid, adipic acid, ascorbic acid, aspartic acid, benzenesulfonic acid, adipic acid, ascorbic acid, aspartic acid, benzenesulfonic acid, citric acid, glutamic acid, glutaric acid, glycerophosphoric acid, glycolic acid, fumaric acid, hydrobromic acid, isobutyric acid, lactic acid, lactobionic acid, lauric acid, maleic acid, malic acid, malonic acid, mandelic acid, methanesulfonic acid.​Naphthalene -1, 5-disulfonic acid, naphthalene-2-sulfonic acid, nicotinic acid, nitric acid, oleic acid, oxalic acid, palmitic acid, nitric acid, oleic acid, oxalic acid, palmitic acid, palmitic acid, phosphoric acid, propionic acid, pyroglutamic acid, salicylic acid, tartaric acid, stearic acid, toic acid, lauric acid, alpha-lipoic acid, R-lipoic acid, myristic acid, myristic oleic acid, palmitic acid, palmitoleic acid, stearic acid, oleic acid, fumaric acid, linoleic acid, linolenic acid, trans-linoleic acid, arachidonic acid.  ​Alternatively,    ​wherein:  ​Each R1, R2, and R3 independently represent:      27. ​A compound represented by formula IX:    ​and a pharmaceutically acceptable hydrate, solvate, prodrug, enantiomer, and stereoisomer thereof;  ​wherein:  ​RH is selected from the group consisting of 1-hydroxy-2-naphthoic acid, 2,2-dichloroacetic acid, 2-hydroxyethylsulfonic acid, 2-oxoglutarate, 4-acetaminobenzoic acid, 4-aminosalicylic acid, acetic acid, adipic acid, ascorbic acid, aspartic acid, benzenesulfonic acid, adipic acid, ascorbic acid, aspartic acid, benzenesulfonic acid, citric acid, glutamic acid, glutaric acid, glycerophosphoric acid, glycolic acid, fumaric acid, hydrobromic acid, isobutyric acid, lactic acid, lactobionic acid, lauric acid, maleic acid, malic acid, malonic acid, mandelic acid, methanesulfonic acid.​Naphthalene -1, 5-disulfonic acid, naphthalene-2-sulfonic acid, nicotinic acid, nitric acid, oleic acid, oxalic acid, palmitic acid, nitric acid, oleic acid, oxalic acid, palmitic acid, palmitic acid, phosphoric acid, propionic acid, pyroglutamic acid, salicylic acid, tartaric acid, stearic acid, toic acid, lauric acid, alpha-lipoic acid, R-lipoic acid, myristic acid, myristic oleic acid, palmitic acid, palmitoleic acid, stearic acid, oleic acid, fumaric acid, linoleic acid, linolenic acid, trans-linoleic acid, arachidonic acid.  ​Alternatively,    ​wherein:  ​Each R1, R2, and R3 independently represent:      28. ​A compound represented by Formula X:    ​and a pharmaceutically acceptable hydrate, solvate, prodrug, enantiomer, and stereoisomer thereof;  ​wherein:  ​RH is selected from the group consisting of 1-hydroxy-2-naphthoic acid, 2,2-dichloroacetic acid, 2-hydroxyethylsulfonic acid, 2-oxoglutarate, 4-acetaminobenzoic acid, 4-aminosalicylic acid, acetic acid, adipic acid, ascorbic acid, aspartic acid, benzenesulfonic acid, adipic acid, ascorbic acid, aspartic acid, benzenesulfonic acid, citric acid, glutamic acid, glutaric acid, glycerophosphoric acid, glycolic acid, fumaric acid, hydrobromic acid, isobutyric acid, lactic acid, lactobionic acid, lauric acid, maleic acid, malic acid, malonic acid, mandelic acid, methanesulfonic acid.​Naphthalene -1, 5-disulfonic acid, naphthalene-2-sulfonic acid, nicotinic acid, nitric acid, oleic acid, oxalic acid, palmitic acid, nitric acid, oleic acid, oxalic acid, palmitic acid, palmitic acid, phosphoric acid, propionic acid, pyroglutamic acid, salicylic acid, tartaric acid, stearic acid, toic acid, lauric acid, alpha-lipoic acid, R-lipoic acid, myristic acid, myristic oleic acid, palmitic acid, palmitoleic acid, stearic acid, oleic acid, fumaric acid, linoleic acid, linolenic acid, trans-linoleic acid, arachidonic acid.  ​Alternatively,    ​wherein:  ​Each R1, R2, and R3 independently represent:      29. ​A pharmaceutical composition comprising the compound of claim 26 and a pharmaceutically acceptable carrier.  30. ​The pharmaceutical composition of claim 29, wherein the pharmaceutical composition is formulated from an effective amount of the compound of claim 26 for oral administration, transmucosal administration, parenteral administration, intravenous administration, subcutaneous administration, rectal administration, oral administration, or transdermal administration.  31. ​A pharmaceutical composition comprising the compound of claim 27 and a pharmaceutically acceptable carrier.  32. ​The pharmaceutical composition of claim 31, wherein the pharmaceutical composition is formulated from an effective amount of the compound of claim 27 for oral administration, transmucosal administration, parenteral administration, intravenous administration, subcutaneous administration, rectal administration, oral administration, or transdermal administration.  33. ​A pharmaceutical composition comprising the compound of claim 28 and a pharmaceutically acceptable carrier.  34. ​The pharmaceutical composition of claim 33, wherein the pharmaceutical composition is formulated from an effective amount of the compound of claim 28 for oral administration, transmucosal administration, parenteral administration, intravenous administration, subcutaneous administration, rectal administration, oral administration, or transdermal administration.  35. ​The compound of claim 26 or the composition according to claim 30, formulated for the treatment of fungal infections, candidiasis, and oral infectious diseases.  36. ​The compound of claim 27 or the composition according to claim 32, formulated for the treatment of fungal infections, candidiasis, and oral infectious diseases.  37. ​The compound of claim 28 or the composition according to claim 34, formulated for the treatment of fungal infections, candidiasis, and oral infectious diseases.  38. ​The compound of claim 26, wherein the compound has the following chemical structure:    39. ​The compound of claim 27, wherein the compound has the following chemical structure:    40. ​The compound of claim 28, wherein the compound has the following chemical structure: | treatment of fungal infectionsmay be formulated for oral, buccal, rectal, topical, transdermal, transmucosal, lozenge, spray, intravenous, oral solution, buccal mucosal layer tablet, parenteral administration, syrup, or injection.Such compositions may be used to treatment of fungal infections. |  |
| 187 | **CN110198707** | 2019 |  | 1. ​A compound as shown in Formula I:    ​and pharmaceutically acceptable hydrates, solvates, enantiomers, and stereoisomers thereof;  ​wherein,  ​RH independently represents:  1 ​-hydroxy -2-naphthoic acid, 2,2-dichloroacetic acid, 2-hydroxyethyl sulfonic acid, 2-oxoglutarate, 4-acetaminobenzoic acid, 4-aminosalicylic acid, acetic acid, adipic acid, ascorbic acid, aspartic acid, benzenesulfonic acid, adipic acid, ascorbic acid, aspartic acid, benzenesulfonic acid, benzoic acid, gluconic acid, gluconic acid, glucuronic acid, fumaric acid, hydrobromic acid, isobutyric acid, lactic acid, lactobionic acid, lauric acid, maleic acid, malic acid, malonic acid, mandelic acid, methanesulfonic acid, naphthalene -1​acid, oleic acid, nicotinic acid, nitric acid, oleic acid, oxalic acid, palmitic acid, nitric acid, oleic acid, oxalic acid, palmitic acid, palmitic acid, phosphoric acid, oxalic acid, palmitic acid, palmitic acid, phosphoric acid, propionic acid, pyroglutamic acid, salicylic acid, tartaric acid, stearic acid, toluenesulfonic acid, lauric acid, alpha-lipoic acid, R-lipoic acid, myristic acid, myristic oleic acid, palmitic acid, palmitoleic acid, stearic acid, oleic acid, fumaric acid, linoleic acid, linolenic acid, linoleic acid, arachidonic acid.  ​or    ​wherein the conditions are:  ​R1, R2, R3 independently represent:      2. ​A compound as shown in Formula II:    ​and pharmaceutically acceptable hydrates, solvates, prodrugs, enantiomers, and stereoisomers thereof;  ​wherein,  ​RH independently represents:  1 ​-hydroxy -2-naphthoic acid, 2,2-dichloroacetic acid, 2-hydroxyethyl sulfonic acid, 2-oxoglutarate, 4-acetaminobenzoic acid, 4-aminosalicylic acid, acetic acid, adipic acid, ascorbic acid, aspartic acid, benzenesulfonic acid, adipic acid, ascorbic acid, aspartic acid, benzenesulfonic acid, benzoic acid, gluconic acid, gluconic acid, glucuronic acid, fumaric acid, hydrobromic acid, isobutyric acid, lactic acid, lactobionic acid, lauric acid, maleic acid, malic acid, malonic acid, mandelic acid, methanesulfonic acid, naphthalene -1​acid, oleic acid, nicotinic acid, nitric acid, oleic acid, oxalic acid, palmitic acid, nitric acid, oleic acid, oxalic acid, palmitic acid, palmitic acid, phosphoric acid, oxalic acid, palmitic acid, palmitic acid, phosphoric acid, propionic acid, pyroglutamic acid, salicylic acid, tartaric acid, stearic acid, toluenesulfonic acid, lauric acid, alpha-lipoic acid, R-lipoic acid, myristic acid, myristic oleic acid, palmitic acid, palmitoleic acid, stearic acid, oleic acid, fumaric acid, linoleic acid, linolenic acid, linoleic acid, arachidonic acid.  ​or    ​wherein the conditions are:  ​R1, R2, R3 independently represent:      3. ​A compound of formula III:    ​and pharmaceutically acceptable hydrates, solvates, prodrugs, enantiomers, and stereoisomers thereof;  ​wherein,  ​RH independently represents:  1 ​-hydroxy -2-naphthoic acid, 2,2-dichloroacetic acid, 2-hydroxyethyl sulfonic acid, 2-oxoglutarate, 4-acetaminobenzoic acid, 4-aminosalicylic acid, acetic acid, adipic acid, ascorbic acid, aspartic acid, benzenesulfonic acid, adipic acid, ascorbic acid, aspartic acid, benzenesulfonic acid, benzoic acid, gluconic acid, gluconic acid, glucuronic acid, fumaric acid, hydrobromic acid, isobutyric acid, lactic acid, lactobionic acid, lauric acid, maleic acid, malic acid, malonic acid, mandelic acid, methanesulfonic acid, naphthalene -1​acid, oleic acid, nicotinic acid, nitric acid, oleic acid, oxalic acid, palmitic acid, nitric acid, oleic acid, oxalic acid, palmitic acid, palmitic acid, phosphoric acid, oxalic acid, palmitic acid, palmitic acid, phosphoric acid, propionic acid, pyroglutamic acid, salicylic acid, tartaric acid, stearic acid, toluenesulfonic acid, lauric acid, alpha-lipoic acid, R-lipoic acid, myristic acid, myristic oleic acid, palmitic acid, palmitoleic acid, stearic acid, oleic acid, fumaric acid, linoleic acid, linolenic acid, linoleic acid, arachidonic acid.  ​or    ​wherein the conditions are:  ​R1, R2, R3 independently represent:      4. ​A compound of formula IV:    ​and pharmaceutically acceptable hydrates, solvates, prodrugs, enantiomers, and stereoisomers thereof;  ​wherein,  ​RH independently represents:  1 ​-hydroxy -2-naphthoic acid, 2,2-dichloroacetic acid, 2-hydroxyethyl sulfonic acid, 2-oxoglutarate, 4-acetaminobenzoic acid, 4-aminosalicylic acid, acetic acid, adipic acid, ascorbic acid, aspartic acid, benzenesulfonic acid, adipic acid, ascorbic acid, aspartic acid, benzenesulfonic acid, benzoic acid, gluconic acid, gluconic acid, glucuronic acid, fumaric acid, hydrobromic acid, isobutyric acid, lactic acid, lactobionic acid, lauric acid, maleic acid, malic acid, malonic acid, mandelic acid, methanesulfonic acid, naphthalene -1​acid, oleic acid, nicotinic acid, nitric acid, oleic acid, oxalic acid, palmitic acid, nitric acid, oleic acid, oxalic acid, palmitic acid, palmitic acid, phosphoric acid, oxalic acid, palmitic acid, palmitic acid, phosphoric acid, propionic acid, pyroglutamic acid, salicylic acid, tartaric acid, stearic acid, toluenesulfonic acid, lauric acid, alpha-lipoic acid, R-lipoic acid, myristic acid, myristic oleic acid, palmitic acid, palmitoleic acid, stearic acid, oleic acid, fumaric acid, linoleic acid, linolenic acid, linoleic acid, arachidonic acid.  ​or    ​wherein the conditions are:  ​R1, R2, R3 independently represent:      5. ​A compound of formula V:    ​and pharmaceutically acceptable hydrates, solvates, prodrugs, enantiomers, and stereoisomers thereof;  ​wherein,  ​RH independently represents:  1 ​-hydroxy -2-naphthoic acid, 2,2-dichloroacetic acid, 2-hydroxyethyl sulfonic acid, 2-oxoglutarate, 4-acetaminobenzoic acid, 4-aminosalicylic acid, acetic acid, adipic acid, ascorbic acid, aspartic acid, benzenesulfonic acid, adipic acid, ascorbic acid, aspartic acid, benzenesulfonic acid, benzoic acid, gluconic acid, gluconic acid, glucuronic acid, fumaric acid, hydrobromic acid, isobutyric acid, lactic acid, lactobionic acid, lauric acid, maleic acid, malic acid, malonic acid, mandelic acid, methanesulfonic acid, naphthalene -1​acid, oleic acid, nicotinic acid, nitric acid, oleic acid, oxalic acid, palmitic acid, nitric acid, oleic acid, oxalic acid, palmitic acid, palmitic acid, phosphoric acid, oxalic acid, palmitic acid, palmitic acid, phosphoric acid, propionic acid, pyroglutamic acid, salicylic acid, tartaric acid, stearic acid, toluenesulfonic acid, lauric acid, alpha-lipoic acid, R-lipoic acid, myristic acid, myristic oleic acid, palmitic acid, palmitoleic acid, stearic acid, oleic acid, fumaric acid, linoleic acid, linolenic acid, linoleic acid, arachidonic acid.  ​or    ​wherein the conditions are:  ​R1, R2, R3 independently represent:      6. ​A compound represented by formula VI:    ​and pharmaceutically acceptable hydrates, solvates, prodrugs, enantiomers, and stereoisomers thereof;  ​wherein,  ​RH independently represents:  1 ​-hydroxy -2-naphthoic acid, 2,2-dichloroacetic acid, 2-hydroxyethyl sulfonic acid, 2-oxoglutarate, 4-acetaminobenzoic acid, 4-aminosalicylic acid, acetic acid, adipic acid, ascorbic acid, aspartic acid, benzenesulfonic acid, adipic acid, ascorbic acid, aspartic acid, benzenesulfonic acid, benzoic acid, gluconic acid, gluconic acid, glucuronic acid, fumaric acid, hydrobromic acid, isobutyric acid, lactic acid, lactobionic acid, lauric acid, maleic acid, malic acid, malonic acid, mandelic acid, methanesulfonic acid, naphthalene -1​acid, oleic acid, nicotinic acid, nitric acid, oleic acid, oxalic acid, palmitic acid, nitric acid, oleic acid, oxalic acid, palmitic acid, palmitic acid, phosphoric acid, oxalic acid, palmitic acid, palmitic acid, phosphoric acid, propionic acid, pyroglutamic acid, salicylic acid, tartaric acid, stearic acid, toluenesulfonic acid, lauric acid, alpha-lipoic acid, R-lipoic acid, myristic acid, myristic oleic acid, palmitic acid, palmitoleic acid, stearic acid, oleic acid, fumaric acid, linoleic acid, linolenic acid, linoleic acid, arachidonic acid.  ​or    ​wherein the conditions are:  ​R1, R2, R3 independently represent:      7. ​A compound represented by formula VII:    ​and pharmaceutically acceptable hydrates, solvates, prodrugs, enantiomers, and stereoisomers thereof;  ​wherein,  ​RH independently represents:  1 ​-hydroxy -2-naphthoic acid, 2,2-dichloroacetic acid, 2-hydroxyethyl sulfonic acid, 2-oxoglutarate, 4-acetaminobenzoic acid, 4-aminosalicylic acid, acetic acid, adipic acid, ascorbic acid, aspartic acid, benzenesulfonic acid, adipic acid, ascorbic acid, aspartic acid, benzenesulfonic acid, benzoic acid, gluconic acid, gluconic acid, glucuronic acid, fumaric acid, hydrobromic acid, isobutyric acid, lactic acid, lactobionic acid, lauric acid, maleic acid, malic acid, malonic acid, mandelic acid, methanesulfonic acid, naphthalene -1​acid, oleic acid, nicotinic acid, nitric acid, oleic acid, oxalic acid, palmitic acid, nitric acid, oleic acid, oxalic acid, palmitic acid, palmitic acid, phosphoric acid, oxalic acid, palmitic acid, palmitic acid, phosphoric acid, propionic acid, pyroglutamic acid, salicylic acid, tartaric acid, stearic acid, toluenesulfonic acid, lauric acid, alpha-lipoic acid, R-lipoic acid, myristic acid, myristic oleic acid, palmitic acid, palmitoleic acid, stearic acid, oleic acid, fumaric acid, linoleic acid, linolenic acid, linoleic acid, arachidonic acid.  ​or    ​wherein the conditions are:  ​R1, R2, R3 independently represent:      8. ​A compound as shown in Formula VIII:    ​and pharmaceutically acceptable hydrates, solvates, prodrugs, enantiomers, and stereoisomers thereof;  ​wherein,  ​RH independently represents:  1 ​-hydroxy -2-naphthoic acid, 2,2-dichloroacetic acid, 2-hydroxyethyl sulfonic acid, 2-oxoglutarate, 4-acetaminobenzoic acid, 4-aminosalicylic acid, acetic acid, adipic acid, ascorbic acid, aspartic acid, benzenesulfonic acid, adipic acid, ascorbic acid, aspartic acid, benzenesulfonic acid, benzoic acid, gluconic acid, gluconic acid, glucuronic acid, fumaric acid, hydrobromic acid, isobutyric acid, lactic acid, lactobionic acid, lauric acid, maleic acid, malic acid, malonic acid, mandelic acid, methanesulfonic acid, naphthalene -1​acid, oleic acid, nicotinic acid, nitric acid, oleic acid, oxalic acid, palmitic acid, nitric acid, oleic acid, oxalic acid, palmitic acid, palmitic acid, phosphoric acid, oxalic acid, palmitic acid, palmitic acid, phosphoric acid, propionic acid, pyroglutamic acid, salicylic acid, tartaric acid, stearic acid, toluenesulfonic acid, lauric acid, alpha-lipoic acid, R-lipoic acid, myristic acid, myristic oleic acid, palmitic acid, palmitoleic acid, stearic acid, oleic acid, fumaric acid, linoleic acid, linolenic acid, linoleic acid, arachidonic acid.  ​or    ​wherein the conditions are:  ​R1, R2, R3 independently represent:      9. ​A compound represented by formula IX:    ​and pharmaceutically acceptable hydrates, solvates, prodrugs, enantiomers, and stereoisomers thereof;  ​wherein,  ​RH independently represents:  1 ​-hydroxy -2-naphthoic acid, 2,2-dichloroacetic acid, 2-hydroxyethyl sulfonic acid, 2-oxoglutarate, 4-acetaminobenzoic acid, 4-aminosalicylic acid, acetic acid, adipic acid, ascorbic acid, aspartic acid, benzenesulfonic acid, adipic acid, ascorbic acid, aspartic acid, benzenesulfonic acid, benzoic acid, gluconic acid, gluconic acid, glucuronic acid, fumaric acid, hydrobromic acid, isobutyric acid, lactic acid, lactobionic acid, lauric acid, maleic acid, malic acid, malonic acid, mandelic acid, methanesulfonic acid, naphthalene -1​acid, oleic acid, nicotinic acid, nitric acid, oleic acid, oxalic acid, palmitic acid, nitric acid, oleic acid, oxalic acid, palmitic acid, palmitic acid, phosphoric acid, oxalic acid, palmitic acid, palmitic acid, phosphoric acid, propionic acid, pyroglutamic acid, salicylic acid, tartaric acid, stearic acid, toluenesulfonic acid, lauric acid, alpha-lipoic acid, R-lipoic acid, myristic acid, myristic oleic acid, palmitic acid, palmitoleic acid, stearic acid, oleic acid, fumaric acid, linoleic acid, linolenic acid, linoleic acid, arachidonic acid.  ​or    ​wherein the conditions are:  ​R1, R2, R3 independently represent:      10. ​A compound represented by Formula X:    ​and pharmaceutically acceptable hydrates, solvates, prodrugs, enantiomers, and stereoisomers thereof;  ​wherein,  ​RH independently represents:  1 ​-hydroxy -2-naphthoic acid, 2,2-dichloroacetic acid, 2-hydroxyethyl sulfonic acid, 2-oxoglutarate, 4-acetaminobenzoic acid, 4-aminosalicylic acid, acetic acid, adipic acid, ascorbic acid, aspartic acid, benzenesulfonic acid, adipic acid, ascorbic acid, aspartic acid, benzenesulfonic acid, benzoic acid, gluconic acid, gluconic acid, glucuronic acid, fumaric acid, hydrobromic acid, isobutyric acid, lactic acid, lactobionic acid, lauric acid, maleic acid, malic acid, malonic acid, mandelic acid, methanesulfonic acid, naphthalene -1​acid, oleic acid, nicotinic acid, nitric acid, oleic acid, oxalic acid, palmitic acid, nitric acid, oleic acid, oxalic acid, palmitic acid, palmitic acid, phosphoric acid, oxalic acid, palmitic acid, palmitic acid, phosphoric acid, propionic acid, pyroglutamic acid, salicylic acid, tartaric acid, stearic acid, toluenesulfonic acid, lauric acid, alpha-lipoic acid, R-lipoic acid, myristic acid, myristic oleic acid, palmitic acid, palmitoleic acid, stearic acid, oleic acid, fumaric acid, linoleic acid, linolenic acid, linoleic acid, arachidonic acid.  ​or    ​wherein the conditions are:  ​R1, R2, R3 independently represent:      11. ​A compound represented by formula XI:    ​and pharmaceutically acceptable hydrates, solvates, prodrugs, enantiomers, and stereoisomers thereof;  ​wherein,  ​RH independently represents:  1 ​-hydroxy -2-naphthoic acid, 2,2-dichloroacetic acid, 2-hydroxyethyl sulfonic acid, 2-oxoglutarate, 4-acetaminobenzoic acid, 4-aminosalicylic acid, acetic acid, adipic acid, ascorbic acid, aspartic acid, benzenesulfonic acid, adipic acid, ascorbic acid, aspartic acid, benzenesulfonic acid, benzoic acid, gluconic acid, gluconic acid, glucuronic acid, fumaric acid, hydrobromic acid, isobutyric acid, lactic acid, lactobionic acid, lauric acid, maleic acid, malic acid, malonic acid, mandelic acid, methanesulfonic acid, naphthalene -1​acid, oleic acid, nicotinic acid, nitric acid, oleic acid, oxalic acid, palmitic acid, nitric acid, oleic acid, oxalic acid, palmitic acid, palmitic acid, phosphoric acid, oxalic acid, palmitic acid, palmitic acid, phosphoric acid, propionic acid, pyroglutamic acid, salicylic acid, tartaric acid, stearic acid, toluenesulfonic acid, lauric acid, alpha-lipoic acid, R-lipoic acid, myristic acid, myristic oleic acid, palmitic acid, palmitoleic acid, stearic acid, oleic acid, fumaric acid, linoleic acid, linolenic acid, linoleic acid, arachidonic acid.  ​or    ​wherein the conditions are:  ​R1, R2, R3 independently represent:      12. ​A compound of formula XII:    ​and pharmaceutically acceptable hydrates, solvates, prodrugs, enantiomers, and stereoisomers thereof;  ​wherein,  ​RH independently represents:  1 ​-hydroxy -2-naphthoic acid, 2,2-dichloroacetic acid, 2-hydroxyethyl sulfonic acid, 2-oxoglutarate, 4-acetaminobenzoic acid, 4-aminosalicylic acid, acetic acid, adipic acid, ascorbic acid, aspartic acid, benzenesulfonic acid, adipic acid, ascorbic acid, aspartic acid, benzenesulfonic acid, benzoic acid, gluconic acid, gluconic acid, glucuronic acid, fumaric acid, hydrobromic acid, isobutyric acid, lactic acid, lactobionic acid, lauric acid, maleic acid, malic acid, malonic acid, mandelic acid, methanesulfonic acid, naphthalene -1​acid, oleic acid, nicotinic acid, nitric acid, oleic acid, oxalic acid, palmitic acid, nitric acid, oleic acid, oxalic acid, palmitic acid, palmitic acid, phosphoric acid, oxalic acid, palmitic acid, palmitic acid, phosphoric acid, propionic acid, pyroglutamic acid, salicylic acid, tartaric acid, stearic acid, toluenesulfonic acid, lauric acid, alpha-lipoic acid, R-lipoic acid, myristic acid, myristic oleic acid, palmitic acid, palmitoleic acid, stearic acid, oleic acid, fumaric acid, linoleic acid, linolenic acid, linoleic acid, arachidonic acid.  ​or    ​wherein the conditions are:  ​R1, R2, R3 independently represent:      13. ​A pharmaceutical composition comprising the compound of claim 1 and a pharmaceutically acceptable carrier.  14. ​A pharmaceutical composition comprising the compound of claim 2 and a pharmaceutically acceptable carrier.  15. ​A pharmaceutical composition comprising the compound of claim 3 and a pharmaceutically acceptable carrier.  16. ​A pharmaceutical composition comprising the compound of claim 4 and a pharmaceutically acceptable carrier.  17. ​A pharmaceutical composition comprising the compound of claim 5 and a pharmaceutically acceptable carrier.  18. ​A pharmaceutical composition comprising the compound of claim 6 and a pharmaceutically acceptable carrier.  19. ​A pharmaceutical composition comprising the compound of claim 7 and a pharmaceutically acceptable carrier.  20. ​A pharmaceutical composition comprising the compound of claim 8 and a pharmaceutically acceptable carrier.  21. ​A pharmaceutical composition comprising the compound of claim 9 and a pharmaceutically acceptable carrier.  22. ​A pharmaceutical composition comprising the compound of claim 10 and a pharmaceutically acceptable carrier.  23. ​A pharmaceutical composition comprising the compound of claim 11 and a pharmaceutically acceptable carrier.  24. ​A pharmaceutical composition comprising the compound of claim 12 and a pharmaceutically acceptable carrier.  25. ​The pharmaceutical composition of claim 13, formulated for treating potential etiology by oral administration, sustained release or sustained release, transmucosal, syrup, topical, parenteral administration, injection, subcutaneous, oral solution, rectal administration, oral administration, or transdermal administration to a patient in need thereof.  26. ​The pharmaceutical composition of claim 14, formulated for treating potential etiology by oral administration, sustained release or sustained release, transmucosal, syrup, topical, parenteral administration, injection, subcutaneous, oral solution, rectal administration, oral administration, or transdermal administration to a patient in need thereof.  27. ​The pharmaceutical composition of claim 15, formulated for treating potential etiology by oral administration, sustained release or sustained release, transmucosal, syrup, topical, parenteral administration, injection, subcutaneous, oral solution, rectal administration, oral administration, or transdermal administration to a patient in need thereof.  28. ​The pharmaceutical composition of claim 16, formulated for treating potential etiology by oral administration, sustained release or sustained release, transmucosal, syrup, topical, parenteral administration, injection, subcutaneous, oral solution, rectal administration, oral administration, or transdermal administration to a patient in need thereof.  29. ​The pharmaceutical composition of claim 17, formulated for treating potential etiology by oral administration, sustained release or sustained release, transmucosal, syrup, topical, parenteral administration, injection, subcutaneous, oral solution, rectal administration, oral administration, or transdermal administration to a patient in need thereof.  30. ​The pharmaceutical composition of claim 18, formulated for treating potential etiology by oral administration, sustained release or sustained release, transmucosal, syrup, topical, parenteral administration, injection, subcutaneous, oral solution, rectal administration, oral administration, or transdermal administration to a patient in need thereof.  31. ​The pharmaceutical composition of claim 19, formulated for treating potential etiology by oral administration, sustained release or sustained release, transmucosal, syrup, topical, parenteral administration, injection, subcutaneous, oral solution, rectal administration, oral administration, or transdermal administration to a patient in need thereof.  32. ​The pharmaceutical composition of claim 20, formulated for treating potential etiology by oral administration, sustained release or sustained release, transmucosal, syrup, topical, parenteral administration, injection, subcutaneous, oral solution, rectal administration, oral administration, or transdermal administration to a patient in need thereof.  33. ​The pharmaceutical composition of claim 21, formulated for the treatment of potential etiology by oral administration, sustained release or sustained release, transmucosal, syrup, topical, parenteral administration, injection, subcutaneous, oral solution, rectal administration, oral administration, or transdermal administration to a patient in need thereof.  34. ​The pharmaceutical composition of claim 22, formulated for treating potential etiology by oral administration, sustained release or sustained release, transmucosal, syrup, topical, parenteral administration, injection, subcutaneous, oral solution, rectal administration, oral administration, or transdermal administration to a patient in need thereof.  35. ​The pharmaceutical composition of claim 23, formulated for treating potential etiology by oral administration, sustained release or sustained release, transmucosal, syrup, topical, parenteral administration, injection, subcutaneous, oral solution, rectal administration, oral administration, or transdermal administration to a patient in need thereof.  36. ​The pharmaceutical composition of claim 24, formulated for treating potential etiology by oral administration, sustained release or sustained release, transmucosal, syrup, topical, parenteral administration, injection, subcutaneous, oral solution, rectal administration, oral administration, or transdermal administration to a patient in need thereof.  37. ​The compound and composition of claim 25, formulated for the treatment of fungal infections, candidiasis, and oral infectious diseases.  38. ​The compound and composition of claim 26, formulated for the treatment of fungal infections, candidiasis, and oral infectious diseases.  39. ​The compound and composition of claim 27, formulated for the treatment of fungal infections, candidiasis, and oral infectious diseases.  40. ​The compound and composition of claim 28, formulated for the treatment of fungal infections, candidiasis, and oral infectious diseases.  41. ​The compound and composition of claim 29, formulated for the treatment of fungal infections, candidiasis, and oral infectious diseases.  42. ​The compound and composition of claim 30, formulated for the treatment of fungal infections, candidiasis, and oral infectious diseases.  43. ​The compound and composition of claim 31, formulated for the treatment of fungal infections, candidiasis, and oral infectious diseases.  44. ​The compound and composition of claim 32, formulated for the treatment of fungal infections, candidiasis, and oral infectious diseases.  45. ​The compound and composition of claim 33, formulated for the treatment of fungal infections, candidiasis, and oral infectious diseases.  46. ​The compound and composition of claim 34, formulated for the treatment of fungal infections, candidiasis, and oral infectious diseases.  47. ​The compound and composition of claim 35, formulated for the treatment of fungal infections, candidiasis, and oral infectious diseases.  48. ​The compound and composition of claim 36, formulated for the treatment of fungal infections, candidiasis, and oral infectious diseases.  49. ​A compound according to claim 1, comprising Formula I:    50. ​A compound according to claim 2, comprising Formula II:    51. ​A compound according to claim 3, comprising Formula III:    52. ​A compound according to claim 4, comprising Formula IV:    53. ​A compound according to claim 8, comprising Formula VIII:    54. ​A compound according to claim 9, comprising Formula IX: | treatment of oral infectious diseases may be formulated for oral, buccal, rectal, topical, transdermal, transmucosal, lozenge, spray, intravenous, oral solution, buccal mucosal layer tablet, parenteral administration, syrup, or injection. Such compositions may be used to treatment of oral infectious diseases. |  |
| 188 | **IL267649** | 2019 |  |  | COMPOSITIONS AND METHODS FOR THE TREATMENT OF CHRONIC PAIN |  |
| 189 | **IL266927** | 2019 |  |  | COMPOSITIONS AND METHODS FOR THE TREATMENT OF FUNGAL INFECTIONS |  |
| 190 | **CN110167548** | 2019 |  | 1. ​A compound as shown in Formula I:    ​and pharmaceutically acceptable salts, hydrates, solvates, prodrugs, enantiomers, and stereoisomers thereof;  ​wherein,  ​R1, R3 and R5 each independently represent OD, OCH3, OCOCH3, NULL,      ​R2, R4, and R6 each independently represent:  ​n is independently 1,2,3, 4 or 5;  ​A is independently 2, 3 or 7;  ​each B is independently 3, 5 or 6;  ​E is independently 1, 2 or 6;  ​C and D are independently H, D,-OH,-OD, C1-C6 alkyl,-NH2 or-COCH3, respectively.  2. ​A pharmaceutical composition comprising the compound of claim 1 and a pharmaceutically acceptable carrier.  3. ​The pharmaceutical composition of claim 2, formulated for the treatment of potential etiology by oral administration, sustained release or sustained release, transmucosal, syrup, topical, parenteral administration, injection, subcutaneous, oral solution, rectal administration, oral administration, or transdermal administration to a patient in need thereof.  4. ​The compound and composition according to claim 3, formulated for the treatment of gastrointestinal polyps, intestinal polyps and inflammation.  5. ​A method for treating at least one disease in gastrointestinal polyps, intestinal polyps, and inflammatory diseases, comprising:  ​Administration of a compound of Formula I to a patient suffering from at least one of a gastrointestinal polyp, an intestinal polyp, and an inflammatory disease: | formulated for oral, buccal, rectal, topical, transdermal,transmucosal, lozenge, spray, intravenous, oral solution, buccal mucosal layer tablet, parenteral administration, syrup, or injection. Such compositions may be used to treatment of gastrointestinal polyps or its associated complications. |  |
| 191 | **IN201917020530** | 2019 |  | 1. A compound of Formula I:and pharmaceutically acceptable salts, hydrates, solvates, prodrugs, enantiomers, and stereoisomers thereof;Wherein,91 2. A Pharmaceutical composition comprising a compound of claim 1 and a pharmaceutically acceptable carrier. 3. The pharmaceutical composition of claim 2, which is formulated to treat the underlying etiology with an effective amount administering the patient in need by oral administration, delayed release or sustained release, transmucosal, syrup, topical, parenteral administration, injection, subdermal, oral solution, rectal administration, buccal administration or transdermal administration. 4. Compounds and compositions of claim 3 are formulated for the treatment of gastrointestinal polyps, intestinal polyps and inflammation. 5. A method of treating at least one of a gastrointestinal polyps, intestinal polyps and inflammatory disease comprising:administering the compound of Formula I to patient suffering from at least one of a gastrointestinal polyps, intestinal polyps and inflammatory disease | pharmaceutical compositions may be formulated for oral, buccal, rectal, topical, transdermal, transmucosal, lozenge, spray, intravenous, oral solution, buccal mucosal layer tablet, parenteral administration, syrup, or injection. Such compositions may be used to treatment of gastrointestinal polyps or its associated complications. |  |
| 192 | **EP3522873** | 2019 |  | A compound of Formula I:  and pharmaceutically acceptable hydrates, solvates, enantiomers, and stereoisomers thereof for use in treatment of xerostomia, dry mouth and dry mouth in Sjögren's syndrome;  Wherein, RH independently represents omega 3 fatty acids, omega 6 fatty acids, alpha lipoic acid or R-lipoic acid.    2. A pharmaceutical composition comprising a compound of claim 1 and a pharmaceutically acceptable carrier.   3. The pharmaceutical composition of claim 2, which is formulated to treat the underlying etiology with an effective amount administering the patient in need by oral administration, delayed release or sustained release, transmucosal, syrup, topical, parenteral administration, injection, subdermal, oral solution, rectal administration, buccal administration or transdermal administration. | formulated for oral, buccal, rectal, topical, transdermal, transmucosal, lozenge, spray, intravenous, oral solution, buccal mucosal layer tablet, parenteral administration, syrup, or injection. Such compositions may be used to treatment of oral mucosal inflammatory, dry mouth or oral dry mouth mediated infectious diseases. |  |
| 193 | **BR112019009615** | 2019 |  |  | pharmaceutical compositions can be formulated for oral, buccal, rectal, topical, transdermal, transmucosal, lozenge, spray, intravenous, oral solution, buccal, parenteral, syrup or injection layer tablet. These compositions can be used for the treatment of gastrointestinal powders or their associated complications. |  |
| 194 | **IN201918031168** | 2019 |  | . A compound of formula I:and pharmaceutically acceptable hydrates, solvates, prodrugs, enantiomers, and stereoisomers thereof;Wherein,R1, R3 represents CD3, CD2, H, D, O, OD, CD3CO, NULL,R2, R4 independently representsWithin the proviso, Wherein n represents 0 to 12;R5 and R6 independently representsor 2. A compound of formula II:and pharmaceutically acceptable hydrates, solvates, prodrugs, enantiomers, and stereoisomers thereof;Wherein,R1, R3 represents CD3, CD2, H, D, O, OD, CD3CO, NULL,R2, R4 independently representsWithin the proviso, Wherein n represents 0 to 12;R5 and R6 independently represents 3. A compound of formula III:and pharmaceutically acceptable hydrates, solvates, prodrugs, enantiomers, and stereoisomers thereof;Wherein,R1, R3, R5 represents CD3, CD2, H, D, O, OD, CD3CO, NULL,R2, R4 independently representsorWithin the proviso, Wherein n represents 0 to 12;R6 independently represents NULL, 4. A compound of formula IV:and pharmaceutically acceptable hydrates, solvates, prodrugs, enantiomers, and stereoisomers thereof;Wherein,R1, R3, R5, R7 represents CD3, CD2, H, D, O, OD, CD3CO, NULL,R2, R4, R6, R8 independently representsWithin the proviso, Wherein n represents 0 to 12;R5 and R6 independently representsor 5. A compound of formula V:and pharmaceutically acceptable hydrates, solvates, prodrugs, enantiomers, and stereoisomers thereof;Wherein,R1, R3, R5 represents CD3, CD2, H, D, O, OD, CD3CO, NULL,R2, R4, R6 independently representsWithin the proviso, Wherein n represents 0 to 12;R5 and R6 independently represents 6. A compound of formula VI:and pharmaceutically acceptable hydrates, solvates, prodrugs, enantiomers, and stereoisomers thereof;Wherein,R1, R3, R5 represents CD3, CD2, H, D, O, OD, CD3CO, NULL,R6 independently represents H, D, NULL,orWithin the proviso,Whereinn represents 0 to 12;R5 and R6 independently represents 7. A compound of formula VII:and pharmaceutically acceptable hydrates, solvates, prodrugs, enantiomers, and stereoisomers thereof;Wherein,R1, R3 represents CD3, CD2, H, D, O, OD, CD3CO, NULL,R2, R4 independently representsWithin the proviso,Whereinn represents 0 to 12;Rs and R6 independently representsor 8. A compound of formula VIII:and pharmaceutically acceptable hydrates, solvates, prodrugs, enantiomers, and stereoisomers thereof;Wherein,R1 represents CD3, CD2, H, D, O, OD, CD3CO, NULL,R2 independently representsWithin the proviso,Whereinn represents 0 to 12;R5 and R6 independently representsor 9. A Pharmaceutical composition comprising a compound of claim 1 and a pharmaceutically acceptable carrier. 10. A Pharmaceutical composition comprising a compound of claim 2 and a pharmaceutically acceptable carrier. 11. A Pharmaceutical composition comprising a compound of claim 3 and a pharmaceutically acceptable carrier. 12. A Pharmaceutical composition comprising a compound of claim 4 and a pharmaceutically acceptable carrier. 13. A Pharmaceutical composition comprising a compound of claim 5 and a pharmaceutically acceptable carrier. 14. A Pharmaceutical composition comprising a compound of claim 6 and a pharmaceutically acceptable carrier. 15. A Pharmaceutical composition comprising a compound of claim 7 and a pharmaceutically acceptable carrier. 16. A Pharmaceutical composition comprising a compound of claim 8 and a pharmaceutically acceptable carrier. 17. The pharmaceutical composition of claim 9, which is formulated to treat the underlying etiology with an effective amount administering the patient in need by oral administration, delayed release or sustained release, transmucosal, syrup, topical, parenteral administration, injection, subdermal, oral solution, rectal administration, buccal administration or transdermal administration. 18. The pharmaceutical composition of claim 10, which is formulated to treat the underlying etiology with an effective amount administering the patient in need by oral administration, delayed release or sustained release, transmucosal, syrup, topical, parenteral administration, injection, subdermal, oral solution, rectal administration, buccal administration or transdermal administration. 19. The pharmaceutical composition of claim 11, which is formulated to treat the underlying etiology with an effective amount administering the patient in need by oral administration, delayed release or sustained release, transmucosal, syrup, topical, parenteral administration, injection, subdermal, oral solution, rectal administration, buccal administration or transdermal administration. 20. The pharmaceutical composition of claim 12, which is formulated to treat the underlying etiology with an effective amount administering the patient in need by oral administration, delayed release or sustained release, transmucosal, syrup, topical, parenteral administration, injection, subdermal, oral solution, rectal administration, buccal administration or transdermal administration. 21. The pharmaceutical composition of claim 13, which is formulated to treat the underlying etiology with an effective amount administering the patient in need by oral administration, delayed release or sustained release, transmucosal, syrup, topical, parenteral administration, injection, subdermal, oral solution, rectal administration, buccal administration or transdermal administration. 22. The pharmaceutical composition of claim 14, which is formulated to treat the underlying etiology with an effective amount administering the patient in need by oral administration, delayed release or sustained release, transmucosal, syrup, topical, parenteral administration, injection, subdermal, oral solution, rectal administration, buccal administration or transdermal administration. 23. The pharmaceutical composition of claim 15, which is formulated to treat the underlying etiology with an effective amount administering the patient in need by oral administration, delayed release or sustained release, transmucosal, syrup, topical, parenteral administration, injection, subdermal, oral solution, rectal administration, buccal administration or transdermal administration. 24. The pharmaceutical composition of claim 16, which is formulated to treat the underlying etiology with an effective amount administering the patient in need by oral administration, delayed release or sustained release, transmucosal, syrup, topical, parenteral administration, injection, subdermal, oral solution, rectal administration, buccal administration or transdermal administration. 25. Compounds and compositions of claim 17 are formulated for the treatment of colorectal cancer, breast cancer (metastatic or as monotherapy/combotherapy), gastric cancer, oesophageal cancer, anal, breast, colorectal, oesophageal, stomach, pancreatic and skin cancers (especially head and neck cancers), actinic keratoses, skin cancers, Bowen's disease, fungal infections, candidiasis and oral infectious diseases. 26. Compounds and compositions of claim 18 are formulated for the treatment of colorectal cancer, breast cancer (metastatic or as monotherapy/combotherapy), gastric cancer, oesophageal cancer, anal, breast, colorectal, oesophageal, stomach, pancreatic and skin cancers (especially head and neck cancers), actinic keratoses, skin cancers, Bowen's disease, fungal infections, candidiasis and oral infectious diseases. 27. Compounds and compositions of claim 19 are formulated for the treatment of colorectal cancer, breast cancer (metastatic or as monotherapy/combotherapy), gastric cancer, oesophageal cancer, anal, breast, colorectal, oesophageal, stomach, pancreatic and skin cancers (especially head and neck cancers), actinic keratoses, skin cancers, Bowen's disease, fungal infections, candidiasis and oral infectious diseases. 28. Compounds and compositions of claim 20 are formulated for the treatment of colorectal cancer, breast cancer (metastatic or as monotherapy/combotherapy), gastric cancer, oesophageal cancer, anal, breast, colorectal, oesophageal, stomach, pancreatic and skin cancers (especially head and neck cancers), actinic keratoses, skin cancers, Bowen's disease, fungal infections, candidiasis and oral infectious diseases. 29. Compounds and compositions of claim 21 are formulated for the treatment of colorectal cancer, breast cancer (metastatic or as monotherapy/combotherapy), gastric cancer, oesophageal cancer, anal, breast, colorectal, oesophageal, stomach, pancreatic and skin cancers (especially head and neck cancers), actinic keratoses, skin cancers, Bowen's disease, fungal infections, candidiasis and oral infectious diseases. 30. Compounds and compositions of claim 22 are formulated for the treatment of colorectal cancer, breast cancer (metastatic or as monotherapy/combotherapy), gastric cancer, oesophageal cancer, anal, breast, colorectal, oesophageal, stomach, pancreatic and skin cancers (especially head and neck cancers), actinic keratoses, skin cancers, Bowen's disease, fungal infections, candidiasis and oral infectious diseases. 31. Compounds and compositions of claim 23 are formulated for the treatment of colorectal cancer, breast cancer (metastatic or as monotherapy/combotherapy), gastric cancer, oesophageal cancer, anal, breast, colorectal, oesophageal, stomach, pancreatic and skin cancers (especially head and neck cancers), actinic keratoses, skin cancers, Bowen's disease, fungal infections, candidiasis and oral infectious diseases. 32. Compounds and compositions of claim 24 are formulated for the treatment of colorectal cancer, breast cancer (metastatic or as monotherapy/combotherapy), gastric cancer, oesophageal cancer, anal, breast, colorectal, oesophageal, stomach, pancreatic and skin cancers (especially head and neck cancers), actinic keratoses, skin cancers, Bowen's disease, fungal infections, candidiasis and oral infectious diseases. | treatment of cancer and infectious diseases may be formulated for oral, buccal, rectal, topical, transdermal, transmucosal, lozenge, spray, intravenous, oral solution, buccal mucosal layer tablet, parenteral administration, syrup, or injection. Such compositions may be used to treatment of cancer, neoplasm, infections and skin diseases. |  |
| 195 | **IN201918031169** | 2019 |  | 1. A compound of formula I:and pharmaceutically acceptable hydrates, solvates, prodrugs, enantiomers, and stereoisomers thereof;Wherein,R1, R3 represents CD3, CD2, H, D, O, OD, CD3CO, NULL,R2, R4 independently representsWithin the proviso, Wherein n represents 0 to 12;R5 and R6 independently representsor 2. A compound of formula II:and pharmaceutically acceptable hydrates, solvates, prodrugs, enantiomers, and stereoisomers thereof;Wherein,R1, R3 represents CD3, CD2, H, D, O, OD, CD3CO, NULL,R2, R4 independently representsWithin the proviso, Wherein n represents 0 to 12;R5 and R6 independently represents 3. A compound of formula III:and pharmaceutically acceptable hydrates, solvates, prodrugs, enantiomers, and stereoisomers thereof;Wherein,R1, R3, R5 represents CD3, CD2, H, D, O, OD, CD3CO, NULL,R2, R4 independently representsorWithin the proviso, Wherein n represents 0 to 12;R6 independently represents NULL, 4. A compound of formula IV:and pharmaceutically acceptable hydrates, solvates, prodrugs, enantiomers, and stereoisomers thereof;Wherein,R1, R3, R5, R7 represents CD3, CD2, H, D, O, OD, CD3CO, NULL,R2, R4, R6, R8 independently representsWithin the proviso, Wherein n represents 0 to 12;R5 and R6 independently representsor 5. A compound of formula V:and pharmaceutically acceptable hydrates, solvates, prodrugs, enantiomers, and stereoisomers thereof;Wherein,R1, R3, R5 represents CD3, CD2, H, D, O, OD, CD3CO, NULL,R2, R4, R6 independently representsWithin the proviso, Wherein n represents 0 to 12;R5 and R6 independently represents 6. A compound of formula VI:and pharmaceutically acceptable hydrates, solvates, prodrugs, enantiomers, and stereoisomers thereof;Wherein,R1, R3, R5 represents CD3, CD2, H, D, O, OD, CD3CO, NULL,R6 independently represents H, D, NULL,orWithin the proviso,Whereinn represents 0 to 12;R5 and R6 independently represents 7. A compound of formula VII:and pharmaceutically acceptable hydrates, solvates, prodrugs, enantiomers, and stereoisomers thereof;Wherein,R1, R3 represents CD3, CD2, H, D, O, OD, CD3CO, NULL,R2, R4 independently representsWithin the proviso,Whereinn represents 0 to 12;Rs and R6 independently representsor 8. A compound of formula VIII:and pharmaceutically acceptable hydrates, solvates, prodrugs, enantiomers, and stereoisomers thereof;Wherein,R1 represents CD3, CD2, H, D, O, OD, CD3CO, NULL,R2 independently representsWithin the proviso,Whereinn represents 0 to 12;R5 and R6 independently representsor 9. A Pharmaceutical composition comprising a compound of claim 1 and a pharmaceutically acceptable carrier. 10. A Pharmaceutical composition comprising a compound of claim 2 and a pharmaceutically acceptable carrier. 11. A Pharmaceutical composition comprising a compound of claim 3 and a pharmaceutically acceptable carrier. 12. A Pharmaceutical composition comprising a compound of claim 4 and a pharmaceutically acceptable carrier. 13. A Pharmaceutical composition comprising a compound of claim 5 and a pharmaceutically acceptable carrier. 14. A Pharmaceutical composition comprising a compound of claim 6 and a pharmaceutically acceptable carrier. 15. A Pharmaceutical composition comprising a compound of claim 7 and a pharmaceutically acceptable carrier. 16. A Pharmaceutical composition comprising a compound of claim 8 and a pharmaceutically acceptable carrier. 17. The pharmaceutical composition of claim 9, which is formulated to treat the underlying etiology with an effective amount administering the patient in need by oral administration, delayed release or sustained release, transmucosal, syrup, topical, parenteral administration, injection, subdermal, oral solution, rectal administration, buccal administration or transdermal administration. 18. The pharmaceutical composition of claim 10, which is formulated to treat the underlying etiology with an effective amount administering the patient in need by oral administration, delayed release or sustained release, transmucosal, syrup, topical, parenteral administration, injection, subdermal, oral solution, rectal administration, buccal administration or transdermal administration. 19. The pharmaceutical composition of claim 11, which is formulated to treat the underlying etiology with an effective amount administering the patient in need by oral administration, delayed release or sustained release, transmucosal, syrup, topical, parenteral administration, injection, subdermal, oral solution, rectal administration, buccal administration or transdermal administration. 20. The pharmaceutical composition of claim 12, which is formulated to treat the underlying etiology with an effective amount administering the patient in need by oral administration, delayed release or sustained release, transmucosal, syrup, topical, parenteral administration, injection, subdermal, oral solution, rectal administration, buccal administration or transdermal administration. 21. The pharmaceutical composition of claim 13, which is formulated to treat the underlying etiology with an effective amount administering the patient in need by oral administration, delayed release or sustained release, transmucosal, syrup, topical, parenteral administration, injection, subdermal, oral solution, rectal administration, buccal administration or transdermal administration. 22. The pharmaceutical composition of claim 14, which is formulated to treat the underlying etiology with an effective amount administering the patient in need by oral administration, delayed release or sustained release, transmucosal, syrup, topical, parenteral administration, injection, subdermal, oral solution, rectal administration, buccal administration or transdermal administration. 23. The pharmaceutical composition of claim 15, which is formulated to treat the underlying etiology with an effective amount administering the patient in need by oral administration, delayed release or sustained release, transmucosal, syrup, topical, parenteral administration, injection, subdermal, oral solution, rectal administration, buccal administration or transdermal administration. 24. The pharmaceutical composition of claim 16, which is formulated to treat the underlying etiology with an effective amount administering the patient in need by oral administration, delayed release or sustained release, transmucosal, syrup, topical, parenteral administration, injection, subdermal, oral solution, rectal administration, buccal administration or transdermal administration. 25. Compounds and compositions of claim 17 are formulated for the treatment of colorectal cancer, breast cancer (metastatic or as monotherapy/combotherapy), gastric cancer, oesophageal cancer, anal, breast, colorectal, oesophageal, stomach, pancreatic and skin cancers (especially head and neck cancers), actinic keratoses, skin cancers, Bowen's disease, fungal infections, candidiasis and oral infectious diseases. 26. Compounds and compositions of claim 18 are formulated for the treatment of colorectal cancer, breast cancer (metastatic or as monotherapy/combotherapy), gastric cancer, oesophageal cancer, anal, breast, colorectal, oesophageal, stomach, pancreatic and skin cancers (especially head and neck cancers), actinic keratoses, skin cancers, Bowen's disease, fungal infections, candidiasis and oral infectious diseases. 27. Compounds and compositions of claim 19 are formulated for the treatment of colorectal cancer, breast cancer (metastatic or as monotherapy/combotherapy), gastric cancer, oesophageal cancer, anal, breast, colorectal, oesophageal, stomach, pancreatic and skin cancers (especially head and neck cancers), actinic keratoses, skin cancers, Bowen's disease, fungal infections, candidiasis and oral infectious diseases. 28. Compounds and compositions of claim 20 are formulated for the treatment of colorectal cancer, breast cancer (metastatic or as monotherapy/combotherapy), gastric cancer, oesophageal cancer, anal, breast, colorectal, oesophageal, stomach, pancreatic and skin cancers (especially head and neck cancers), actinic keratoses, skin cancers, Bowen's disease, fungal infections, candidiasis and oral infectious diseases. 29. Compounds and compositions of claim 21 are formulated for the treatment of colorectal cancer, breast cancer (metastatic or as monotherapy/combotherapy), gastric cancer, oesophageal cancer, anal, breast, colorectal, oesophageal, stomach, pancreatic and skin cancers (especially head and neck cancers), actinic keratoses, skin cancers, Bowen's disease, fungal infections, candidiasis and oral infectious diseases. 30. Compounds and compositions of claim 22 are formulated for the treatment of colorectal cancer, breast cancer (metastatic or as monotherapy/combotherapy), gastric cancer, oesophageal cancer, anal, breast, colorectal, oesophageal, stomach, pancreatic and skin cancers (especially head and neck cancers), actinic keratoses, skin cancers, Bowen's disease, fungal infections, candidiasis and oral infectious diseases. 31. Compounds and compositions of claim 23 are formulated for the treatment of colorectal cancer, breast cancer (metastatic or as monotherapy/combotherapy), gastric cancer, oesophageal cancer, anal, breast, colorectal, oesophageal, stomach, pancreatic and skin cancers (especially head and neck cancers), actinic keratoses, skin cancers, Bowen's disease, fungal infections, candidiasis and oral infectious diseases. 32. Compounds and compositions of claim 24 are formulated for the treatment of colorectal cancer, breast cancer (metastatic or as monotherapy/combotherapy), gastric cancer, oesophageal cancer, anal, breast, colorectal, oesophageal, stomach, pancreatic and skin cancers (especially head and neck cancers), actinic keratoses, skin cancers, Bowen's disease, fungal infections, candidiasis and oral infectious diseases. | treatment of cancer and infectious diseases may be formulated for oral, buccal, rectal, topical, transdermal, transmucosal, lozenge, spray, intravenous, oral solution, buccal mucosal layer tablet, parenteral administration, syrup, or injection. Such compositions may be used to treatment of cancer, neoplasm, infections and skin diseases. |  |
| 196 | **IN201918031170** | 2019 |  | Top of Form  1. A compound of formula I:and pharmaceutically acceptable hydrates, solvates, prodrugs, enantiomers, and stereoisomers thereof;Wherein,R1, R3 represents CD3, CD2, H, D, O, OD, CD3CO, NULL,R2, R4 independently representsWithin the proviso, Wherein n represents 0 to 12;R5 and R6 independently representsor 2. A compound of formula II:and pharmaceutically acceptable hydrates, solvates, prodrugs, enantiomers, and stereoisomers thereof;Wherein,R1, R3 represents CD3, CD2, H, D, O, OD, CD3CO, NULL,R2, R4 independently representsWithin the proviso, Wherein n represents 0 to 12;R5 and R6 independently represents 3. A compound of formula III:and pharmaceutically acceptable hydrates, solvates, prodrugs, enantiomers, and stereoisomers thereof;Wherein,R1, R3, R5 represents CD3, CD2, H, D, O, OD, CD3CO, NULL,R2, R4 independently representsorWithin the proviso, Wherein n represents 0 to 12;R6 independently represents NULL, 4. A compound of formula IV:and pharmaceutically acceptable hydrates, solvates, prodrugs, enantiomers, and stereoisomers thereof;Wherein,R1, R3, R5, R7 represents CD3, CD2, H, D, O, OD, CD3CO, NULL,R2, R4, R6, R8 independently representsWithin the proviso, Wherein n represents 0 to 12;R5 and R6 independently representsor 5. A compound of formula V:and pharmaceutically acceptable hydrates, solvates, prodrugs, enantiomers, and stereoisomers thereof;Wherein,R1, R3, R5 represents CD3, CD2, H, D, O, OD, CD3CO, NULL,R2, R4, R6 independently representsWithin the proviso, Wherein n represents 0 to 12;R5 and R6 independently represents 6. A compound of formula VI:and pharmaceutically acceptable hydrates, solvates, prodrugs, enantiomers, and stereoisomers thereof;Wherein,R1, R3, R5 represents CD3, CD2, H, D, O, OD, CD3CO, NULL,R6 independently represents H, D, NULL,orWithin the proviso,Whereinn represents 0 to 12;R5 and R6 independently represents 7. A compound of formula VII:and pharmaceutically acceptable hydrates, solvates, prodrugs, enantiomers, and stereoisomers thereof;Wherein,R1, R3 represents CD3, CD2, H, D, O, OD, CD3CO, NULL,R2, R4 independently representsWithin the proviso,Whereinn represents 0 to 12;Rs and R6 independently representsor 8. A compound of formula VIII:and pharmaceutically acceptable hydrates, solvates, prodrugs, enantiomers, and stereoisomers thereof;Wherein,R1 represents CD3, CD2, H, D, O, OD, CD3CO, NULL,R2 independently representsWithin the proviso,Whereinn represents 0 to 12;R5 and R6 independently representsor 9. A Pharmaceutical composition comprising a compound of claim 1 and a pharmaceutically acceptable carrier. 10. A Pharmaceutical composition comprising a compound of claim 2 and a pharmaceutically acceptable carrier. 11. A Pharmaceutical composition comprising a compound of claim 3 and a pharmaceutically acceptable carrier. 12. A Pharmaceutical composition comprising a compound of claim 4 and a pharmaceutically acceptable carrier. 13. A Pharmaceutical composition comprising a compound of claim 5 and a pharmaceutically acceptable carrier. 14. A Pharmaceutical composition comprising a compound of claim 6 and a pharmaceutically acceptable carrier. 15. A Pharmaceutical composition comprising a compound of claim 7 and a pharmaceutically acceptable carrier. 16. A Pharmaceutical composition comprising a compound of claim 8 and a pharmaceutically acceptable carrier. 17. The pharmaceutical composition of claim 9, which is formulated to treat the underlying etiology with an effective amount administering the patient in need by oral administration, delayed release or sustained release, transmucosal, syrup, topical, parenteral administration, injection, subdermal, oral solution, rectal administration, buccal administration or transdermal administration. 18. The pharmaceutical composition of claim 10, which is formulated to treat the underlying etiology with an effective amount administering the patient in need by oral administration, delayed release or sustained release, transmucosal, syrup, topical, parenteral administration, injection, subdermal, oral solution, rectal administration, buccal administration or transdermal administration. 19. The pharmaceutical composition of claim 11, which is formulated to treat the underlying etiology with an effective amount administering the patient in need by oral administration, delayed release or sustained release, transmucosal, syrup, topical, parenteral administration, injection, subdermal, oral solution, rectal administration, buccal administration or transdermal administration. 20. The pharmaceutical composition of claim 12, which is formulated to treat the underlying etiology with an effective amount administering the patient in need by oral administration, delayed release or sustained release, transmucosal, syrup, topical, parenteral administration, injection, subdermal, oral solution, rectal administration, buccal administration or transdermal administration. 21. The pharmaceutical composition of claim 13, which is formulated to treat the underlying etiology with an effective amount administering the patient in need by oral administration, delayed release or sustained release, transmucosal, syrup, topical, parenteral administration, injection, subdermal, oral solution, rectal administration, buccal administration or transdermal administration. 22. The pharmaceutical composition of claim 14, which is formulated to treat the underlying etiology with an effective amount administering the patient in need by oral administration, delayed release or sustained release, transmucosal, syrup, topical, parenteral administration, injection, subdermal, oral solution, rectal administration, buccal administration or transdermal administration. 23. The pharmaceutical composition of claim 15, which is formulated to treat the underlying etiology with an effective amount administering the patient in need by oral administration, delayed release or sustained release, transmucosal, syrup, topical, parenteral administration, injection, subdermal, oral solution, rectal administration, buccal administration or transdermal administration. 24. The pharmaceutical composition of claim 16, which is formulated to treat the underlying etiology with an effective amount administering the patient in need by oral administration, delayed release or sustained release, transmucosal, syrup, topical, parenteral administration, injection, subdermal, oral solution, rectal administration, buccal administration or transdermal administration. 25. Compounds and compositions of claim 17 are formulated for the treatment of colorectal cancer, breast cancer (metastatic or as monotherapy/combotherapy), gastric cancer, oesophageal cancer, anal, breast, colorectal, oesophageal, stomach, pancreatic and skin cancers (especially head and neck cancers), actinic keratoses, skin cancers, Bowen's disease, fungal infections, candidiasis and oral infectious diseases. 26. Compounds and compositions of claim 18 are formulated for the treatment of colorectal cancer, breast cancer (metastatic or as monotherapy/combotherapy), gastric cancer, oesophageal cancer, anal, breast, colorectal, oesophageal, stomach, pancreatic and skin cancers (especially head and neck cancers), actinic keratoses, skin cancers, Bowen's disease, fungal infections, candidiasis and oral infectious diseases. 27. Compounds and compositions of claim 19 are formulated for the treatment of colorectal cancer, breast cancer (metastatic or as monotherapy/combotherapy), gastric cancer, oesophageal cancer, anal, breast, colorectal, oesophageal, stomach, pancreatic and skin cancers (especially head and neck cancers), actinic keratoses, skin cancers, Bowen's disease, fungal infections, candidiasis and oral infectious diseases. 28. Compounds and compositions of claim 20 are formulated for the treatment of colorectal cancer, breast cancer (metastatic or as monotherapy/combotherapy), gastric cancer, oesophageal cancer, anal, breast, colorectal, oesophageal, stomach, pancreatic and skin cancers (especially head and neck cancers), actinic keratoses, skin cancers, Bowen's disease, fungal infections, candidiasis and oral infectious diseases. 29. Compounds and compositions of claim 21 are formulated for the treatment of colorectal cancer, breast cancer (metastatic or as monotherapy/combotherapy), gastric cancer, oesophageal cancer, anal, breast, colorectal, oesophageal, stomach, pancreatic and skin cancers (especially head and neck cancers), actinic keratoses, skin cancers, Bowen's disease, fungal infections, candidiasis and oral infectious diseases. 30. Compounds and compositions of claim 22 are formulated for the treatment of colorectal cancer, breast cancer (metastatic or as monotherapy/combotherapy), gastric cancer, oesophageal cancer, anal, breast, colorectal, oesophageal, stomach, pancreatic and skin cancers (especially head and neck cancers), actinic keratoses, skin cancers, Bowen's disease, fungal infections, candidiasis and oral infectious diseases. 31. Compounds and compositions of claim 23 are formulated for the treatment of colorectal cancer, breast cancer (metastatic or as monotherapy/combotherapy), gastric cancer, oesophageal cancer, anal, breast, colorectal, oesophageal, stomach, pancreatic and skin cancers (especially head and neck cancers), actinic keratoses, skin cancers, Bowen's disease, fungal infections, candidiasis and oral infectious diseases. 32. Compounds and compositions of claim 24 are formulated for the treatment of colorectal cancer, breast cancer (metastatic or as monotherapy/combotherapy), gastric cancer, oesophageal cancer, anal, breast, colorectal, oesophageal, stomach, pancreatic and skin cancers (especially head and neck cancers), actinic keratoses, skin cancers, Bowen's disease, fungal infections, candidiasis and oral infectious diseases.  Bottom of Form | treatment of cancer and infectious diseases may be formulated for oral, buccal, rectal, topical, transdermal, transmucosal, lozenge, spray, intravenous, oral solution, buccal mucosal layer tablet, parenteral administration, syrup, or injection. Such compositions may be used to treatment of cancer, neoplasm, infections and skin diseases. |  |
| 197 | **IN201918031167** | 2019 |  | 1. A compound of formula I:and pharmaceutically acceptable hydrates, solvates, prodrugs, enantiomers, and stereoisomers thereof;Wherein,R1, R3 represents CD3, CD2, H, D, O, OD, CD3CO, NULL,R2, R4 independently representsWithin the proviso, Wherein n represents 0 to 12;R5 and R6 independently representsor 2. A compound of formula II:and pharmaceutically acceptable hydrates, solvates, prodrugs, enantiomers, and stereoisomers thereof;Wherein,R1, R3 represents CD3, CD2, H, D, O, OD, CD3CO, NULL,R2, R4 independently representsWithin the proviso, Wherein n represents 0 to 12;R5 and R6 independently represents 3. A compound of formula III:and pharmaceutically acceptable hydrates, solvates, prodrugs, enantiomers, and stereoisomers thereof;Wherein,R1, R3, R5 represents CD3, CD2, H, D, O, OD, CD3CO, NULL,R2, R4 independently representsorWithin the proviso, Wherein n represents 0 to 12;R6 independently represents NULL, 4. A compound of formula IV:and pharmaceutically acceptable hydrates, solvates, prodrugs, enantiomers, and stereoisomers thereof;Wherein,R1, R3, R5, R7 represents CD3, CD2, H, D, O, OD, CD3CO, NULL,R2, R4, R6, R8 independently representsWithin the proviso, Wherein n represents 0 to 12;R5 and R6 independently representsor 5. A compound of formula V:and pharmaceutically acceptable hydrates, solvates, prodrugs, enantiomers, and stereoisomers thereof;Wherein,R1, R3, R5 represents CD3, CD2, H, D, O, OD, CD3CO, NULL,R2, R4, R6 independently representsWithin the proviso, Wherein n represents 0 to 12;R5 and R6 independently represents 6. A compound of formula VI:and pharmaceutically acceptable hydrates, solvates, prodrugs, enantiomers, and stereoisomers thereof;Wherein,R1, R3, R5 represents CD3, CD2, H, D, O, OD, CD3CO, NULL,R6 independently represents H, D, NULL,orWithin the proviso,Whereinn represents 0 to 12;R5 and R6 independently represents 7. A compound of formula VII:and pharmaceutically acceptable hydrates, solvates, prodrugs, enantiomers, and stereoisomers thereof;Wherein,R1, R3 represents CD3, CD2, H, D, O, OD, CD3CO, NULL,R2, R4 independently representsWithin the proviso,Whereinn represents 0 to 12;Rs and R6 independently representsor 8. A compound of formula VIII:and pharmaceutically acceptable hydrates, solvates, prodrugs, enantiomers, and stereoisomers thereof;Wherein,R1 represents CD3, CD2, H, D, O, OD, CD3CO, NULL,R2 independently representsWithin the proviso,Whereinn represents 0 to 12;R5 and R6 independently representsor 9. A Pharmaceutical composition comprising a compound of claim 1 and a pharmaceutically acceptable carrier. 10. A Pharmaceutical composition comprising a compound of claim 2 and a pharmaceutically acceptable carrier. 11. A Pharmaceutical composition comprising a compound of claim 3 and a pharmaceutically acceptable carrier. 12. A Pharmaceutical composition comprising a compound of claim 4 and a pharmaceutically acceptable carrier. 13. A Pharmaceutical composition comprising a compound of claim 5 and a pharmaceutically acceptable carrier. 14. A Pharmaceutical composition comprising a compound of claim 6 and a pharmaceutically acceptable carrier. 15. A Pharmaceutical composition comprising a compound of claim 7 and a pharmaceutically acceptable carrier. 16. A Pharmaceutical composition comprising a compound of claim 8 and a pharmaceutically acceptable carrier. 17. The pharmaceutical composition of claim 9, which is formulated to treat the underlying etiology with an effective amount administering the patient in need by oral administration, delayed release or sustained release, transmucosal, syrup, topical, parenteral administration, injection, subdermal, oral solution, rectal administration, buccal administration or transdermal administration. 18. The pharmaceutical composition of claim 10, which is formulated to treat the underlying etiology with an effective amount administering the patient in need by oral administration, delayed release or sustained release, transmucosal, syrup, topical, parenteral administration, injection, subdermal, oral solution, rectal administration, buccal administration or transdermal administration. 19. The pharmaceutical composition of claim 11, which is formulated to treat the underlying etiology with an effective amount administering the patient in need by oral administration, delayed release or sustained release, transmucosal, syrup, topical, parenteral administration, injection, subdermal, oral solution, rectal administration, buccal administration or transdermal administration. 20. The pharmaceutical composition of claim 12, which is formulated to treat the underlying etiology with an effective amount administering the patient in need by oral administration, delayed release or sustained release, transmucosal, syrup, topical, parenteral administration, injection, subdermal, oral solution, rectal administration, buccal administration or transdermal administration. 21. The pharmaceutical composition of claim 13, which is formulated to treat the underlying etiology with an effective amount administering the patient in need by oral administration, delayed release or sustained release, transmucosal, syrup, topical, parenteral administration, injection, subdermal, oral solution, rectal administration, buccal administration or transdermal administration. 22. The pharmaceutical composition of claim 14, which is formulated to treat the underlying etiology with an effective amount administering the patient in need by oral administration, delayed release or sustained release, transmucosal, syrup, topical, parenteral administration, injection, subdermal, oral solution, rectal administration, buccal administration or transdermal administration. 23. The pharmaceutical composition of claim 15, which is formulated to treat the underlying etiology with an effective amount administering the patient in need by oral administration, delayed release or sustained release, transmucosal, syrup, topical, parenteral administration, injection, subdermal, oral solution, rectal administration, buccal administration or transdermal administration. 24. The pharmaceutical composition of claim 16, which is formulated to treat the underlying etiology with an effective amount administering the patient in need by oral administration, delayed release or sustained release, transmucosal, syrup, topical, parenteral administration, injection, subdermal, oral solution, rectal administration, buccal administration or transdermal administration. 25. Compounds and compositions of claim 17 are formulated for the treatment of colorectal cancer, breast cancer (metastatic or as monotherapy/combotherapy), gastric cancer, oesophageal cancer, anal, breast, colorectal, oesophageal, stomach, pancreatic and skin cancers (especially head and neck cancers), actinic keratoses, skin cancers, Bowen's disease, fungal infections, candidiasis and oral infectious diseases. 26. Compounds and compositions of claim 18 are formulated for the treatment of colorectal cancer, breast cancer (metastatic or as monotherapy/combotherapy), gastric cancer, oesophageal cancer, anal, breast, colorectal, oesophageal, stomach, pancreatic and skin cancers (especially head and neck cancers), actinic keratoses, skin cancers, Bowen's disease, fungal infections, candidiasis and oral infectious diseases. 27. Compounds and compositions of claim 19 are formulated for the treatment of colorectal cancer, breast cancer (metastatic or as monotherapy/combotherapy), gastric cancer, oesophageal cancer, anal, breast, colorectal, oesophageal, stomach, pancreatic and skin cancers (especially head and neck cancers), actinic keratoses, skin cancers, Bowen's disease, fungal infections, candidiasis and oral infectious diseases. 28. Compounds and compositions of claim 20 are formulated for the treatment of colorectal cancer, breast cancer (metastatic or as monotherapy/combotherapy), gastric cancer, oesophageal cancer, anal, breast, colorectal, oesophageal, stomach, pancreatic and skin cancers (especially head and neck cancers), actinic keratoses, skin cancers, Bowen's disease, fungal infections, candidiasis and oral infectious diseases. 29. Compounds and compositions of claim 21 are formulated for the treatment of colorectal cancer, breast cancer (metastatic or as monotherapy/combotherapy), gastric cancer, oesophageal cancer, anal, breast, colorectal, oesophageal, stomach, pancreatic and skin cancers (especially head and neck cancers), actinic keratoses, skin cancers, Bowen's disease, fungal infections, candidiasis and oral infectious diseases. 30. Compounds and compositions of claim 22 are formulated for the treatment of colorectal cancer, breast cancer (metastatic or as monotherapy/combotherapy), gastric cancer, oesophageal cancer, anal, breast, colorectal, oesophageal, stomach, pancreatic and skin cancers (especially head and neck cancers), actinic keratoses, skin cancers, Bowen's disease, fungal infections, candidiasis and oral infectious diseases. 31. Compounds and compositions of claim 23 are formulated for the treatment of colorectal cancer, breast cancer (metastatic or as monotherapy/combotherapy), gastric cancer, oesophageal cancer, anal, breast, colorectal, oesophageal, stomach, pancreatic and skin cancers (especially head and neck cancers), actinic keratoses, skin cancers, Bowen's disease, fungal infections, candidiasis and oral infectious diseases. 32. Compounds and compositions of claim 24 are formulated for the treatment of colorectal cancer, breast cancer (metastatic or as monotherapy/combotherapy), gastric cancer, oesophageal cancer, anal, breast, colorectal, oesophageal, stomach, pancreatic and skin cancers (especially head and neck cancers), actinic keratoses, skin cancers, Bowen's disease, fungal infections, candidiasis and oral infectious diseases. | treatment of cancer and infectious diseases may be formulated for oral, buccal, rectal, topical, transdermal, transmucosal, lozenge, spray, intravenous, oral solution, buccal mucosal layer tablet, parenteral administration, syrup, or injection. Such compositions may be used to treatment of cancer, neoplasm, infections and skin diseases. |  |
| 198 | **AU2019214557** | 2019 |  | 1. A pharmaceutical composition comprising:  a) a therapeutically effective amount of an antimuscarinic or an anticholinergic agent or a pharmaceutically acceptable salt or a stereoisomer thereof; and  b) a therapeutically effective amount of lipoic acid or a pharmaceutically acceptable salt or stereoisomer or prodrug thereof  2. The pharmaceutical composition as claimed in claim 1, wherein the antimuscarinic or anticholinergic agent is selected from a compound of Formula I:    Formula I  or a pharmaceutically acceptable salt or a stereoisomer thereof, wherein  RH  , hydrochloric acid, 1-hydroxy-2-naphthoic acid, 2,2-dichloroacetic acid, 2-hydroxyethanesulfonic acid, 2-oxoglutaric acid, 4 acetamidobenzoic acid, 4-aminosalicylic acid, acetic acid, adipic acid, ascorbic acid, aspartic acid, benzenesulfonic acid, benzoic acid, camphoric acid, camphor-O-sulfonic acid, capric acid (decanoic acid), caproic acid (hexanoic acid), carbonic acid, cinnamic acid, citric acid, cyclamic acid, dodecylsulfuric acid, ethane-1,2-disulfonic acid, ethanesulfonic acid, formic acid, fumaric acid, galactaric acid, gentisic acid, glucoheptonic acid, gluconic acid, glucuronic acid, glutamic acid, glutaric acid, glycerophosphoric acid, glycolic acid, hippuric acid, hydrobromic acid, isobutyric acid, lactic acid, lactobionic acid, lauric acid, maleic acid, malic acid, malonic acid, mandelic acid, methanesulfonic acid, naphthalene-1,5-disulfonic acid, naphthalene-2-sulfonic acid, nicotinic acid, nitric acid, oleic acid, oxalic acid, palmitic acid, pamoic acid, phosphoric acid, proprionic acid, pyroglutamic acid, salicylic acid, sebacic acid, stearic acid, succinic acid, sulfuric acid, tartaric acid, thiocyanic acid, toluenesulfonic acid, undecylenic acid, omega 3 fatty acids, omega 6 fatty acids, n-acetyl cysteine (nac), furoate, methyl furoate, ethyl furoate, aminocaproic acid, caproic acid, caprilic acid, capric acid, lauric acid, alpha lipoic acid, R-lipoic acid, myristic acid, myristoleic acid, palmitic acid, palmitoleic acid, stearic acid, oleic acid, elaidic acid, linoleic acid, linolenic acid, linolelaidic acid or arachidonic acid;  a compound of Formula II:    Formula II  or a pharmaceutically acceptable salt or stereoisomer thereof, wherein,  RH  , hydrochloric acid, 1-hydroxy-2-naphthoic acid, 2,2-dichloroacetic acid, 2-hydroxyethanesulfonic acid, 2-oxoglutaric acid, 4 acetamidobenzoic acid, 4-aminosalicylic acid, acetic acid, adipic acid, ascorbic acid, aspartic acid, benzenesulfonic acid, benzoic acid, camphoric acid, camphor-I0-sulfonic acid, capric acid (decanoic acid), caproic acid (hexanoic acid), carbonic acid, cinnamic acid, citric acid, cyclamic acid, dodecylsulfuric acid, ethane-1,2-disulfonic acid, ethanesulfonic acid, formic acid, fumaric acid, galactaric acid, gentisic acid, glucoheptonic acid, gluconic acid , glucuronic acid, glutamic acid, glutaric acid, glycerophosphoric acid, glycolic acid, hippuric acid, hydrobromic acid, isobutyric acid, lactic acid, lactobionic acid, lauric acid, maleic acid, malic acid, malonic acid, mandelic acid, methanesulfonic acid, naphthalene-1,5-disulfonic acid, naphthalene-2-sulfonic acid, nicotinic acid, nitric acid, oleic acid, oxalic acid, palmitic acid, pamoic acid, phosphoric acid, proprionic acid, pyroglutamic acid, salicylic acid, sebacic acid, stearic acid, succinic acid, sulfuric acid, tartaric acid, thiocyanic acid, toluenesulfonic acid, undecylenic acid, omega 3 fatty acids, omega 6 fatty acids, n-acetyl cysteine (nac), furoate, methyl furoate, ethyl furoate, aminocaproic acid, caproic acid, caprilic acid, capric acid, lauric acid, alpha lipoic acid, R-lipoic acid, myristic acid, myristoleic acid, palmitic acid, palmitoleic acid, stearic acid, oleic acid, elaidic acid, linoleic acid, linolenic acid, linolelaidic acid or arachidonic acid; or  a compound of Formula III:    Formula III  or a pharmaceutically acceptable salt or a stereoisomer thereof; wherein,  RH  , hydrochloric acid, 1-hydroxy-2-naphthoic acid, 2,2-dichloroacetic acid, 2-hydroxyethanesulfonic acid, 2-oxoglutaric acid, 4 acetamidobenzoic acid, 4-aminosalicylic acid, acetic acid, adipic acid, ascorbic acid, aspartic acid, benzenesulfonic acid, benzoic acid, camphoric acid, camphor-0-sulfonic acid, capric acid (decanoic acid), caproic acid (hexanoic acid), carbonic acid, cinnamic acid, citric acid, cyclamic acid, dodecylsulfuric acid, ethane-1,2-disulfonic acid, ethanesulfonic acid, formic acid, fumaric acid, galactaric acid, gentisic acid, glucoheptonic acid, gluconic acid , glucuronic acid, glutamic acid, glutaric acid, glycerophosphoric acid, glycolic acid, hippuric acid, hydrobromic acid, isobutyric acid, lactic acid, lactobionic acid, lauric acid, maleic acid, malic acid, malonic acid, mandelic acid, methanesulfonic acid, naphthalene-1,5-disulfonic acid, naphthalene-2-sulfonic acid, nicotinic acid, nitric acid, oleic acid, oxalic acid, palmitic acid, pamoic acid, phosphoric acid, proprionic acid, pyroglutamic acid, salicylic acid, sebacic acid, stearic acid, succinic acid, sulfuric acid, tartaric acid, thiocyanic acid, toluenesulfonic acid, undecylenic acid, omega 3 fatty acids, omega 6 fatty acids, n-acetyl cysteine (nac), furoate, methyl furoate, ethyl furoate, aminocaproic acid, caproic acid, caprilic acid, capric acid, lauric acid, alpha lipoic acid, R-lipoic acid, myristic acid, myristoleic acid, palmitic acid, palmitoleic acid, stearic acid, oleic acid, elaidic ascid, linoleic acid, linolenic acid, linolelaidic acid or arachidonic acid.  3.    The pharmaceutical composition as claimed in claim 1, wherein the lipoic acid is a compound of Formula IV:    Formula IV  or a pharmaceutically acceptable salt or stereoisomer thereof; wherein,  RH is null, H, sodium, potassium, magnesium, calcium, arginine, glutamate, lysine, glycine, proline, pyridoxine, pyridoxamine, choline, taurine, malic acid, PHMB, polyhexanide or guanidine; or  the lipoic acid prodrug is choline ester prodrug compound of Formula V:    Formula V  or a pharmaceutically acceptable salt or a stereoisomer thereof; wherein,  RH is H, chloride, iodine, glutamic acid, aspartic acid, lysine, ketorolac, ketoprofen, naproxen, bromine, diclofenac, nepafenac, bromfenac or glycine.  4.    The pharmaceutical composition as claimed in claim 1, wherein the antimuscarinic or an anticholinergic agent or pharmaceutically acceptable salt or a stereoisomer thereof, is present in a therapeutically effective dose range of 0.1 mg to 200 mg.  5.    The pharmaceutical composition as claimed in claim 1, wherein the lipoic acid or a pharmaceutically acceptable salt or a stereoisomer thereof, is present in a dose of from 10 mg to 2 g.  6.    The pharmaceutical composition as claimed in claim 1, wherein the effective dose of the compounds is in the range of about 0.01 mg/kg body weight/day to about 100 mg/kg body weight/day.  7.    A physical mixture comprising a therapeutically effective amount of an antimuscarinic or an anticholinergic agent or a pharmaceutically acceptable salt or a stereoisomer thereof; and a therapeutically effective amount of lipoic acid or a pharmaceutically acceptable salt or stereoisomer or prodrug thereof  8.    The physical mixture as claimed in claim 7, wherein the antimuscarinic or anticholinergic agent is selected from a compound of Formula I:    Formula I  or a pharmaceutically acceptable salt or a stereoisomer thereof, wherein  RH  , hydrochloric acid, 1-hydroxy-2-naphthoic acid, 2,2-dichloroacetic acid, 2-hydroxyethanesulfonic acid, 2-oxoglutaric acid, 4 acetamidobenzoic acid, 4-aminosalicylic acid, acetic acid, adipic acid, ascorbic acid, aspartic acid, benzenesulfonic acid, benzoic acid, camphoric acid, camphor-I0-sulfonic acid, capric acid (decanoic acid), caproic acid (hexanoic acid), carbonic acid, cinnamic acid, citric acid, cyclamic acid, dodecylsulfuric acid, ethane-1,2-disulfonic acid, ethanesulfonic acid, formic acid, fumaric acid, galactaric acid, gentisic acid, glucoheptonic acid, gluconic acid, glucuronic acid, glutamic acid, glutaric acid, glycerophosphoric acid, glycolic acid, hippuric acid, hydrobromic acid, isobutyric acid, lactic acid, lactobionic acid, lauric acid, maleic acid, malic acid, malonic acid, mandelic acid, methanesulfonic acid, naphthalene-1,5-disulfonic acid, naphthalene-2-sulfonic acid, nicotinic acid, nitric acid, oleic acid, oxalic acid, palmitic acid, pamoic acid, phosphoric acid, proprionic acid, pyroglutamic acid, salicylic acid, sebacic acid, stearic acid, succinic acid, sulfuric acid, tartaric acid, thiocyanic acid, toluenesulfonic acid, undecylenic acid, omega 3 fatty acids, omega 6 fatty acids, n-acetyl cysteine (nac), furoate, methyl furoate, ethyl furoate, aminocaproic acid, caproic acid, caprilic acid, capric acid, lauric acid, alpha lipoic acid, R-lipoic acid, myristic acid, myristoleic acid, palmitic acid, palmitoleic acid, stearic acid, oleic acid, elaidic acid, linoleic acid, linolenic acid, linolelaidic acid or arachidonic acid;  a compound of Formula II:    Formula II  or a pharmaceutically acceptable salt or stereoisomer thereof, wherein,  RH  , hydrochloric acid, 1-hydroxy-2-naphthoic acid, 2,2-dichloroacetic acid, 2-hydroxyethanesulfonic acid, 2-oxoglutaric acid, 4 acetamidobenzoic acid, 4-aminosalicylic acid, acetic acid, adipic acid, ascorbic acid, aspartic acid, benzenesulfonic acid, benzoic acid, camphoric acid, camphor-0-sulfonic acid, capric acid (decanoic acid), caproic acid (hexanoic acid), carbonic acid, cinnamic acid, citric acid, cyclamic acid, dodecylsulfuric acid, ethane-1,2-disulfonic acid, ethanesulfonic acid, formic acid, fumaric acid, galactaric acid, gentisic acid, glucoheptonic acid, gluconic acid , glucuronic acid, glutamic acid, glutaric acid, glycerophosphoric acid, glycolic acid, hippuric acid, hydrobromic acid, isobutyric acid, lactic acid, lactobionic acid, lauric acid, maleic acid, malic acid, malonic acid, mandelic acid, methanesulfonic acid, naphthalene-1,5-disulfonic acid, naphthalene-2-sulfonic acid, nicotinic acid, nitric acid, oleic acid, oxalic acid, palmitic acid, pamoic acid, phosphoric acid, proprionic acid, pyroglutamic acid, salicylic acid, sebacic acid, stearic acid, succinic acid, sulfuric acid, tartaric acid, thiocyanic acid, toluenesulfonic acid, undecylenic acid, omega 3 fatty acids, omega 6 fatty acids, n-acetyl cysteine (nac), furoate, methyl furoate, ethyl furoate, aminocaproic acid, caproic acid, caprilic acid, capric acid, lauric acid, alpha lipoic acid, R-lipoic acid, myristic acid, myristoleic acid, palmitic acid, palmitoleic acid, stearic acid, oleic acid, elaidic acid, linoleic acid, linolenic acid, linolelaidic acid or arachidonic acid; or  a compound of Formula III:    Formula III  or a pharmaceutically acceptable salt or a stereoisomer thereof; wherein,  RH  , hydrochloric acid, 1-hydroxy-2-naphthoic acid, 2,2-dichloroacetic acid, 2-hydroxyethanesulfonic acid, 2-oxoglutaric acid, 4 acetamidobenzoic acid, 4-aminosalicylic acid, acetic acid, adipic acid, ascorbic acid, aspartic acid, benzenesulfonic acid, benzoic acid, camphoric acid, camphor-I0-sulfonic acid, capric acid (decanoic acid), caproic acid (hexanoic acid), carbonic acid, cinnamic acid, citric acid, cyclamic acid, dodecylsulfuric acid, ethane-1,2-disulfonic acid, ethanesulfonic acid, formic acid, fumaric acid, galactaric acid, gentisic acid, glucoheptonic acid, gluconic acid , glucuronic acid, glutamic acid, glutaric acid, glycerophosphoric acid, glycolic acid, hippuric acid, hydrobromic acid, isobutyric acid, lactic acid, lactobionic acid, lauric acid, maleic acid, malic acid, malonic acid, mandelic acid, methanesulfonic acid, naphthalene-1,5-disulfonic acid, naphthalene-2-sulfonic acid, nicotinic acid, nitric acid, oleic acid, oxalic acid, palmitic acid, pamoic acid, phosphoric acid, proprionic acid, pyroglutamic acid, salicylic acid, sebacic acid, stearic acid, succinic acid, sulfuric acid, tartaric acid, thiocyanic acid, toluenesulfonic acid, undecylenic acid, omega 3 fatty acids, omega 6 fatty acids, n-acetyl cysteine (nac), furoate, methyl furoate, ethyl furoate, aminocaproic acid, caproic acid, caprilic acid, capric acid, lauric acid, alpha lipoic acid, R-lipoic acid, myristic acid, myristoleic acid, palmitic acid, palmitoleic acid, stearic acid, oleic acid, elaidic acid, linoleic acid, linolenic acid, linolelaidic acid or arachidonic acid.  9.    The physical mixture as claimed in claim 7, wherein the lipoic acid is a compound of Formula IV:    Formula IV  or a pharmaceutically acceptable salt or stereoisomer thereof; wherein,  RH is null, H, sodium, potassium, magnesium, calcium, arginine, glutamate, lysine, glycine, proline, pyridoxine, pyridoxamine, choline, taurine, malic acid, PHMB, polyhexanide or guanidine; or  the lipoic acid prodrug is choline ester prodrug compound of Formula V:    Formula V  or a pharmaceutically acceptable salt or a stereoisomer thereof; wherein,  RH is H, chloride, iodine, glutamic acid, aspartic acid, lysine, ketorolac, ketoprofen, naproxen, bromine, diclofenac, nepafenac, bromfenac or glycine.  10.  The physical mixture of claim 7 comprising a compound of Formula I, and a compound of Formula IV or V.  11.  The physical mixture of claim 7 comprising a compound of Formula II, and a compound of Formula IV or V.  12.  The physical mixture of claim 7 comprising a compound of Formula III, and a compound of Formula IV or V  13.  The physical mixture of claim 10, wherein the compound of Formula I is pilocarpine HCl and the compound of Formula IV is R-(+)-Lipoic acid.  14.  A pharmaceutical composition comprising a compound of Formula I and a compound of Formula IV or a physical mixture thereof  15.  The pharmaceutical composition of claim 15, wherein compound of Formula I is present in a therapeutically effective dose range of 0.01 mg to 200 mg and the compound of Formula IV is present in a therapeutically effective dose range from 5 mg to 4 g.  16.  The pharmaceutical composition of claim 14, wherein the compound of Formula I is pilocarpine HCl and the compound of Formula IV is R-(+)-Lipoic acid or the physical mixture thereof.  17.  The pharmaceutical composition as claimed in any of claims 1-6 or 14-16 further comprising at least one pharmaceutically acceptable excipient.  18.  The composition as claimed in claim 17, wherein said composition is formulated for oral, nasal, dermal, ocular, topical, rectal, vaginal, aerosol or parenteral administration.  19.  The composition as claimed in claim 18, wherein said composition is for the treatment of xerostomia, and burning mouth syndrome or a complication thereof  20.  The composition as claimed in claim 18, wherein said composition is for the treatment of the ocular disease or disorder selected from the group consisting of presbyopia, glaucoma and its related conditions.  21.  A method of treating xerostomia and complication thereof in a subject of need thereof, the method comprising administering to said subject a therapeutically effective amount of the composition as claimed in any of claims any of claims 1-6 or 14-20. | The antimuscarinic or anticholinergic agent is a compound of Formula I, Formula II, or Formula III and lipoic acid is a compound of Formula IV or Formula V. The Pharmaceutical composition is a physical mixture of an antimuscarinic or an anticholinergic agent and lipoic acid. |  |
| 199 | **CA3089894** | 2019 |  | 1. A pharmaceutical composition comprising: a) a therapeutically effective amount of an antimuscarinic or an anticholinergic agent or a pharmaceutically acceptable salt or a stereoisomer thereof; and b) a therapeutically effective amount of lipoic acid or a pharmaceutically acceptable salt or stereoisomer or prodrug thereof.  2. The pharmaceutical composition as claimed in claim 1, wherein the antimuscarinic or anticholinergic agent is selected from a compound of Formula I:  ,s=s'  RH  Formula I or a pharmaceutically acceptable salt or a stereoisomer thereof, wherein  RH 1S  OH , hydrochloric acid, 1-hydroxy-2-naphthoic acid, 2,2-dichloroacetic acid, 2-hydroxyethanesulfonic acid, 2-oxoglutaric acid, 4acetamidobenzoic acid, 4-aminosalicylic acid, acetic acid, adipic acid, ascorbic acid, aspartic acid, benzenesulfonic acid, benzoic acid, camphoric acid, camphor-10sulfonic acid, capric acid (decanoic acid), caproic acid (hexanoic acid), carbonic acid, cinnamic acid, citric acid, cyclamic acid, dodecylsulfuric acid, ethane-1,2-disulfonic acid, ethanesulfonic acid, formic acid, fumaric acid, galactaric acid, gentisic acid, glucoheptonic acid, gluconic acid, glucuronic acid, glutamic acid, glutaric acid, glycerophosphoric acid, glycolic acid, hippuric acid, hydrobromic acid, isobutyric acid, lactic acid, lactobionic acid, lauric acid, maleic acid, malic acid, malonic acid, mandelic acid, methanesulfonic acid, naphthalene-1,5-disulfonic acid, naphthalene-2sulfonic acid, nicotinic acid, nitric acid, oleic acid, oxalic acid, palmitic acid, pamoic acid, phosphoric acid, proprionic acid, pyroglutamic acid, salicylic acid, sebacic acid, stearic acid, succinic acid, sulfuric acid, tartaric acid, thiocyanic acid, toluenesulfonic acid, undecylenic acid,  CA 03089894 2020-07-28  WO 2019/150341  PCT/IB2019/050901  omega 3 fatty acids, omega 6 fatty acids, n-acetyl cysteine (nac), furoate, methyl furoate, ethyl furoate, aminocaproic acid, caproic acid, caprilic acid, capric acid, lauric acid, alpha lipoic acid, R-lipoic acid, myristic acid, myristoleic acid, palmitic acid, palmitoleic acid, stearic acid, oleic acid, elaidic acid, linoleic acid, linolenic acid, linolelaidic acid or arachidonic acid; a compound of Formula II:  RH  Formula II or a pharmaceutically acceptable salt or stereoisomer thereof, wherein,  RH is OH , hydrochloric acid, 1 -hydroxy-2-naphthoic acid, 2,2-dichloroacetic acid, 2-hydroxyethanesulfonic acid, 2-oxoglutaric acid, 4acetamidobenzoic acid, 4-aminosalicylic acid, acetic acid, adipic acid, ascorbic acid, aspartic acid, benzenesulfonic acid, benzoic acid, camphoric acid, camphor-1 0sulfonic acid, capric acid (decanoic acid), caproic acid (hexanoic acid), carbonic acid, cinnamic acid, citric acid, cyclamic acid, dodecylsulfuric acid, ethane-1,2-disulfonic acid, ethanesulfonic acid, formic acid, fumaric acid, galactaric acid, gentisic acid, glucoheptonic acid, gluconic acid , glucuronic acid, glutamic acid, glutaric acid, glycerophosphoric acid, glycolic acid, hippuric acid, hydrobromic acid, isobutyric acid, lactic acid, lactobionic acid, lauric acid, maleic acid, malic acid, malonic acid, mandelic acid, methanesulfonic acid, naphthalene-1 ,5-disulfonic acid, naphthalene-2sulfonic acid, nicotinic acid, nitric acid, oleic acid, oxalic acid, palmitic acid, pamoic acid, phosphoric acid, proprionic acid, pyroglutamic acid, salicylic acid, sebacic acid, stearic acid, succinic acid, sulfuric acid, tartaric acid, thiocyanic acid, toluenesulfonic acid, undecylenic acid, omega 3 fatty acids, omega 6 fatty acids, n-acetyl cysteine (nac), furoate, methyl furoate, ethyl furoate, aminocaproic acid, caproic acid, caprilic acid, capric acid, lauric acid, alpha lipoic acid, R-lipoic acid, myristic acid, myristoleic acid, palmitic acid, palmitoleic acid,  CA 03089894 2020-07-28  WO 2019/150341  PCT/IB2019/050901  stearic acid, oleic acid, elaidic acid, linoleic acid, linolenic acid, linolelaidic acid or arachidonic acid; or a compound of Formula III:  RH  H 2 N N+  Formula III or a pharmaceutically acceptable salt or a stereoisomer thereof; wherein,  RH 1S  OH , hydrochloric acid, 1-hydroxy-2-naphthoic acid, 2,2-dichloroacetic acid, 2-hydroxyethanesulfonic acid, 2-oxoglutaric acid, 4acetamidobenzoic acid, 4-aminosalicylic acid, acetic acid, adipic acid, ascorbic acid, aspartic acid, benzenesulfonic acid, benzoic acid, camphoric acid, camphor-10sulfonic acid, capric acid (decanoic acid), caproic acid (hexanoic acid), carbonic acid, cinnamic acid, citric acid, cyclamic acid, dodecylsulfuric acid, ethane-1,2-disulfonic acid, ethanesulfonic acid, formic acid, fumaric acid, galactaric acid, gentisic acid, glucoheptonic acid, gluconic acid , glucuronic acid, glutamic acid, glutaric acid, glycerophosphoric acid, glycolic acid, hippuric acid, hydrobromic acid, isobutyric acid, lactic acid, lactobionic acid, lauric acid, maleic acid, malic acid, malonic acid, mandelic acid, methanesulfonic acid, naphthalene-1,5-disulfonic acid, naphthalene-2sulfonic acid, nicotinic acid, nitric acid, oleic acid, oxalic acid, palmitic acid, pamoic acid, phosphoric acid, proprionic acid, pyroglutamic acid, salicylic acid, sebacic acid, stearic acid, succinic acid, sulfuric acid, tartaric acid, thiocyanic acid, toluenesulfonic acid, undecylenic acid, omega 3 fatty acids, omega 6 fatty acids, n-acetyl cysteine (nac), furoate, methyl furoate, ethyl furoate, aminocaproic acid, caproic acid, caprilic acid, capric acid, lauric acid, alpha lipoic acid, R-lipoic acid, myristic acid, myristoleic acid, palmitic acid, palmitoleic acid, stearic acid, oleic acid, elaidic ascid, linoleic acid, linolenic acid, linolelaidic acid or arachidonic acid.  3. The pharmaceutical composition as claimed in claim 1, wherein the lipoic acid is a compound of Formula IV:  CA 03089894 2020-07-28  WO 2019/150341  PCT/IB2019/050901  SOW6/5  RH  Formula IV or a pharmaceutically acceptable salt or stereoisomer thereof; wherein,  RH is null, H, sodium, potassium, magnesium, calcium, arginine, glutamate, lysine, 5 glycine, proline, pyridoxine, pyridoxamine, choline, taurine, malic acid, PEIMB, polyhexanide or guanidine; or the lipoic acid prodrug is choline ester prodrug compound of Formula V:  CH3 +=  N \_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_  H' \  RH 0  Formula V 10 or a pharmaceutically acceptable salt or a stereoisomer thereof; wherein,  RH is H, chloride, iodine, glutamic acid, aspartic acid, lysine, ketorolac, ketoprofen, naproxen, bromine, diclofenac, nepafenac, bromfenac or glycine.  4. The pharmaceutical composition as claimed in claim 1, wherein the antimuscarinic or an 15 anticholinergic agent or pharmaceutically acceptable salt or a stereoisomer thereof, is present in a therapeutically effective dose range of 0.1 mg to 200 mg.  5. The pharmaceutical composition as claimed in claim 1, wherein the lipoic acid or a pharmaceutically acceptable salt or a stereoisomer thereof, is present in a dose of from 10 mg to 2 g. 20 6. The pharmaceutical composition as claimed in claim 1, wherein the effective dose of the compounds is in the range of about 0.01 mg/kg body weight/day to about 100 mg/kg body weight/day.  CA 03089894 2020-07-28  WO 2019/150341  PCT/IB2019/050901  7. A physical mixture comprising a therapeutically effective amount of an antimuscarinic or an anticholinergic agent or a pharmaceutically acceptable salt or a stereoisomer thereof; and a therapeutically effective amount of lipoic acid or a pharmaceutically acceptable salt or stereoisomer or prodrug thereof.  8. The physical mixture as claimed in claim 7, wherein the antimuscarinic or anticholinergic agent is selected from a compound of Formula I:  .%`  RH  Formula I or a pharmaceutically acceptable salt or a stereoisomer thereof, wherein  RH 1S OH , hydrochloric acid, 1-hydroxy-2-naphthoic acid, 2,2-dichloroacetic acid, 2-hydroxyethanesulfonic acid, 2-oxoglutaric acid, 4acetamidobenzoic acid, 4-aminosalicylic acid, acetic acid, adipic acid, ascorbic acid, aspartic acid, benzenesulfonic acid, benzoic acid, camphoric acid, camphor-10sulfonic acid, capric acid (decanoic acid), caproic acid (hexanoic acid), carbonic acid, cinnamic acid, citric acid, cyclamic acid, dodecylsulfuric acid, ethane-1,2-disulfonic acid, ethanesulfonic acid, formic acid, fumaric acid, galactaric acid, gentisic acid, glucoheptonic acid, gluconic acid, glucuronic acid, glutamic acid, glutaric acid, glycerophosphoric acid, glycolic acid, hippuric acid, hydrobromic acid, isobutyric acid, lactic acid, lactobionic acid, lauric acid, maleic acid, malic acid, malonic acid, mandelic acid, methanesulfonic acid, naphthalene-1,5-disulfonic acid, naphthalene-2sulfonic acid, nicotinic acid, nitric acid, oleic acid, oxalic acid, palmitic acid, pamoic acid, phosphoric acid, proprionic acid, pyroglutamic acid, salicylic acid, sebacic acid, stearic acid, succinic acid, sulfuric acid, tartaric acid, thiocyanic acid, toluenesulfonic acid, undecylenic acid, omega 3 fatty acids, omega 6 fatty acids, n-acetyl cysteine (nac), furoate, methyl furoate, ethyl furoate, aminocaproic acid, caproic acid, caprilic acid, capric acid, lauric acid, alpha  CA 03089894 2020-07-28  WO 2019/150341  PCT/IB2019/050901  lipoic acid, R-lipoic acid, myristic acid, myristoleic acid, palmitic acid, palmitoleic acid, stearic acid, oleic acid, elaidic acid, linoleic acid, linolenic acid, linolelaidic acid or arachidonic acid; a compound of Formula II: ,--s .õõiiiii  RH  Formula II or a pharmaceutically acceptable salt or stereoisomer thereof, wherein,  RH is  OH , hydrochloric acid, 1 -hydroxy-2-naphthoic acid, 2,2-dichloroacetic acid, 2-hydroxyethanesulfonic acid, 2-oxoglutaric acid, 4acetamidobenzoic acid, 4-aminosalicylic acid, acetic acid, adipic acid, ascorbic acid, aspartic acid, benzenesulfonic acid, benzoic acid, camphoric acid, camphor-1 0sulfonic acid, capric acid (decanoic acid), caproic acid (hexanoic acid), carbonic acid, cinnamic acid, citric acid, cyclamic acid, dodecylsulfuric acid, ethane-1,2-disulfonic acid, ethanesulfonic acid, formic acid, fumaric acid, galactaric acid, gentisic acid, glucoheptonic acid, gluconic acid , glucuronic acid, glutamic acid, glutaric acid, glycerophosphoric acid, glycolic acid, hippuric acid, hydrobromic acid, isobutyric acid, lactic acid, lactobionic acid, lauric acid, maleic acid, malic acid, malonic acid, mandelic acid, methanesulfonic acid, naphthalene-1 ,5-disulfonic acid, naphthalene-2sulfonic acid, nicotinic acid, nitric acid, oleic acid, oxalic acid, palmitic acid, pamoic acid, phosphoric acid, proprionic acid, pyroglutamic acid, salicylic acid, sebacic acid, stearic acid, succinic acid, sulfuric acid, tartaric acid, thiocyanic acid, toluenesulfonic acid, undecylenic acid, omega 3 fatty acids, omega 6 fatty acids, n-acetyl cysteine (nac), furoate, methyl furoate, ethyl furoate, aminocaproic acid, caproic acid, caprilic acid, capric acid, lauric acid, alpha lipoic acid, R-lipoic acid, myristic acid, myristoleic acid, palmitic acid, palmitoleic acid, stearic acid, oleic acid, elaidic acid, linoleic acid, linolenic acid, linolelaidic acid or arachidonic acid; or  CA 03089894 2020-07-28  WO 2019/150341  PCT/IB2019/050901  a compound of Formula III:  RH  H2N 0  Formula III or a pharmaceutically acceptable salt or a stereoisomer thereof; wherein,  RH is OH , hydrochloric acid, 1-hydroxy-2-naphthoic acid, 2,2-dichloroacetic acid, 2-hydroxyethanesulfonic acid, 2-oxoglutaric acid, 4acetamidobenzoic acid, 4-aminosalicylic acid, acetic acid, adipic acid, ascorbic acid, aspartic acid, benzenesulfonic acid, benzoic acid, camphoric acid, camphor-10sulfonic acid, capric acid (decanoic acid), caproic acid (hexanoic acid), carbonic acid, cinnamic acid, citric acid, cyclamic acid, dodecylsulfuric acid, ethane-1,2-disulfonic acid, ethanesulfonic acid, formic acid, fumaric acid, galactaric acid, gentisic acid, glucoheptonic acid, gluconic acid , glucuronic acid, glutamic acid, glutaric acid, glycerophosphoric acid, glycolic acid, hippuric acid, hydrobromic acid, isobutyric acid, lactic acid, lactobionic acid, lauric acid, maleic acid, malic acid, malonic acid, mandelic acid, methanesulfonic acid, naphthalene-1,5-disulfonic acid, naphthalene-2sulfonic acid, nicotinic acid, nitric acid, oleic acid, oxalic acid, palmitic acid, pamoic acid, phosphoric acid, proprionic acid, pyroglutamic acid, salicylic acid, sebacic acid, stearic acid, succinic acid, sulfuric acid, tartaric acid, thiocyanic acid, toluenesulfonic acid, undecylenic acid, omega 3 fatty acids, omega 6 fatty acids, n-acetyl cysteine (nac), furoate, methyl furoate, ethyl furoate, aminocaproic acid, caproic acid, caprilic acid, capric acid, lauric acid, alpha lipoic acid, R-lipoic acid, myristic acid, myristoleic acid, palmitic acid, palmitoleic acid, stearic acid, oleic acid, elaidic acid, linoleic acid, linolenic acid, linolelaidic acid or arachidonic acid.  9. The physical mixture as claimed in claim 7, wherein the lipoic acid is a compound of  Formula IV:  CA 03089894 2020-07-28  WO 2019/150341  PCT/IB2019/050901  RH  SOS  Formula IV or a pharmaceutically acceptable salt or stereoisomer thereof; wherein,  RH is null, H, sodium, potassium, magnesium, calcium, arginine, glutamate, lysine, glycine, proline, pyridoxine, pyridoxamine, choline, taurine, malic acid,  PEIMB, polyhexanide or guanidine; or the lipoic acid prodrug is choline ester prodrug compound of Formula V:  CH3 +=  N \_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_  H' \  RH 0  Formula V or a pharmaceutically acceptable salt or a stereoisomer thereof; wherein,  RH is H, chloride, iodine, glutamic acid, aspartic acid, lysine, ketorolac, ketoprofen, naproxen, bromine, diclofenac, nepafenac, bromfenac or glycine.  10. The physical mixture of claim 7 comprising a compound of Formula I, and a compound of Formula IV or V.  11. The physical mixture of claim 7 comprising a compound of Formula II, and a compound of Formula IV or V.  12. The physical mixture of claim 7 comprising a compound of Formula III, and a compound of Formula IV or V.  13. The physical mixture of claim 10, wherein the compound of Formula I is pilocarpine HC1 and the compound of Formula IV is R-(+)-Lipoic acid.  14. A pharmaceutical composition comprising a compound of Formula I and a compound of  Formula IV or a physical mixture thereof.  CA 03089894 2020-07-28  WO 2019/150341  PCT/IB2019/050901  15. The pharmaceutical composition of claim 15, wherein compound of Formula I is present in a therapeutically effective dose range of 0.01 mg to 200 mg and the compound of  Formula IV is present in a therapeutically effective dose range from 5 mg to 4 g.  16. The pharmaceutical composition of claim 14, wherein the compound of  Formula I is 5 pilocarpine HC1 and the compound of Formula IV is R-H-Lipoic acid or the physical mixture thereof.  17. The pharmaceutical composition as claimed in any of claims 1-6 or 14-16 further comprising at least one pharmaceutically acceptable excipient.  18. The composition as claimed in claim 17, wherein said composition is formulated for oral, 10 nasal, dermal, ocular, topical, rectal, vaginal, aerosol or parenteral administration.  19. The composition as claimed in claim 18, wherein said composition is for the treatment of xerostomia, and burning mouth syndrome or a complication thereof.  20. The composition as claimed in claim 18, wherein said composition is for the treatment of the ocular disease or disorder selected from the group consisting of presbyopia, glaucoma 15 and its related conditions.  21. A method of treating xerostomia and complication thereof in a subject of need thereof, the method comprising administering to said subject a therapeutically effective amount of the composition as claimed in any of claims any of claims 1-6 or 14-20. | The antimuscarinic or anticholinergic agent is a compound of Formula I, Formula II, or Formula III and lipoic acid is a compound of Formula IV or Formula V. The Pharmaceutical composition is a physical mixture of an antimuscarinic or an anticholinergic agent and lipoic acid. |  |
| 200 | **WO2019150341** | 2019 |  | 1. A pharmaceutical composition comprising:  a) a therapeutically effective amount of an antimuscarinic or an anticholinergic agent or a pharmaceutically acceptable salt or a stereoisomer thereof; and  b) a therapeutically effective amount of lipoic acid or a pharmaceutically acceptable salt or stereoisomer or prodrug thereof.  2. The pharmaceutical composition as claimed in claim 1, wherein the antimuscarinic or anticholinergic agent is selected from a compound of Formula I:    Formula I  or a pharmaceutically acceptable salt or a stereoisomer thereof, wherein  o  RH  hydrochloric acid, 1 -hydroxy-2-naphthoic acid,  2,2-dichloroacetic acid, 2-hydroxyethanesulfonic acid, 2-oxoglutaric acid, 4- acetamidobenzoic acid, 4-aminosalicylic acid, acetic acid, adipic acid, ascorbic acid, aspartic acid, benzenesulfonic acid, benzoic acid, camphoric acid, camphor- lO-sulfonic acid, capric acid (decanoic acid), caproic acid (hexanoic acid), carbonic acid, cinnamic acid, citric acid, cyclamic acid, dodecylsulfuric acid, ethane- l,2-disulfonic acid, ethanesulfonic acid, formic acid, fumaric acid, galactaric acid, gentisic acid, glucoheptonic acid, gluconic acid, glucuronic acid, glutamic acid, glutaric acid, glycerophosphoric acid, glycolic acid, hippuric acid, hydrobromic acid, isobutyric acid, lactic acid, lactobionic acid, lauric acid, maleic acid, malic acid, malonic acid, mandelic acid, methanesulfonic acid, naphthalene-l,5-disulfonic acid, naphthalene-2-sulfonic acid, nicotinic acid, nitric acid, oleic acid, oxalic acid, palmitic acid, pamoic acid, phosphoric acid, proprionic acid, pyroglutamic acid, salicylic acid, sebacic acid, stearic acid, succinic acid, sulfuric acid, tartaric acid, thiocyanic acid, toluenesulfonic acid, undecylenic acid, omega 3 fatty acids, omega 6 fatty acids, n-acetyl cysteine (nac), furoate, methyl furoate, ethyl furoate, aminocaproic acid, caproic acid, caprilic acid, capric acid, lauric acid, alpha lipoic acid, R-lipoic acid, myristic acid, myristoleic acid, palmitic acid, palmitoleic acid, stearic acid, oleic acid, elaidic acid, linoleic acid, linolenic acid, linolelaidic acid or arachidonic acid;  a compound of Formula II:    Formula II  or a pharmaceutically acceptable salt or stereoisomer thereof, wherein,  o  RH  , hydrochloric acid, 1 -hydroxy-2-naphthoic acid,  2,2-dichloroacetic acid, 2-hydroxyethanesulfonic acid, 2-oxoglutaric acid, 4-acetamidobenzoic acid, 4-aminosalicylic acid, acetic acid, adipic acid, ascorbic acid, aspartic acid, benzenesulfonic acid, benzoic acid, camphoric acid, camphor- lO-sulfonic acid, capric acid (decanoic acid), caproic acid (hexanoic acid), carbonic acid, cinnamic acid, citric acid, cyclamic acid, dodecylsulfuric acid, ethane- l,2-disulfonic acid, ethanesulfonic acid, formic acid, fumaric acid, galactaric acid, gentisic acid, glucoheptonic acid, gluconic acid , glucuronic acid, glutamic acid, glutaric acid, glycerophosphoric acid, glycolic acid, hippuric acid, hydrobromic acid, isobutyric acid, lactic acid, lactobionic acid, lauric acid, maleic acid, malic acid, malonic acid, mandelic acid, methanesulfonic acid, naphthalene-l,5-disulfonic acid, naphthalene-2-sulfonic acid, nicotinic acid, nitric acid, oleic acid, oxalic acid, palmitic acid, pamoic acid, phosphoric acid, proprionic acid, pyroglutamic acid, salicylic acid, sebacic acid, stearic acid, succinic acid, sulfuric acid, tartaric acid, thiocyanic acid, toluenesulfonic acid, undecylenic acid, omega 3 fatty acids, omega 6 fatty acids, n-acetyl cysteine (nac), furoate, methyl furoate, ethyl furoate, aminocaproic acid, caproic acid, caprilic acid, capric acid, lauric acid, alpha lipoic acid, R-lipoic acid, myristic acid, myristoleic acid, palmitic acid, palmitoleic acid, stearic acid, oleic acid, elaidic acid, linoleic acid, linolenic acid, linolelaidic acid or arachidonic acid; or  a compound of Formula III:  RH    Formula III  or a pharmaceutically acceptable salt or a stereoisomer thereof; wherein,  o  RH  hydrochloric acid, 1 -hydroxy-2-naphthoic acid,  2,2-dichloroacetic acid, 2-hydroxyethanesulfonic acid, 2-oxoglutaric acid, 4- acetamidobenzoic acid, 4-aminosalicylic acid, acetic acid, adipic acid, ascorbic acid, aspartic acid, benzenesulfonic acid, benzoic acid, camphoric acid, camphor- lO-sulfonic acid, capric acid (decanoic acid), caproic acid (hexanoic acid), carbonic acid, cinnamic acid, citric acid, cyclamic acid, dodecylsulfuric acid, ethane- l,2-disulfonic acid, ethanesulfonic acid, formic acid, fumaric acid, galactaric acid, gentisic acid, glucoheptonic acid, gluconic acid , glucuronic acid, glutamic acid, glutaric acid, glycerophosphoric acid, glycolic acid, hippuric acid, hydrobromic acid, isobutyric acid, lactic acid, lactobionic acid, lauric acid, maleic acid, malic acid, malonic acid, mandelic acid, methanesulfonic acid, naphthalene-l,5-disulfonic acid, naphthalene-2-sulfonic acid, nicotinic acid, nitric acid, oleic acid, oxalic acid, palmitic acid, pamoic acid, phosphoric acid, proprionic acid, pyroglutamic acid, salicylic acid, sebacic acid, stearic acid, succinic acid, sulfuric acid, tartaric acid, thiocyanic acid, toluenesulfonic acid, undecylenic acid, omega 3 fatty acids, omega 6 fatty acids, n-acetyl cysteine (nac), furoate, methyl furoate, ethyl furoate, aminocaproic acid, caproic acid, caprilic acid, capric acid, lauric acid, alpha lipoic acid, R-lipoic acid, myristic acid, myristoleic acid, palmitic acid, palmitoleic acid, stearic acid, oleic acid, elaidic ascid, linoleic acid, linolenic acid, linolelaidic acid or arachidonic acid.  3. The pharmaceutical composition as claimed in claim 1, wherein the lipoic acid is a compound of Formula IV:    Formula IV  or a pharmaceutically acceptable salt or stereoisomer thereof; wherein,  RH is null, H, sodium, potassium, magnesium, calcium, arginine, glutamate, lysine, glycine, proline, pyridoxine, pyridoxamine, choline, taurine, malic acid, PHMB, polyhexanide or guanidine; or  the lipoic acid prodrug is choline ester prodrug compound of Formula V:    Formula V  or a pharmaceutically acceptable salt or a stereoisomer thereof; wherein,  RH is H, chloride, iodine, glutamic acid, aspartic acid, lysine, ketorolac, ketoprofen, naproxen, bromine, diclofenac, nepafenac, bromfenac or glycine.  4 The pharmaceutical composition as claimed in claim 1 , wherein the antimuscarinic or an anticholinergic agent or pharmaceutically acceptable salt or a stereoisomer thereof, is present in a therapeutically effective dose range of 0.1 mg to 200 mg.  5 The pharmaceutical composition as claimed in claim 1, wherein the lipoic acid or a pharmaceutically acceptable salt or a stereoisomer thereof, is present in a dose of from 10 mg to 2 g.  6 The pharmaceutical composition as claimed in claim 1, wherein the effective dose of the compounds is in the range of about 0.01 mg/kg body weight/day to about 100 mg/kg body weight/day.  7. A physical mixture comprising a therapeutically effective amount of an antimuscarinic or an anticholinergic agent or a pharmaceutically acceptable salt or a stereoisomer thereof; and a therapeutically effective amount of lipoic acid or a pharmaceutically acceptable salt or stereoisomer or prodrug thereof.  8. The physical mixture as claimed in claim 7, wherein the antimuscarinic or anticholinergic agent is selected from a compound of Formula I:    Formula I  or a pharmaceutically acceptable salt or a stereoisomer thereof, wherein  o  RH  hydrochloric acid, 1 -hydroxy-2-naphthoic acid,  2,2-dichloroacetic acid, 2-hydroxyethanesulfonic acid, 2-oxoglutaric acid, 4- acetamidobenzoic acid, 4-aminosalicylic acid, acetic acid, adipic acid, ascorbic acid, aspartic acid, benzenesulfonic acid, benzoic acid, camphoric acid, camphor- lO-sulfonic acid, capric acid (decanoic acid), caproic acid (hexanoic acid), carbonic acid, cinnamic acid, citric acid, cyclamic acid, dodecylsulfuric acid, ethane- l,2-disulfonic acid, ethanesulfonic acid, formic acid, fumaric acid, galactaric acid, gentisic acid, glucoheptonic acid, gluconic acid, glucuronic acid, glutamic acid, glutaric acid, glycerophosphoric acid, glycolic acid, hippuric acid, hydrobromic acid, isobutyric acid, lactic acid, lactobionic acid, lauric acid, maleic acid, malic acid, malonic acid, mandelic acid, methanesulfonic acid, naphthalene-l,5-disulfonic acid, naphthalene-2-sulfonic acid, nicotinic acid, nitric acid, oleic acid, oxalic acid, palmitic acid, pamoic acid, phosphoric acid, proprionic acid, pyroglutamic acid, salicylic acid, sebacic acid, stearic acid, succinic acid, sulfuric acid, tartaric acid, thiocyanic acid, toluenesulfonic acid, undecylenic acid, omega 3 fatty acids, omega 6 fatty acids, n-acetyl cysteine (nac), furoate, methyl furoate, ethyl furoate, aminocaproic acid, caproic acid, caprilic acid, capric acid, lauric acid, alpha lipoic acid, R-lipoic acid, myristic acid, myristoleic acid, palmitic acid, palmitoleic acid, stearic acid, oleic acid, elaidic acid, linoleic acid, linolenic acid, linolelaidic acid or arachidonic acid;  a compound of Formula II:    Formula II  or a pharmaceutically acceptable salt or stereoisomer thereof, wherein,  o  RH  hydrochloric acid, 1 -hydroxy-2-naphthoic acid,  2,2-dichloroacetic acid, 2-hydroxyethanesulfonic acid, 2-oxoglutaric acid, 4-acetamidobenzoic acid, 4-aminosalicylic acid, acetic acid, adipic acid, ascorbic acid, aspartic acid, benzenesulfonic acid, benzoic acid, camphoric acid, camphor- lO-sulfonic acid, capric acid (decanoic acid), caproic acid (hexanoic acid), carbonic acid, cinnamic acid, citric acid, cyclamic acid, dodecylsulfuric acid, ethane- l,2-disulfonic acid, ethanesulfonic acid, formic acid, fumaric acid, galactaric acid, gentisic acid, glucoheptonic acid, gluconic acid , glucuronic acid, glutamic acid, glutaric acid, glycerophosphoric acid, glycolic acid, hippuric acid, hydrobromic acid, isobutyric acid, lactic acid, lactobionic acid, lauric acid, maleic acid, malic acid, malonic acid, mandelic acid, methanesulfonic acid, naphthalene-l,5-disulfonic acid, naphthalene-2-sulfonic acid, nicotinic acid, nitric acid, oleic acid, oxalic acid, palmitic acid, pamoic acid, phosphoric acid, proprionic acid, pyroglutamic acid, salicylic acid, sebacic acid, stearic acid, succinic acid, sulfuric acid, tartaric acid, thiocyanic acid, toluenesulfonic acid, undecylenic acid, omega 3 fatty acids, omega 6 fatty acids, n-acetyl cysteine (nac), furoate, methyl furoate, ethyl furoate, aminocaproic acid, caproic acid, caprilic acid, capric acid, lauric acid, alpha lipoic acid, R-lipoic acid, myristic acid, myristoleic acid, palmitic acid, palmitoleic acid, stearic acid, oleic acid, elaidic acid, linoleic acid, linolenic acid, linolelaidic acid or arachidonic acid; or  a compound of Formula III:  RH    Formula III  or a pharmaceutically acceptable salt or a stereoisomer thereof; wherein,  o  RH  ; hydrochloric acid, 1 -hydroxy-2-naphthoic acid,  2,2-dichloroacetic acid, 2-hydroxyethanesulfonic acid, 2-oxoglutaric acid, 4- acetamidobenzoic acid, 4-aminosalicylic acid, acetic acid, adipic acid, ascorbic acid, aspartic acid, benzenesulfonic acid, benzoic acid, camphoric acid, camphor- lO-sulfonic acid, capric acid (decanoic acid), caproic acid (hexanoic acid), carbonic acid, cinnamic acid, citric acid, cyclamic acid, dodecylsulfuric acid, ethane- l,2-disulfonic acid, ethanesulfonic acid, formic acid, fumaric acid, galactaric acid, gentisic acid, glucoheptonic acid, gluconic acid , glucuronic acid, glutamic acid, glutaric acid, glycerophosphoric acid, glycolic acid, hippuric acid, hydrobromic acid, isobutyric acid, lactic acid, lactobionic acid, lauric acid, maleic acid, malic acid, malonic acid, mandelic acid, methanesulfonic acid, naphthalene-l,5-disulfonic acid, naphthalene-2-sulfonic acid, nicotinic acid, nitric acid, oleic acid, oxalic acid, palmitic acid, pamoic acid, phosphoric acid, proprionic acid, pyroglutamic acid, salicylic acid, sebacic acid, stearic acid, succinic acid, sulfuric acid, tartaric acid, thiocyanic acid, toluenesulfonic acid, undecylenic acid, omega 3 fatty acids, omega 6 fatty acids, n-acetyl cysteine (nac), furoate, methyl furoate, ethyl furoate, aminocaproic acid, caproic acid, caprilic acid, capric acid, lauric acid, alpha lipoic acid, R-lipoic acid, myristic acid, myristoleic acid, palmitic acid, palmitoleic acid, stearic acid, oleic acid, elaidic acid, linoleic acid, linolenic acid, linolelaidic acid or arachidonic acid.  9. The physical mixture as claimed in claim 7, wherein the lipoic acid is a compound of Formula IV:    Formula IV  or a pharmaceutically acceptable salt or stereoisomer thereof; wherein,  RH is null, H, sodium, potassium, magnesium, calcium, arginine, glutamate, lysine, glycine, proline, pyridoxine, pyridoxamine, choline, taurine, malic acid, PHMB, polyhexanide or guanidine; or  the lipoic acid prodrug is choline ester prodrug compound of Formula V:    Formula V  or a pharmaceutically acceptable salt or a stereoisomer thereof; wherein,  RH is H, chloride, iodine, glutamic acid, aspartic acid, lysine, ketorolac, ketoprofen, naproxen, bromine, diclofenac, nepafenac, bromfenac or glycine.  10. The physical mixture of claim 7 comprising a compound of Formula I, and a compound of Formula IV or V.  11. The physical mixture of claim 7 comprising a compound of Formula II, and a compound of Formula IV or V.  12. The physical mixture of claim 7 comprising a compound of Formula III, and a compound of Formula IV or V  13. The physical mixture of claim 10, wherein the compound of Formula I is pilocarpine HC1 and the compound of Formula IV is R-(+)-Lipoic acid.  14. A pharmaceutical composition comprising a compound of Formula I and a compound of Formula IV or a physical mixture thereof.  15. The pharmaceutical composition of claim 15, wherein compound of Formula I is present in a therapeutically effective dose range of 0.01 mg to 200 mg and the compound of Formula IV is present in a therapeutically effective dose range from 5 mg to 4 g.  16. The pharmaceutical composition of claim 14, wherein the compound of Formula I is pilocarpine HC1 and the compound of Formula IV is R-(+)-Lipoic acid or the physical mixture thereof.  17. The pharmaceutical composition as claimed in any of claims 1-6 or 14-16 further comprising at least one pharmaceutically acceptable excipient.  18. The composition as claimed in claim 17, wherein said composition is formulated for oral, nasal, dermal, ocular, topical, rectal, vaginal, aerosol or parenteral administration.  19. The composition as claimed in claim 18, wherein said composition is for the treatment of xerostomia, and burning mouth syndrome or a complication thereof.  20. The composition as claimed in claim 18, wherein said composition is for the treatment of the ocular disease or disorder selected from the group consisting of presbyopia, glaucoma and its related conditions.  21. A method of treating xerostomia and complication thereof in a subject of need thereof, the method comprising administering to said subject a therapeutically effective amount of the composition as claimed in any of claims any of claims 1-6 or 14-20. | The antimuscarinic or anticholinergic agent is a compound of Formula I, Formula II, or Formula III and lipoic acid is a compound of Formula IV or Formula V. The Pharmaceutical composition is a physical mixture of an antimuscarinic or an anticholinergic agent and lipoic acid. |  |
| 201 | **CN110099681** | 2019 |  | 1. ​A compound of formula I and a pharmaceutically acceptable hydrate, solvate, enantiomer, and stereoisomer thereof,    ​wherein,  ​RH-INDEPENDENTLY REPRESENTATION  1 ​-hydroxy -2-naphthoic acid, 2,2-dichloroacetic acid, 2-hydroxyethanesulfonic acid, 2-oxoglutarate, 4-acetaminobenzoic acid, 4-aminosalicylic acid, acetic acid, adipic acid, ascorbic acid, aspartic acid, benzenesulfonic acid, adipic acid, ascorbic acid, aspartic acid, benzenesulfonic acid, citric acid, gluconic acid, glutamic acid, glutaric acid, glycerophosphoric acid, glycolic acid, fumaric acid, hydrobromic acid, isobutyric acid, lactic acid, lactobionic acid, lauric acid, maleic acid, malic acid, malonic acid, mandelic acid, methanesulfonic acid.​Naphthalene -1, 5-disulfonic acid, naphthalene-2-sulfonic acid, nicotinic acid, nitric acid, oleic acid, oxalic acid, palmitic acid, bis-hydroxynaphthoic acid, phosphoric acid, oxalic acid, palmitic acid, bis-hydroxynaphthoic acid, phosphoric acid, propionic acid, pyroglutamic acid, salicylic acid, tartaric acid, caprylic acid, toic acid, lauric acid, alpha lipoic acid, R-lipoic acid, myristic acid, carnitine acid, palmitic acid, palmitoleic acid, stearic acid, oleic acid, fumaric acid, linoleic acid, linolenic acid, linoleic acid or arachidonic acid.  2. ​A compound of formula II and a pharmaceutically acceptable hydrate, solvate, prodrug, enantiomer, and stereoisomer thereof,    ​wherein,  ​RH-INDEPENDENTLY REPRESENTATION  1 ​-hydroxy -2-naphthoic acid, 2,2-dichloroacetic acid, 2-hydroxyethanesulfonic acid, 2-oxoglutarate, 4-acetaminobenzoic acid, 4-aminosalicylic acid, acetic acid, adipic acid, ascorbic acid, aspartic acid, benzenesulfonic acid, adipic acid, ascorbic acid, aspartic acid, benzenesulfonic acid, citric acid, gluconic acid, glutamic acid, glutaric acid, glycerophosphoric acid, glycolic acid, fumaric acid, hydrobromic acid, isobutyric acid, lactic acid, lactobionic acid, lauric acid, maleic acid, malic acid, malonic acid, mandelic acid, methanesulfonic acid.​Naphthalene -1, 5-disulfonic acid, naphthalene-2-sulfonic acid, nicotinic acid, nitric acid, oleic acid, oxalic acid, palmitic acid, bis-hydroxynaphthoic acid, phosphoric acid, oxalic acid, palmitic acid, bis-hydroxynaphthoic acid, phosphoric acid, propionic acid, pyroglutamic acid, salicylic acid, tartaric acid, caprylic acid, toic acid, lauric acid, alpha lipoic acid, R-lipoic acid, myristic acid, carnitine acid, palmitic acid, palmitoleic acid, stearic acid, oleic acid, fumaric acid, linoleic acid, linolenic acid, linoleic acid or arachidonic acid.  3. ​A compound of formula III and a pharmaceutically acceptable hydrate, solvate, prodrug, enantiomer, and stereoisomer thereof,    ​wherein,  ​RH-INDEPENDENTLY REPRESENTATION  1 ​-hydroxy -2-naphthoic acid, 2,2-dichloroacetic acid, 2-hydroxyethanesulfonic acid, 2-oxoglutarate, 4-acetaminobenzoic acid, 4-aminosalicylic acid, acetic acid, adipic acid, ascorbic acid, aspartic acid, benzenesulfonic acid, adipic acid, ascorbic acid, aspartic acid, benzenesulfonic acid, citric acid, gluconic acid, glutamic acid, glutaric acid, glycerophosphoric acid, glycolic acid, fumaric acid, hydrobromic acid, isobutyric acid, lactic acid, lactobionic acid, lauric acid, maleic acid, malic acid, malonic acid, mandelic acid, methanesulfonic acid.​Naphthalene -1, 5-disulfonic acid, naphthalene-2-sulfonic acid, nicotinic acid, nitric acid, oleic acid, oxalic acid, palmitic acid, bis-hydroxynaphthoic acid, phosphoric acid, oxalic acid, palmitic acid, bis-hydroxynaphthoic acid, phosphoric acid, propionic acid, pyroglutamic acid, salicylic acid, tartaric acid, caprylic acid, toic acid, lauric acid, alpha lipoic acid, R-lipoic acid, myristic acid, carnitine acid, palmitic acid, palmitoleic acid, stearic acid, oleic acid, fumaric acid, linoleic acid, linolenic acid, linoleic acid or arachidonic acid.  4. ​A compound of formula IV and a pharmaceutically acceptable hydrate, solvate, prodrug, enantiomer, and stereoisomer thereof,    ​wherein,  ​RH-INDEPENDENTLY REPRESENTATION  1 ​-hydroxy -2-naphthoic acid, 2,2-dichloroacetic acid, 2-hydroxyethanesulfonic acid, 2-oxoglutarate, 4-acetaminobenzoic acid, 4-aminosalicylic acid, acetic acid, adipic acid, ascorbic acid, aspartic acid, benzenesulfonic acid, adipic acid, ascorbic acid, aspartic acid, benzenesulfonic acid, citric acid, gluconic acid, glutamic acid, glutaric acid, glycerophosphoric acid, glycolic acid, fumaric acid, hydrobromic acid, isobutyric acid, lactic acid, lactobionic acid, lauric acid, maleic acid, malic acid, malonic acid, mandelic acid, methanesulfonic acid.​Naphthalene -1, 5-disulfonic acid, naphthalene-2-sulfonic acid, nicotinic acid, nitric acid, oleic acid, oxalic acid, palmitic acid, bis-hydroxynaphthoic acid, phosphoric acid, oxalic acid, palmitic acid, bis-hydroxynaphthoic acid, phosphoric acid, propionic acid, pyroglutamic acid, salicylic acid, tartaric acid, caprylic acid, toic acid, lauric acid, alpha lipoic acid, R-lipoic acid, myristic acid, carnitine acid, palmitic acid, palmitoleic acid, stearic acid, oleic acid, fumaric acid, linoleic acid, linolenic acid, linoleic acid or arachidonic acid.  5. ​A compound of formula V and a pharmaceutically acceptable hydrate, solvate, prodrug, enantiomer, and stereoisomer thereof,    ​wherein,  ​RH-INDEPENDENTLY REPRESENTATION  1 ​-hydroxy -2-naphthoic acid, 2,2-dichloroacetic acid, 2-hydroxyethanesulfonic acid, 2-oxoglutarate, 4-acetaminobenzoic acid, 4-aminosalicylic acid, acetic acid, adipic acid, ascorbic acid, aspartic acid, benzenesulfonic acid, adipic acid, ascorbic acid, aspartic acid, benzenesulfonic acid, citric acid, gluconic acid, glutamic acid, glutaric acid, glycerophosphoric acid, glycolic acid, fumaric acid, hydrobromic acid, isobutyric acid, lactic acid, lactobionic acid, lauric acid, maleic acid, malic acid, malonic acid, mandelic acid, methanesulfonic acid.​Naphthalene -1, 5-disulfonic acid, naphthalene-2-sulfonic acid, nicotinic acid, nitric acid, oleic acid, oxalic acid, palmitic acid, bis-hydroxynaphthoic acid, phosphoric acid, oxalic acid, palmitic acid, bis-hydroxynaphthoic acid, phosphoric acid, propionic acid, pyroglutamic acid, salicylic acid, tartaric acid, caprylic acid, toic acid, lauric acid, alpha lipoic acid, R-lipoic acid, myristic acid, carnitine acid, palmitic acid, palmitoleic acid, stearic acid, oleic acid, fumaric acid, linoleic acid, linolenic acid, linoleic acid or arachidonic acid.  6. ​A pharmaceutical composition comprising the compound of claim 1 and a pharmaceutically acceptable carrier.  7. ​A pharmaceutical composition comprising the compound of claim 2 and a pharmaceutically acceptable carrier.  8. ​A pharmaceutical composition comprising the compound of claim 3 and a pharmaceutically acceptable carrier.  9. ​A pharmaceutical composition comprising the compound of claim 4 and a pharmaceutically acceptable carrier.  10. ​A pharmaceutical composition comprising the compound of claim 5 and a pharmaceutically acceptable carrier.  11. ​The pharmaceutical composition of claim 6, wherein the pharmaceutical composition is formulated to be administered by oral administration, delayed release or sustained release, transmucosal, syrup, topical, parenteral administration, injection, subcutaneous, oral solution, rectal administration, buccal administration, or transdermal administration to treat potential etiology in an effective amount to a patient in need.  12. ​The pharmaceutical composition of claim 7, wherein the pharmaceutical composition is formulated to be administered by oral administration, delayed release or sustained release, transmucosal, syrup, topical, parenteral administration, injection, subcutaneous, oral solution, rectal administration, buccal administration, or transdermal administration to treat potential etiology in an effective amount to a patient in need.  13. ​The pharmaceutical composition of claim 8, wherein the pharmaceutical composition is formulated to be administered by oral administration, delayed release or sustained release, transmucosal, syrup, topical, parenteral administration, injection, subcutaneous, oral solution, rectal administration, buccal administration, or transdermal administration to be administered in an effective amount to a patient in need thereof to treat potential etiology.  14. ​The pharmaceutical composition of claim 9, wherein the pharmaceutical composition is formulated to be administered by oral administration, delayed release or sustained release, transmucosal, syrup, topical, parenteral administration, injection, subcutaneous, oral solution, rectal administration, buccal administration, or transdermal administration to treat potential etiology in an effective amount to a patient in need.  15. ​The pharmaceutical composition of claim 10, wherein the pharmaceutical composition is formulated to be administered by oral administration, delayed release or sustained release, transmucosal, syrup, topical, parenteral administration, injection, subcutaneous, oral solution, rectal administration, buccal administration, or transdermal administration to treat potential etiology in an effective amount to a patient in need.  16. ​The compound and composition of claim 11, wherein the compound and composition are formulated for the treatment of oral dryness, dry mouth, and dry mouth.  17. ​The compound and composition of claim 12, wherein the compound and composition are formulated for the treatment of oral dryness, dry mouth, and dry mouth.  18. ​The compound and composition of claim 13, wherein the compound and composition are formulated for the treatment of oral dryness, dry mouth, and dry mouth.  19. ​The compound and composition of claim 14, wherein the compound and composition are formulated for the treatment of oral dryness, dry mouth, and dry mouth.  20. ​The compound and composition of claim 15, wherein the compound and composition are formulated for the treatment of oral dryness, dry mouth, and dry mouth. | formulated for oral, buccal, rectal, topical, transdermal, transmucosal, lozenge, spray, intravenous, oral solution, buccal mucosal layer tablet, parenteral administration, syrup, or injection. Such compositions may be used to treatment of oral mucosal inflammatory, dry mouth or oral dry mouth mediated infectious diseases. |  |
| 202 | **AU2017385977** | 2019 |  | A compound of formula VI which is selected from the group consisting of:    and a combination thereof.  2.       A pharmaceutical composition comprising a compound of claim 1 and a pharmaceutically acceptable carrier.  3.        The pharmaceutical composition of claim 2, wherin said pharmaceutical composition is formulated to treat a patient in need with an effective amout of said pharmaceutical composition by oral administration, delayed release or sustained release, transmucosal administration, syrup, topical administration, parenteral administration, injection, subdermal administration, oral solution, rectal administration, buccal administration, or transdermal administration.  4.        The pharmceutical compositions of claim 2 or claim 3, wherein said pharmaceutical composition is formulated for the treatment of a pain selected from the group consisting of chronic pain, surgery pain, wound pain, ulcer pain, neuropathic pain, central nerve damage pain, and peripheral nerve damage pain, and any combination thereof.  5.        A method of treating a pain in a patient in need thereof, the method comprising the step of administering to the patient an effective amount of:  i. a compound of claim 1; and/or  ii. a pharmaceutical composition of any one of claims 2-4.  wherein the pain is one or more selected from the group consisting of chronic pain, surgery pain, wound pain, ulcer pain, neuropathic pain, and central and peripheral nerve damage pain, and any combination thereof, to thereby treat the pain in the patient.  6.        Use of a compound according to claim 1, and/or a pharmaceutical composition according to any one of claims 2-4, in the manufacture of a medicament for the treatment of a pain selected from the group consisting of chronic pain, surgery pain, wound pain, ulcer pain, neuropathic pain, central nerve damage pain, and peripheral nerve damage pain, and any combination thereof.  7.        A compound of claim 1, or a pharmaceutical composition of any one of claims 2-4, for use in treating a pain, wherein the pain is one or more selected from the group consisting of chronic pain, surgery pain, wound pain, ulcer pain, neuropathic pain, and central and peripheral nerve damage pain, and any combination thereof. | treatment of chronic pain may be formulated for oral, buccal, rectal, topical, transdermal, transmucosal, lozenge, spray, intravenous, oral solution, buccal mucosal layer tablet, parenteral administration, syrup, or injection. Such compositions may be used to treatment of chronic pain. |  |
| 203 | **MX2019000279** | 2019 |  |  | treatment of cancer and infectious diseases may be formulated for oral, buccal, rectal, topical, transdermal, transmucosal, lozenge, spray, intravenous, oral solution, buccal mucosal layer tablet, parenteral administration, syrup, or injection. Such compositions may be used to treatment of cancer, neoplasm, infections and skin diseases. |  |
| 204 | **IL266545** | 2019 |  |  | COMPOSITIONS AND METHODS FOR THE TREATMENT OF GASTROINTESTINAL POLYPS |  |
| 205 | **IL266926** | 2019 |  |  | COMPOSITIONS AND METHODS FOR THE TREATMENT OF ORAL INFECTIOUS DISEASES |  |
| 206 | **NZ755490** | 2019 |  |  | treatment of chronic pain may be formulated for oral, buccal, rectal, topical, transdermal, transmucosal, lozenge, spray, intravenous, oral solution, buccal mucosal layer tablet, parenteral administration, syrup, or injection. Such compositions may be used to treatment of chronic pain. |  |
| 207 | **IN201947021083** | 2019 |  | A compound of Formula **I :**  Formula **I**  and pharmaceutically acceptable hydrates, solvates, enantiomers, and stereoisomers thereof;  wherein,  **RH** represents selected from l-hydroxy-2-naphthoic acid, 2,2-dichloroacetic acid, 2-  hydroxyethanesulfonic acid, 2-oxoglutaric acid, 4-acetamidobenzoic acid, 4-aminosalicylic  acid, acetic acid, adipic acid, ascorbic acid, aspartic acid, benzenesulfonic acid, benzoic acid,  camphoric acid, camphor- 10-sulfonic acid, capric acid (decanoic acid), caproic acid (hexanoic  acid), carbonic acid, cinnamic acid, citric acid, cyclamic acid, dodecylsulfuric acid, ethane- 1,2-  disulfonic acid, ethanesulfonic acid, formic acid, galactaric acid, gentisic acid, glucoheptonic  acid, gluconic acid , glucuronic acid, glutamic acid, glutaric acid, glycerophosphoric acid,  glycolic acid, hippuric acid, hydrobromic acid, isobutyric acid, lactic acid, lactobionic acid,  lauric acid, maleic acid, malic acid, malonic acid, mandelic acid, methanesulfonic acid,  naphthalene- 1,5-disulfonic acid, naphthalene-2-sulfonic acid, nicotinic acid, nitric acid, oleic  acid, oxalic acid, palmitic acid, pamoic acid, phosphoric acid, proprionic acid, pyroglutamic  acid, salicylic acid, sebacic acid, stearic acid, succinic acid, sulfuric acid, tartaric acid,  thiocyanic acid, toluenesulfonic acid, undecylenic acid, omega 3 fatty acids, omega 6 fatty  acids, n-acetyl cysteine (nac), furoate, methyl furoate, ethyl furoate, aminocaproic acid, caproic  acid, caprilic acid, capric acid, lauric acid, alpha lipoic acid, **R**-lipoic acid, myristic acid,  myristoleic acid, palmitic acid, palmitoleic acid, stearic acid, oleic acid, elaidic acid, linoleic  acid, linolenic acid, linolelaidic acid and arachidonic acid;  or  wherein,  each Ri, R2 and R3 independently represents  2. A compound of Formula **II:**  Formula **II**  and pharmaceutically acceptable hydrates, solvates, prodrugs, enantiomers, and stereoisomers  thereof;  wherein,  RH is selected from l-hydroxy-2-naphthoic acid, 2,2-dichloroacetic acid, 2-  hydroxyethanesulfonic acid, 2-oxoglutaric acid, 4-acetamidobenzoic acid, 4-aminosalicylic  acid, acetic acid, adipic acid, ascorbic acid, aspartic acid, benzenesulfonic acid, benzoic acid,  camphoric acid, camphor- 10-sulfonic acid, capric acid (decanoic acid), caproic acid (hexanoic  acid), carbonic acid, cinnamic acid, citric acid, cyclamic acid, dodecylsulfuric acid, ethane- 1,2-  disulfonic acid, ethanesulfonic acid, formic acid, galactaric acid, gentisic acid, glucoheptonic  acid, gluconic acid , glucuronic acid, glutamic acid, glutaric acid, glycerophosphoric acid,  glycolic acid, hippuric acid, hydrobromic acid, isobutyric acid, lactic acid, lactobionic acid,  lauric acid, maleic acid, malic acid, malonic acid, mandelic acid, methanesulfonic acid,  naphthalene- 1,5-disulfonic acid, naphthalene-2-sulfonic acid, nicotinic acid, nitric acid, oleic  acid, oxalic acid, palmitic acid, pamoic acid, phosphoric acid, proprionic acid, pyroglutamic  acid, salicylic acid, sebacic acid, stearic acid, succinic acid, sulfuric acid, tartaric acid,  thiocyanic acid, toluenesulfonic acid, undecylenic acid, omega 3 fatty acids, omega 6 fatty  acids, n-acetyl cysteine (nac), furoate, methyl furoate, ethyl furoate, aminocaproic acid, caproic  acid, caprilic acid, capric acid, lauric acid, alpha lipoic acid, R-lipoic acid, myristic acid,  myristoleic acid, palmitic acid, palmitoleic acid, stearic acid, oleic acid, elaidic acid, linoleic  acid, linolenic acid, linolelaidic acid and arachidonic acid;  or  wherein,  each Ri, R2 and R3 independently represents  3. A compound of Formula **III:**  Formula **III**  and pharmaceutically acceptable hydrates, solvates, prodrugs, enantiomers, and stereoisomers  thereof;  wherein,  **RH** is selected from l-hydroxy-2-naphthoic acid, 2,2-dichloroacetic acid, 2-  hydroxyethanesulfonic acid, 2-oxoglutaric acid, 4-acetamidobenzoic acid, 4-aminosalicylic  acid, acetic acid, adipic acid, ascorbic acid, aspartic acid, benzenesulfonic acid, benzoic acid,  camphoric acid, camphor- 10-sulfonic acid, capric acid (decanoic acid), caproic acid (hexanoic  acid), carbonic acid, cinnamic acid, citric acid, cyclamic acid, dodecylsulfuric acid, ethane- 1,2-  disulfonic acid, ethanesulfonic acid, formic acid, galactaric acid, gentisic acid, glucoheptonic  acid, gluconic acid , glucuronic acid, glutamic acid, glutaric acid, glycerophosphoric acid,  glycolic acid, hippuric acid, hydrobromic acid, isobutyric acid, lactic acid, lactobionic acid,  lauric acid, maleic acid, malic acid, malonic acid, mandelic acid, methanesulfonic acid,  naphthalene- 1,5-disulfonic acid, naphthalene-2-sulfonic acid, nicotinic acid, nitric acid, oleic  acid, oxalic acid, palmitic acid, pamoic acid, phosphoric acid, proprionic acid, pyroglutamic  acid, salicylic acid, sebacic acid, stearic acid, succinic acid, sulfuric acid, tartaric acid,  thiocyanic acid, toluenesulfonic acid, undecylenic acid, omega 3 fatty acids, omega 6 fatty  acids, n-acetyl cysteine (nac), furoate, methyl furoate, ethyl furoate, aminocaproic acid, caproic  acid, caprilic acid, capric acid, lauric acid, alpha lipoic acid, R-lipoic acid, myristic acid,  myristoleic acid, palmitic acid, palmitoleic acid, stearic acid, oleic acid, elaidic acid, linoleic  acid, linolenic acid, linolelaidic acid and arachidonic acid;  or  wherein,  each Ri, R2 and R3 independently represents  4. A compound of Formula IV:  Formula IV  and pharmaceutically acceptable hydrates, solvates, prodrugs, enantiomers, and stereoisomers  thereof;  wherein,  RH is selected from l-hydroxy-2-naphthoic acid, 2,2-dichloroacetic acid, 2-  hydroxyethanesulfonic acid, 2-oxoglutaric acid, 4-acetamidobenzoic acid, 4-aminosalicylic  acid, acetic acid, adipic acid, ascorbic acid, aspartic acid, benzenesulfonic acid, benzoic acid,  camphoric acid, camphor- 10-sulfonic acid, capric acid (decanoic acid), caproic acid (hexanoic  acid), carbonic acid, cinnamic acid, citric acid, cyclamic acid, dodecylsulfuric acid, ethane- 1,2-  disulfonic acid, ethanesulfonic acid, formic acid, galactaric acid, gentisic acid, glucoheptonic  acid, gluconic acid , glucuronic acid, glutamic acid, glutaric acid, glycerophosphoric acid,  glycolic acid, hippuric acid, hydrobromic acid, isobutyric acid, lactic acid, lactobionic acid,  lauric acid, maleic acid, malic acid, malonic acid, mandelic acid, methanesulfonic acid,  naphthalene- 1,5-disulfonic acid, naphthalene-2-sulfonic acid, nicotinic acid, nitric acid, oleic  acid, oxalic acid, palmitic acid, pamoic acid, phosphoric acid, proprionic acid, pyroglutamic  acid, salicylic acid, sebacic acid, stearic acid, succinic acid, sulfuric acid, tartaric acid,  thiocyanic acid, toluenesulfonic acid, undecylenic acid, omega 3 fatty acids, omega 6 fatty  acids, n-acetyl cysteine (nac), furoate, methyl furoate, ethyl furoate, aminocaproic acid, caproic  acid, caprilic acid, capric acid, lauric acid, alpha lipoic acid, R-lipoic acid, myristic acid,  myristoleic acid, palmitic acid, palmitoleic acid, stearic acid, oleic acid, elaidic acid, linoleic  acid, linolenic acid, linolelaidic acid and arachidonic acid;  or  wherein,  each Ri, R2 and R3 independently represents  5. A compound of Formula V:  Formula V  and pharmaceutically acceptable hydrates, solvates, prodrugs, enantiomers, and stereoisomers  thereof;  wherein,  RH is selected from l-hydroxy-2-naphthoic acid, 2,2-dichloroacetic acid, 2-  hydroxyethanesulfonic acid, 2-oxoglutaric acid, 4-acetamidobenzoic acid, 4-aminosalicylic  acid, acetic acid, adipic acid, ascorbic acid, aspartic acid, benzenesulfonic acid, benzoic acid,  camphoric acid, camphor- 10-sulfonic acid, capric acid (decanoic acid), caproic acid (hexanoic  acid), carbonic acid, cinnamic acid, citric acid, cyclamic acid, dodecylsulfuric acid, ethane- 1,2-  disulfonic acid, ethanesulfonic acid, formic acid, galactaric acid, gentisic acid, glucoheptonic  acid, gluconic acid , glucuronic acid, glutamic acid, glutaric acid, glycerophosphoric acid,  glycolic acid, hippuric acid, hydrobromic acid, isobutyric acid, lactic acid, lactobionic acid,  lauric acid, maleic acid, malic acid, malonic acid, mandelic acid, methanesulfonic acid,  naphthalene- 1,5-disulfonic acid, naphthalene-2-sulfonic acid, nicotinic acid, nitric acid, oleic  acid, oxalic acid, palmitic acid, pamoic acid, phosphoric acid, proprionic acid, pyroglutamic  acid, salicylic acid, sebacic acid, stearic acid, succinic acid, sulfuric acid, tartaric acid,  thiocyanic acid, toluenesulfonic acid, undecylenic acid, omega 3 fatty acids, omega 6 fatty  acids, n-acetyl cysteine (nac), furoate, methyl furoate, ethyl furoate, aminocaproic acid, caproic  acid, caprilic acid, capric acid, lauric acid, alpha lipoic acid, R-lipoic acid, myristic acid,  myristoleic acid, palmitic acid, palmitoleic acid, stearic acid, oleic acid, elaidic acid, linoleic  acid, linolenic acid, linolelaidic acid and arachidonic acid  or  wherein,  each Ri, R2 and R3 independently represents  6. A Pharmaceutical composition comprising a compound of claim 1 and a pharmaceutically  acceptable carrier.  7. A Pharmaceutical composition comprising a compound of claim 2 and a pharmaceutically  acceptable carrier.  8. A Pharmaceutical composition comprising a compound of claim 3 and a pharmaceutically  acceptable carrier.  9. A Pharmaceutical composition comprising a compound of claim 4 and a pharmaceutically  acceptable carrier.  10. A Pharmaceutical composition comprising a compound of claim 5 and a pharmaceutically  acceptable carrier.  11. The pharmaceutical composition of claim 6, wherein said pharmaceutical composition is  formulated with an effective amount of compound of claim 1 for oral administration,  transmucosal administration, parenteral administration, intravenous administration,  subdermal administration, rectal administration, buccal administration or transdermal  administration.  12. The pharmaceutical composition of claim 7, wherein said pharmaceutical composition is  formulated with an effective amount of compound of claim 2 for oral administration,  transmucosal administration, topical administration, parenteral administration, intravenous  administration, subdermal administration, rectal administration, buccal administration or  transdermal administration.  13. The pharmaceutical composition of claim 8, wherein said pharmaceutical composition is  formulated with an effective amount of compound of claim 3 for oral administration,  transmucosal administration, topical administration, parenteral administration, intravenous  administration, subdermal administration, rectal administration, buccal administration or  transdermal administration.  14. The pharmaceutical composition of claim 9, wherein said pharmaceutical composition is  formulated with an effective amount compound of claim 4 for oral administration,  transmucosal administration, topical administration, parenteral administration, intravenous  administration, subdermal administration, rectal administration, buccal administration or  transdermal administration.  15. The pharmaceutical composition of claim 10, wherein said pharmaceutical composition is  formulated with an effective amount of compound of claim 5 for oral administration,  transmucosal administration, topical administration, parenteral administration, intravenous  administration, subdermal administration, rectal administration, buccal administration or  transdermal administration.  16. Compounds of claim 1 or compositions of claim 1 1 are formulated for the treatment of  fungal infections, candidiasis and oral infectious diseases.  17. Compounds of claim 2 or compositions of claim 12 are formulated for the treatment of  fungal infections, candidiasis and oral infectious diseases.  18. Compounds of claim 3 or compositions of claim 13 are formulated for the treatment of  fungal infections, candidiasis and oral infectious diseases.  19. Compounds of claim 4 or compositions of claim 14 are formulated for the treatment of  fungal infections, candidiasis and oral infectious diseases.  20. Compounds of claim 5 or compositions of claim 15 are formulated for the treatment of  fungal infections, candidiasis and oral infectious diseases.  21. A compound of claim 1, wherein the compound has the chemical structure of:  A compound of claim 2, wherein the compound has the chemical structure of:  23. A compound of claim 3, wherein the compound has the chemical structure of:  24. A compound of claim 4, wherein the compound has the chemical structure of:  25. A compound of claim 5, wherein the compound has the chemical structure of:  26. A compound of formula VIII:  Formula VIII  and pharmaceutically acceptable hydrates, solvates, prodrugs, enantiomers, and stereoisomers  thereof;  wherein,  RH is selected from l-hydroxy-2-naphthoic acid, 2,2-dichloroacetic acid, 2-  hydroxyethanesulfonic acid, 2-oxoglutaric acid, 4-acetamidobenzoic acid, 4-aminosalicylic  acid, acetic acid, adipic acid, ascorbic acid, aspartic acid, benzenesulfonic acid, benzoic acid,  camphoric acid, camphor- 10-sulfonic acid, capric acid (decanoic acid), caproic acid (hexanoic  acid), carbonic acid, cinnamic acid, citric acid, cyclamic acid, dodecylsulfuric acid, ethane- 1,2-  disulfonic acid, ethanesulfonic acid, formic acid, galactaric acid, gentisic acid, glucoheptonic  acid, gluconic acid , glucuronic acid, glutamic acid, glutaric acid, glycerophosphoric acid,  glycolic acid, hippuric acid, hydrobromic acid, isobutyric acid, lactic acid, lactobionic acid,  lauric acid, maleic acid, malic acid, malonic acid, mandelic acid, methanesulfonic acid,  naphthalene- 1,5-disulfonic acid, naphthalene-2-sulfonic acid, nicotinic acid, nitric acid, oleic  acid, oxalic acid, palmitic acid, pamoic acid, phosphoric acid, proprionic acid, pyroglutamic  acid, salicylic acid, sebacic acid, stearic acid, succinic acid, sulfuric acid, tartaric acid,  thiocyanic acid, toluenesulfonic acid, undecylenic acid, omega 3 fatty acids, omega 6 fatty  acids, n-acetyl cysteine (nac), furoate, methyl furoate, ethyl furoate, aminocaproic acid, caproic  acid, caprilic acid, capric acid, lauric acid, alpha lipoic acid, R-lipoic acid, myristic acid,  myristoleic acid, palmitic acid, palmitoleic acid, stearic acid, oleic acid, elaidic acid, linoleic  acid, linolenic acid, linolelaidic acid and arachidonic acid  27. A compound of formula IX:  Formula IX  and pharmaceutically acceptable hydrates, solvates, prodrugs, enantiomers, and stereoisomers  thereof;  wherein,  RH is selected from l-hydroxy-2-naphthoic acid, 2,2-dichloroacetic acid, 2-  hydroxyethanesulfonic acid, 2-oxoglutaric acid, 4-acetamidobenzoic acid, 4-aminosalicylic  acid, acetic acid, adipic acid, ascorbic acid, aspartic acid, benzenesulfonic acid, benzoic acid,  camphoric acid, camphor- 10-sulfonic acid, capric acid (decanoic acid), caproic acid (hexanoic  acid), carbonic acid, cinnamic acid, citric acid, cyclamic acid, dodecylsulfuric acid, ethane- 1,2-  disulfonic acid, ethanesulfonic acid, formic acid, galactaric acid, gentisic acid, glucoheptonic  acid, gluconic acid , glucuronic acid, glutamic acid, glutaric acid, glycerophosphoric acid,  glycolic acid, hippuric acid, hydrobromic acid, isobutyric acid, lactic acid, lactobionic acid,  lauric acid, maleic acid, malic acid, malonic acid, mandelic acid, methanesulfonic acid,  naphthalene- 1,5-disulfonic acid, naphthalene-2-sulfonic acid, nicotinic acid, nitric acid, oleic  acid, oxalic acid, palmitic acid, pamoic acid, phosphoric acid, proprionic acid, pyroglutamic  acid, salicylic acid, sebacic acid, stearic acid, succinic acid, sulfuric acid, tartaric acid,  thiocyanic acid, toluenesulfonic acid, undecylenic acid, omega 3 fatty acids, omega 6 fatty  acids, n-acetyl cysteine (nac), furoate, methyl furoate, ethyl furoate, aminocaproic acid, caproic  acid, caprilic acid, capric acid, lauric acid, alpha lipoic acid, R-lipoic acid, myristic acid,  myristoleic acid, palmitic acid, palmitoleic acid, stearic acid, oleic acid, elaidic acid, linoleic  acid, linolenic acid, linolelaidic acid and arachidonic acid  and pharmaceutically acceptable hydrates, solvates, prodrugs, enantiomers, and stereoisomers  thereof;  wherein,  RH is selected from l-hydroxy-2-naphthoic acid, 2,2-dichloroacetic acid, 2-  hydroxyethanesulfonic acid, 2-oxoglutaric acid, 4-acetamidobenzoic acid, 4-aminosalicylic  acid, acetic acid, adipic acid, ascorbic acid, aspartic acid, benzenesulfonic acid, benzoic acid,  camphoric acid, camphor- 10-sulfonic acid, capric acid (decanoic acid), caproic acid (hexanoic  acid), carbonic acid, cinnamic acid, citric acid, cyclamic acid, dodecylsulfuric acid, ethane- 1,2-  disulfonic acid, ethanesulfonic acid, formic acid, galactaric acid, gentisic acid, glucoheptonic  acid, gluconic acid , glucuronic acid, glutamic acid, glutaric acid, glycerophosphoric acid,  glycolic acid, hippuric acid, hydrobromic acid, isobutyric acid, lactic acid, lactobionic acid,  lauric acid, maleic acid, malic acid, malonic acid, mandelic acid, methanesulfonic acid,  naphthalene- 1,5-disulfonic acid, naphthalene-2-sulfonic acid, nicotinic acid, nitric acid, oleic  acid, oxalic acid, palmitic acid, pamoic acid, phosphoric acid, proprionic acid, pyroglutamic  acid, salicylic acid, sebacic acid, stearic acid, succinic acid, sulfuric acid, tartaric acid,  thiocyanic acid, toluenesulfonic acid, undecylenic acid, omega 3 fatty acids, omega 6 fatty  acids, n-acetyl cysteine (nac), furoate, methyl furoate, ethyl furoate, aminocaproic acid, caproic  acid, caprilic acid, capric acid, lauric acid, alpha lipoic acid, R-lipoic acid, myristic acid,  myristoleic acid, palmitic acid, palmitoleic acid, stearic acid, oleic acid, elaidic acid, linoleic  acid, linolenic acid, linolelaidic acid and arachidonic acid  or  29. A Pharmaceutical composition comprising a compound of claim 26 and a  pharmaceutically acceptable carrier.  30. The pharmaceutical composition of claim 29, wherein said pharmaceutical composition is  formulated with an effective amount of compound of claim 26 for oral administration,  transmucosal administration, parenteral administration, intravenous administration,  subdermal administration, rectal administration, buccal administration or transdermal  administration.  31. A Pharmaceutical composition comprising a compound of claim 27 and a  pharmaceutically acceptable carrier.  32. The pharmaceutical composition of claim 31, wherein said pharmaceutical composition is  formulated with an effective amount of compound of claim 27 for oral administration,  transmucosal administration, parenteral administration, intravenous administration,  subdermal administration, rectal administration, buccal administration or transdermal  administration.  33. A Pharmaceutical composition comprising a compound of claim 28 and a  pharmaceutically acceptable carrier.  34. The pharmaceutical composition of claim 33, wherein said pharmaceutical composition is  formulated with an effective amount of compound of claim 28 for oral administration,  transmucosal administration, parenteral administration, intravenous administration,  subdermal administration, rectal administration, buccal administration or transdermal  administration.  35. Compounds of claim 26 or compositions of claim 30 are formulated for the treatment of  fungal infections, candidiasis and oral infectious diseases.  36. Compounds of claim 27 or compositions of claim 32 are formulated for the treatment of  fungal infections, candidiasis and oral infectious diseases.  37. Compounds of claim 28 or compositions of claim 34 are formulated for the treatment of  fungal infections, candidiasis and oral infectious diseases.  38. A compound of claim 26, wherein the compound has the chemical structure of: | treatment of fungal infections may be formulated for oral buccal rectal topical transdermal transmucosal lozenge spray intravenous oral solution buccal mucosal layer tablet parenteral administration syrup or injection. Such compositions may be used to treatment of fungal infections. |  |
| 208 | **IN201947026630** | 208 |  |  | treatment of chronic pain may be formulated for oral buccal rectal topical transdermal transmucosal lozenge spray intravenous oral solution buccal mucosal layer tablet parenteral administration syrup or injection. Such compositions may be used to treatment of chronic pain. |  |
| 209 | **IN201947026629** | 2019 |  |  | formulated for oral administration intravenous spray parenteral lozenge solution syrup sachet transdermal administration or injection. Such compositions may be used to treatment of inflammation or its associated complications. |  |
| 210 | **BR112019006904** | 2019 |  |  | treatment of xerostomia may be formulated for oral, buccal, rectal, topical, transdermal, transmucosal, spray-oral administration, intravenous administration, by oral solution​, compressed from the oral mucous layer, parenteral administration, by syrup, or by injection. Such compositions can be used for the treatment of inflammation of the buccal mucosa, dry mouth, or oral infectious diseases mediated by dry mouth. |  |
| 211 | **NZ754155** | 2019 |  |  | formulated for oral, buccal, rectal, topical, transdermal, transmucosal, lozenge, spray, intravenous, oral solution, buccal mucosal layer tablet, parenteral administration, syrup, or injection. Such compositions may be used in the treatment of fungal infections, candidiasis and oral infectious diseases. |  |
| 212 | **NZ754205** | 2019 |  |  | formulated for oral, buccal, rectal, topical, transdermal, transmucosal, lozenge, spray, intravenous, oral solution, buccal mucosal layer tablet, parenteral administration, syrup, or injection. Such compositions may be used to treat a fungal infection, candidiasis and/or oral infectious diseases. |  |
| 213 | **AU2017363973** | 20  19 |  | A compound of Formula IV:    Formula IV  and pharmaceutically acceptable hydrates, solvates, enantiomers, and stereoisomers thereof;  wherein,  RH independently represents  1-hydroxy-2-naphthoic acid, 2,2-dichloroacetic acid, 2-hydroxyethanesulfonic acid, 2 oxoglutaric acid, 4-acetamidobenzoic acid, 4-aminosalicylic acid, adipic acid, ascorbic acid, aspartic acid, benzoic acid, camphoric acid, camphor-I0-sulfonic acid, capric acid (decanoic acid), caproic acid (hexanoic acid), carbonic acid, cinnamic acid, citric acid, cyclamic acid, dodecylsulfuric acid, ethane-1,2-disulfonic acid, ethanesulfonic acid, formic acid, galactaric acid, gentisic acid, glucoheptonic acid, gluconic acid , glucuronic acid, glutamic acid, glutaric acid, glycerophosphoric acid, glycolic acid, hippuric acid, isobutyric acid, lactic acid, lactobionic acid, lauric acid, maleic acid, malic acid, malonic acid, mandelic acid, naphthalene 1,5-disulfonic acid, naphthalene-2-sulfonic acid, nicotinic acid, nitric acid, oleic acid, oxalic acid, palmitic acid, pamoic acid, pyroglutamic acid, salicylic acid, sebacic acid, stearic acid, succinic acid, tartaric acid, thiocyanic acid, undecylenic acid, omega 3 fatty acids, omega 6 fatty acids, n-acetyl cysteine (nac), furoate, methyl furoate, ethyl furoate, aminocaproic acid, caproic acid, caprilic acid, capric acid, lauric acid, alpha lipoic acid, R-lipoic acid, myristic acid, myristoleic acid, palmitic acid, palmitoleic acid, stearic acid, oleic acid, elaidic acid, linoleic acid, linolenic acid, linolelaidic acid, arachidonic acid  or    wherein, within the proviso  R', R2, R3 independently represents        Formula V  and pharmaceutically acceptable hydrates, solvates, enantiomers, and stereoisomers thereof;  wherein,  RH independently represents  1-hydroxy-2-naphthoic acid, 2,2-dichloroacetic acid, 2-hydroxyethanesulfonic acid, 2 oxoglutaric acid, 4-acetamidobenzoic acid, 4-aminosalicylic acid, adipic acid, ascorbic acid, aspartic acid, benzoic acid, camphoric acid, camphor-I0-sulfonic acid, capric acid (decanoic acid), caproic acid (hexanoic acid), carbonic acid, cinnamic acid, citric acid, cyclamic acid, dodecylsulfuric acid, ethane-1,2-disulfonic acid, ethanesulfonic acid, formic acid, galactaric acid, gentisic acid, glucoheptonic acid, gluconic acid , glucuronic acid, glutamic acid, glutaric acid, glycerophosphoric acid, glycolic acid, hippuric acid, isobutyric acid, lactic acid, lactobionic acid, lauric acid, maleic acid, malic acid, malonic acid, mandelic acid, naphthalene 1,5-disulfonic acid, naphthalene-2-sulfonic acid, nicotinic acid, nitric acid, oleic acid, oxalic acid, palmitic acid, pamoic acid, proprionic acid, pyroglutamic acid, salicylic acid, sebacic acid, stearic acid, succinic acid, tartaric acid, thiocyanic acid, undecylenic acid, omega 3 fatty acids, omega 6 fatty acids, n-acetyl cysteine (nac), furoate, methyl furoate, ethyl furoate, aminocaproic acid, caproic acid, caprilic acid, capric acid, lauric acid, alpha lipoic acid, R-lipoic acid, myristic acid, myristoleic acid, palmitic acid, palmitoleic acid, stearic acid, oleic acid, elaidic acid, linoleic acid, linolenic acid, linolelaidic acid, arachidonic acid  or    wherein, within the proviso  R', R2, R3 independently represents        4.       A pharmaceutical composition comprising a compound according to any one of claims 1 to 3 and a pharmaceutically acceptable carrier.  5.        The pharmaceutical composition of claim 4, which is formulated for one or more of oral administration, delayed release or sustained release, transmucosal, syrup, topical, parenteral administration, injection, subdermal, oral solution, rectal administration, buccal administration, and/or transdermal administration.  6.        The pharmaceutical composition of claim 4 or claim 5, which is formulated for the treatment of a fungal infection, a candidiasis infection, and/or an oral infectious disease. 7. A method of treating an infection in a patient in need thereof, the method comprising the step of administering to the patient an effective amount of:  i. a compound according to any one of claims I to 3; and/or ii. a pharmaceutical composition according to any one of claims 4-6; wherein the infection is a candidiasis infection.  8.        Use of a compound according to any one of claims 1 to 3, and/or a pharmaceutical composition according to any one of claims 4-6 in the manufacture of a medicament for the treatment a candidiasis infection. | formulated for oral, buccal, rectal, topical, transdermal, transmucosal, lozenge, spray, intravenous, oral solution, buccal mucosal layer tablet, parenteral administration, syrup, or injection. Such compositions may be used to treatment of oral infectious diseases. | , |
| 214 | **IN201947021051** | 2019 |  | A compound of Formula I:and pharmaceutically acceptable hydrates, solvates, enantiomers, and stereoisomers thereof; Wherein,RH independently representsl-hydroxy-2-naphthoic acid, 2,2-dichloroacetic acid, 2-hydroxyethanesulfonic acid, 2-oxoglutaric acid, 4-acetamidobenzoic acid, 4-aminosalicylic acid, acetic acid, adipic acid, ascorbic acid, aspartic acid, benzenesulfonic acid, benzoic acid, camphoric acid, camphor-10-sulfonic acid, capric acid (decanoic acid), caproic acid (hexanoic acid), carbonic acid, cinnamic acid, citric acid, cyclamic acid, dodecylsulfuric acid, ethane- 1,2-disulfonic acid, ethanesulfonic acid, formic acid, galactaric acid, gentisic acid, glucoheptonic acid, gluconic acid , glucuronic acid, glutamic acid, glutaric acid, glycerophosphoric acid, glycolic acid, hippuric acid, hydrobromic acid, isobutyric acid, lactic acid, lactobionic acid, lauric acid, maleic acid, malic acid, malonic acid, mandelic acid, methanesulfonic acid, naphthalene- 1,5-disulfonic acid, naphthalene-2-sulfonic acid, nicotinic acid, nitric acid, oleic acid, oxalic acid, palmitic acid, pamoic acid, phosphoric acid, proprionic acid, pyroglutamic acid, salicylic acid, sebacic acid, stearic acid, succinic acid, sulfuric acid, tartaric acid, thiocyanic acid, toluenesulfonic acid, undecylenic acid, omega 3 fatty acids, omega 6 fatty acids, n-acetyl cysteine (nac), furoate,113 WO 2018/096405 PCT/IB2017/052244 methyl furoate, ethyl furoate, aminocaproic acid, caproic acid, caprilic acid, capric acid, lauric acid, alpha lipoic acid, R-lipoic acid, myristic acid, myristoleic acid, palmitic acid, palmitoleic acid, stearic acid, oleic acid, elaidic acid, linoleic acid, linolenic acid, linolelaidic acid, arachidonic acidwherein, within the provisoR1, R2, R3 independently represents and pharmaceutically acceptable hydrates, solvates, prodrugs, enantiomers, and stereoisomers thereof;Wherein,RH independently representsl-hydroxy-2-naphthoic acid, 2,2-dichloroacetic acid, 2-hydroxyethanesulfonic acid, 2-oxoglutaric acid, 4-acetamidobenzoic acid, 4-aminosalicylic acid, acetic acid, adipic acid, ascorbic acid, aspartic acid, benzenesulfonic acid, benzoic acid, camphoric acid, camphor-10-sulfonic acid, capric acid (decanoic acid), caproic acid (hexanoic acid), carbonic acid, cinnamic acid, citric acid, cyclamic acid, dodecylsulfuric acid, ethane- 1,2-disulfonic acid, ethanesulfonic acid, formic acid, galactaric acid, gentisic acid, glucoheptonic acid, gluconic acid , glucuronic acid, glutamic acid, glutaric acid, glycerophosphoric acid, glycolic acid, hippuric acid, hydrobromic acid, isobutyric acid, lactic acid, lactobionic acid, lauric acid, maleic acid, malic116 WO 2018/096405 PCT/IB2017/052244 acid, malonic acid, mandelic acid, methanesulfonic acid, naphthalene- 1,5-disulfonic acid, naphthalene-2-sulfonic acid, nicotinic acid, nitric acid, oleic acid, oxalic acid, palmitic acid, pamoic acid, phosphoric acid, proprionic acid, pyroglutamic acid, salicylic acid, sebacic acid, stearic acid, succinic acid, sulfuric acid, tartaric acid, thiocyanic acid, toluenesulfonic acid, undecylenic acid, omega 3 fatty acids, omega 6 fatty acids, n-acetyl cysteine (nac), furoate, methyl furoate, ethyl furoate, aminocaproic acid, caproic acid, caprilic acid, capric acid, lauric acid, alpha lipoic acid, R-lipoic acid, myristic acid, myristoleic acid, palmitic acid, palmitoleic acid, stearic acid, oleic acid, elaidic acid, linoleic acid, linolenic acid, linolelaidic acid, arachidonic acid WO 2018/096405 PCT/IB2017/052244 Wherein,RH independently representsl-hydroxy-2-naphthoic acid, 2,2-dichloroacetic acid, 2-hydroxyethanesulfonic acid, 2-oxoglutaric acid, 4-acetamidobenzoic acid, 4-aminosalicylic acid, acetic acid, adipic acid, ascorbic acid, aspartic acid, benzenesulfonic acid, benzoic acid, camphoric acid, camphor-10-sulfonic acid, capric acid (decanoic acid), caproic acid (hexanoic acid), carbonic acid, cinnamic acid, citric acid, cyclamic acid, dodecylsulfuric acid, ethane- 1,2-disulfonic acid, ethanesulfonic acid, formic acid, galactaric acid, gentisic acid, glucoheptonic acid, gluconic acid , glucuronic acid, glutamic acid, glutaric acid, glycerophosphoric acid, glycolic acid, hippuric acid, hydrobromic acid, isobutyric acid, lactic acid, lactobionic acid, lauric acid, maleic acid, malic acid, malonic acid, mandelic acid, methanesulfonic acid, naphthalene- 1,5-disulfonic acid, naphthalene-2-sulfonic acid, nicotinic acid, nitric acid, oleic acid, oxalic acid, palmitic acid, pamoic acid, phosphoric acid, proprionic acid, pyroglutamic acid, salicylic acid, sebacic acid, stearic acid, succinic acid, sulfuric acid, tartaric acid, thiocyanic acid, toluenesulfonic acid, undecylenic acid, omega 3 fatty acids, omega 6 fatty acids, n-acetyl cysteine (nac), furoate, methyl furoate, ethyl furoate, aminocaproic acid, caproic acid, caprilic acid, capric acid, lauric acid, alpha lipoic acid, R-lipoic acid, myristic acid, myristoleic acid, palmitic acid, palmitoleic acid, stearic acid, oleic acid, elaidic acid, linoleic acid, linolenic acid, linolelaidic acid, arachidonic acidwherein, within the provisoR1, R2, R3 independently represents120 and pharmaceutically acceptable hydrates, solvates, prodrugs, enantiomers, and stereoisomers thereof;Wherein,RH independently representsl-hydroxy-2-naphthoic acid, 2,2-dichloroacetic acid, 2-hydroxyethanesulfonic acid, 2-oxoglutaric acid, 4-acetamidobenzoic acid, 4-aminosalicylic acid, acetic acid, adipic acid, ascorbic acid, aspartic acid, benzenesulfonic acid, benzoic acid, camphoric acid, camphor- 10-sulfonic acid, capric acid (decanoic acid), caproic acid (hexanoic acid), carbonic acid, cinnamic acid, citric acid, cyclamic acid, dodecylsulfuric acid, ethane- 1,2-disulfonic acid, ethanesulfonic acid, formic acid, galactaric acid, gentisic acid, glucoheptonic acid, gluconic acid , glucuronic acid, glutamic acid, glutaric acid, glycerophosphoric acid, glycolic acid, hippuric acid, hydrobromic acid, isobutyric acid, lactic acid, lactobionic acid, lauric acid, maleic acid, malic acid, malonic acid, mandelic acid, methanesulfonic acid, naphthalene- 1,5-disulfonic acid, naphthalene-2-sulfonic acid, nicotinic acid, nitric acid, oleic acid, oxalic acid, palmitic acid, pamoic acid, phosphoric acid, proprionic acid, pyroglutamic acid, salicylic acid, sebacic acid, stearic acid, succinic acid, sulfuric acid, tartaric acid, thiocyanic acid, toluenesulfonic acid,123 WO 2018/096405 PCT/IB2017/052244 undecylenic acid, omega 3 fatty acids, omega 6 fatty acids, n-acetyl cysteine (nac), furoate, methyl furoate, ethyl furoate, aminocaproic acid, caproic acid, caprilic acid, capric acid, lauric acid, alpha lipoic acid, R-lipoic acid, myristic acid, myristoleic acid, palmitic acid, palmitoleic acid, stearic acid, oleic acid, elaidic acid, linoleic acid, linolenic acid, linolelaidic acid, arachidonic acidwherein, within the provisoR1, R2, R3 independently represents WO 2018/096405 PCT/IB2017/052244 l-hydroxy-2-naphthoic acid, 2,2-dichloroacetic acid, 2-hydroxyethanesulfonic acid, 2-oxoglutaric acid, 4-acetamidobenzoic acid, 4-aminosalicylic acid, acetic acid, adipic acid, ascorbic acid, aspartic acid, benzenesulfonic acid, benzoic acid, camphoric acid, camphor-10-sulfonic acid, capric acid (decanoic acid), caproic acid (hexanoic acid), carbonic acid, cinnamic acid, citric acid, cyclamic acid, dodecylsulfuric acid, ethane- 1,2-disulfonic acid, ethanesulfonic acid, formic acid, galactaric acid, gentisic acid, glucoheptonic acid, gluconic acid , glucuronic acid, glutamic acid, glutaric acid, glycerophosphoric acid, glycolic acid, hippuric acid, hydrobromic acid, isobutyric acid, lactic acid, lactobionic acid, lauric acid, maleic acid, malic acid, malonic acid, mandelic acid, methanesulfonic acid, naphthalene- 1,5-disulfonic acid, naphthalene-2-sulfonic acid, nicotinic acid, nitric acid, oleic acid, oxalic acid, palmitic acid, pamoic acid, phosphoric acid, proprionic acid, pyroglutamic acid, salicylic acid, sebacic acid, stearic acid, succinic acid, sulfuric acid, tartaric acid, thiocyanic acid, toluenesulfonic acid, undecylenic acid, omega 3 fatty acids, omega 6 fatty acids, n-acetyl cysteine (nac), furoate, methyl furoate, ethyl furoate, aminocaproic acid, caproic acid, caprilic acid, capric acid, lauric acid, alpha lipoic acid, R-lipoic acid, myristic acid, myristoleic acid, palmitic acid, palmitoleic acid, stearic acid, oleic acid, elaidic acid, linoleic acid, linolenic acid, linolelaidic acid, arachidonic acidwherein, within the provisoR1, R2, R3 independently represents WO 2018/096405 PCT/IB2017/052244 and pharmaceutical^ acceptable hydrates, solvates, prodrugs, enantiomers, and stereoisomers thereof;Wherein,RH independently representsl-hydroxy-2-naphthoic acid, 2,2-dichloroacetic acid, 2-hydroxyethanesulfonic acid, 2-oxoglutaric acid, 4-acetamidobenzoic acid, 4-aminosalicylic acid, acetic acid, adipic acid, ascorbic acid, aspartic acid, benzenesulfonic acid, benzoic acid, camphoric acid, camphor-10-sulfonic acid, capric acid (decanoic acid), caproic acid (hexanoic acid), carbonic acid, cinnamic acid, citric acid, cyclamic acid, dodecylsulfuric acid, ethane-1,2-disulfonic acid, ethanesulfonic acid, formic acid, galactaric acid, gentisic acid, glucoheptonic acid, gluconic acid , glucuronic acid, glutamic acid, glutaric acid, glycerophosphoric acid, glycolic acid, hippuric acid, hydrobromic acid, isobutyric acid, lactic acid, lactobionic acid, lauric acid, maleic acid, malic acid, malonic acid, mandelic acid, methanesulfonic acid, naphthalene- 1,5-disulfonic acid, naphthalene-2-sulfonic acid, nicotinic acid, nitric acid, oleic acid, oxalic acid, palmitic acid, pamoic acid, phosphoric acid, proprionic acid, pyroglutamic acid, salicylic acid, sebacic acid, stearic acid, succinic acid, sulfuric acid, tartaric acid, thiocyanic acid, toluenesulfonic acid, undecylenic acid, omega 3 fatty acids, omega 6 fatty acids, n-acetyl cysteine (nac), furoate, methyl furoate, ethyl furoate, aminocaproic acid, caproic acid, caprilic acid, capric acid, lauric acid, alpha lipoic acid, R-lipoic acid, myristic acid, myristoleic acid, palmitic acid, palmitoleic acid, stearic acid, oleic acid, elaidic acid, linoleic acid, linolenic acid, linolelaidic acid, arachidonic acidwherein, within the provisoR1, R2, R3 independently represents130 and pharmaceutically acceptable hydrates, solvates, prodrugs, enantiomers, and stereoisomers thereof;Wherein,RH independently representsl-hydroxy-2-naphthoic acid, 2,2-dichloroacetic acid, 2-hydroxyethanesulfonic acid, 2-oxoglutaric acid, 4-acetamidobenzoic acid, 4-aminosalicylic acid, acetic acid, adipic acid, ascorbic acid, aspartic acid, benzenesulfonic acid, benzoic acid, camphoric acid, camphor- 10-sulfonic acid, capric acid (decanoic acid), caproic acid (hexanoic acid), carbonic acid, cinnamic acid, citric acid, cyclamic acid, dodecylsulfuric acid, ethane- 1,2-disulfonic acid, ethanesulfonic acid, formic acid, galactaric acid, gentisic acid, glucoheptonic acid, gluconic acid , glucuronic acid, glutamic acid, glutaric acid, glycerophosphoric acid, glycolic acid, hippuric acid, hydrobromic acid, isobutyric acid, lactic acid, lactobionic acid, lauric acid, maleic acid, malic acid, malonic acid, mandelic acid, methanesulfonic acid, naphthalene- 1,5-disulfonic acid, naphthalene-2-sulfonic acid, nicotinic acid, nitric acid, oleic acid, oxalic acid, palmitic acid, pamoic acid, phosphoric acid, proprionic acid, pyroglutamic acid, salicylic acid, sebacic acid, stearic acid, succinic acid, sulfuric acid, tartaric acid, thiocyanic acid, toluenesulfonic acid, undecylenic acid, omega 3 fatty acids, omega 6 fatty acids, n-acetyl cysteine (nac), furoate, methyl furoate, ethyl furoate, aminocaproic acid, caproic acid, caprilic acid, capric acid, lauric133 WO 2018/096405 PCT/IB2017/052244 acid, alpha lipoic acid, R-lipoic acid, myristic acid, myristoleic acid, palmitic acid, palmitoleic acid, stearic acid, oleic acid, elaidic acid, linoleic acid, linolenic acid, linolelaidic acid, arachidonic acidwherein, within the provisoR\ R2, R3 independently represents and pharmaceutical^ acceptable hydrates, solvates, prodrugs, enantiomers, and stereoisomers thereof;Wherein,RH independently representsl-hydroxy-2-naphthoic acid, 2,2-dichloroacetic acid, 2-hydroxyethanesulfonic acid, 2-oxoglutaric acid, 4-acetamidobenzoic acid, 4-aminosalicylic acid, acetic acid, adipic acid, ascorbic acid, aspartic acid, benzenesulfonic acid, benzoic acid, camphoric acid, camphor-10-sulfonic acid, capric acid (decanoic acid), caproic acid (hexanoic acid), carbonic acid, cinnamic acid, citric acid, cyclamic acid, dodecylsulfuric acid, ethane-1,2-disulfonic acid, ethanesulfonic acid, formic acid, galactaric acid, gentisic acid, glucoheptonic acid, gluconic acid , glucuronic136 WO 2018/096405 PCT/IB2017/052244 acid, glutamic acid, glutaric acid, glycerophosphoric acid, glycolic acid, hippuric acid, hydrobromic acid, isobutyric acid, lactic acid, lactobionic acid, lauric acid, maleic acid, malic acid, malonic acid, mandelic acid, methanesulfonic acid, naphthalene- 1,5-disulfonic acid, naphthalene-2-sulfonic acid, nicotinic acid, nitric acid, oleic acid, oxalic acid, palmitic acid, pamoic acid, phosphoric acid, proprionic acid, pyroglutamic acid, salicylic acid, sebacic acid, stearic acid, succinic acid, sulfuric acid, tartaric acid, thiocyanic acid, toluenesulfonic acid, undecylenic acid, omega 3 fatty acids, omega 6 fatty acids, n-acetyl cysteine (nac), furoate, methyl furoate, ethyl furoate, aminocaproic acid, caproic acid, caprilic acid, capric acid, lauric acid, alpha lipoic acid, R-lipoic acid, myristic acid, myristoleic acid, palmitic acid, palmitoleic acid, stearic acid, oleic acid, elaidic acid, linoleic acid, linolenic acid, linolelaidic acid, arachidonic acidwherein, within the provisoR1, R2, R3 independently represents WO 2018/096405 PCT/IB2017/052244 Wherein,RH independently representsl-hydroxy-2-naphthoic acid, 2,2-dichloroacetic acid, 2-hydroxyethanesulfonic acid, 2-oxoglutaric acid, 4-acetamidobenzoic acid, 4-aminosalicylic acid, acetic acid, adipic acid, ascorbic acid, aspartic acid, benzenesulfonic acid, benzoic acid, camphoric acid, camphor-10-sulfonic acid, capric acid (decanoic acid), caproic acid (hexanoic acid), carbonic acid, cinnamic acid, citric acid, cyclamic acid, dodecylsulfuric acid, ethane- 1,2-disulfonic acid, ethanesulfonic acid, formic acid, galactaric acid, gentisic acid, glucoheptonic acid, gluconic acid , glucuronic acid, glutamic acid, glutaric acid, glycerophosphoric acid, glycolic acid, hippuric acid, hydrobromic acid, isobutyric acid, lactic acid, lactobionic acid, lauric acid, maleic acid, malic acid, malonic acid, mandelic acid, methanesulfonic acid, naphthalene- 1,5-disulfonic acid, naphthalene-2-sulfonic acid, nicotinic acid, nitric acid, oleic acid, oxalic acid, palmitic acid, pamoic acid, phosphoric acid, proprionic acid, pyroglutamic acid, salicylic acid, sebacic acid, stearic acid, succinic acid, sulfuric acid, tartaric acid, thiocyanic acid, toluenesulfonic acid, undecylenic acid, omega 3 fatty acids, omega 6 fatty acids, n-acetyl cysteine (nac), furoate, methyl furoate, ethyl furoate, aminocaproic acid, caproic acid, caprilic acid, capric acid, lauric acid, alpha lipoic acid, R-lipoic acid, myristic acid, myristoleic acid, palmitic acid, palmitoleic acid, stearic acid, oleic acid, elaidic acid, linoleic acid, linolenic acid, linolelaidic acid, arachidonic acidwherein, within the provisoR1, R2, R3 independently represents140 and pharmaceutically acceptable hydrates, solvates, prodrugs, enantiomers, and stereoisomers thereof;Wherein,RH independently representsl-hydroxy-2-naphthoic acid, 2,2-dichloroacetic acid, 2-hydroxyethanesulfonic acid, 2-oxoglutaric acid, 4-acetamidobenzoic acid, 4-aminosalicylic acid, acetic acid, adipic acid, ascorbic acid, aspartic acid, benzenesulfonic acid, benzoic acid, camphoric acid, camphor- 10-sulfonic acid, capric acid (decanoic acid), caproic acid (hexanoic acid), carbonic acid, cinnamic acid, citric acid, cyclamic acid, dodecylsulfuric acid, ethane- 1,2-disulfonic acid, ethanesulfonic acid, formic acid, galactaric acid, gentisic acid, glucoheptonic acid, gluconic acid , glucuronic acid, glutamic acid, glutaric acid, glycerophosphoric acid, glycolic acid, hippuric acid, hydrobromic acid, isobutyric acid, lactic acid, lactobionic acid, lauric acid, maleic acid, malic acid, malonic acid, mandelic acid, methanesulfonic acid, naphthalene- 1,5-disulfonic acid, naphthalene-2-sulfonic acid, nicotinic acid, nitric acid, oleic acid, oxalic acid, palmitic acid, pamoic acid, phosphoric acid, proprionic acid, pyroglutamic acid, salicylic acid, sebacic acid, stearic acid, succinic acid, sulfuric acid, tartaric acid, thiocyanic acid, toluenesulfonic acid, undecylenic acid, omega 3 fatty acids, omega 6 fatty acids, n-acetyl cysteine (nac), furoate, methyl furoate, ethyl furoate, aminocaproic acid, caproic acid, caprilic acid, capric acid, lauric acid, alpha lipoic acid, R-lipoic acid, myristic acid, myristoleic acid, palmitic acid, palmitoleic143 WO 2018/096405 PCT/IB2017/052244 acid, stearic acid, oleic acid, elaidic acid, linoleic acid, linolenic acid, linolelaidic acid, arachidonic acidwherein, within the provisoR1, R2, R3 independently represents ll. A compound of Formula XI:and pharmaceutically acceptable hydrates, solvates, prodrugs, enantiomers, and stereoisomers thereof;Wherein,RH independently representsl-hydroxy-2-naphthoic acid, 2,2-dichloroacetic acid, 2-hydroxyethanesulfonic acid, 2-oxoglutaric acid, 4-acetamidobenzoic acid, 4-aminosalicylic acid, acetic acid, adipic acid, ascorbic acid, aspartic acid, benzenesulfonic acid, benzoic acid, camphoric acid, camphor- 10-sulfonic acid, capric acid (decanoic acid), caproic acid (hexanoic acid), carbonic acid, cinnamic acid, citric acid, cyclamic acid, dodecylsulfuric acid, ethane- 1,2-disulfonic acid, ethanesulfonic acid, formic acid, galactaric acid, gentisic acid, glucoheptonic acid, gluconic acid , glucuronic146 WO 2018/096405 PCT/IB2017/052244 acid, glutamic acid, glutaric acid, glycerophosphoric acid, glycolic acid, hippuric acid, hydrobromic acid, isobutyric acid, lactic acid, lactobionic acid, lauric acid, maleic acid, malic acid, malonic acid, mandelic acid, methanesulfonic acid, naphthalene- 1,5-disulfonic acid, naphthalene-2-sulfonic acid, nicotinic acid, nitric acid, oleic acid, oxalic acid, palmitic acid, pamoic acid, phosphoric acid, proprionic acid, pyroglutamic acid, salicylic acid, sebacic acid, stearic acid, succinic acid, sulfuric acid, tartaric acid, thiocyanic acid, toluenesulfonic acid, undecylenic acid, omega 3 fatty acids, omega 6 fatty acids, n-acetyl cysteine (nac), furoate, methyl furoate, ethyl furoate, aminocaproic acid, caproic acid, caprilic acid, capric acid, lauric acid, alpha lipoic acid, R-lipoic acid, myristic acid, myristoleic acid, palmitic acid, palmitoleic acid, stearic acid, oleic acid, elaidic acid, linoleic acid, linolenic acid, linolelaidic acid, arachidonic acidwherein, within the provisoR1, R2, R3 independently represents WO 2018/096405 PCT/IB2017/052244 l-hydroxy-2-naphthoic acid, 2,2-dichloroacetic acid, 2-hydroxyethanesulfonic acid, 2-oxoglutaric acid, 4-acetamidobenzoic acid, 4-aminosalicylic acid, acetic acid, adipic acid, ascorbic acid, aspartic acid, benzenesulfonic acid, benzoic acid, camphoric acid, camphor-10-sulfonic acid, capric acid (decanoic acid), caproic acid (hexanoic acid), carbonic acid, cinnamic acid, citric acid, cyclamic acid, dodecylsulfuric acid, ethane-1,2-disulfonic acid, ethanesulfonic acid, formic acid, galactaric acid, gentisic acid, glucoheptonic acid, gluconic acid , glucuronic acid, glutamic acid, glutaric acid, glycerophosphoric acid, glycolic acid, hippuric acid, hydrobromic acid, isobutyric acid, lactic acid, lactobionic acid, lauric acid, maleic acid, malic acid, malonic acid, mandelic acid, methanesulfonic acid, naphthalene- 1,5-disulfonic acid, naphthalene-2-sulfonic acid, nicotinic acid, nitric acid, oleic acid, oxalic acid, palmitic acid, pamoic acid, phosphoric acid, proprionic acid, pyroglutamic acid, salicylic acid, sebacic acid, stearic acid, succinic acid, sulfuric acid, tartaric acid, thiocyanic acid, toluenesulfonic acid, undecylenic acid, omega 3 fatty acids, omega 6 fatty acids, n-acetyl cysteine (nac), furoate, methyl furoate, ethyl furoate, aminocaproic acid, caproic acid, caprilic acid, capric acid, lauric acid, alpha lipoic acid, R-lipoic acid, myristic acid, myristoleic acid, palmitic acid, palmitoleic acid, stearic acid, oleic acid, elaidic acid, linoleic acid, linolenic acid, linolelaidic acid, arachidonic acidwherein, within the provisoR1, R2, R3 independently represents 13. A Pharmaceutical composition comprising a compound of claim 1 and a pharmaceutically acceptable carrier.14. A Pharmaceutical composition comprising a compound of claim 2 and a pharmaceutically acceptable carrier.15. A Pharmaceutical composition comprising a compound of claim 3 and a pharmaceutically acceptable carrier.16. A Pharmaceutical composition comprising a compound of claim 4 and a pharmaceutically acceptable carrier.17. A Pharmaceutical composition comprising a compound of claim 5 and a pharmaceutically acceptable carrier.18. A Pharmaceutical composition comprising a compound of claim 6 and a pharmaceutically acceptable carrier.19. A Pharmaceutical composition comprising a compound of claim 7 and a pharmaceutically acceptable carrier.152 WO 2018/096405 PCT/IB2017/052244 20. A Pharmaceutical composition comprising a compound of claim 8 and a pharmaceutically acceptable carrier.21. A Pharmaceutical composition comprising a compound of claim 9 and a pharmaceutically acceptable carrier.22. A Pharmaceutical composition comprising a compound of claim 10 and a pharmaceutically acceptable carrier.23. A Pharmaceutical composition comprising a compound of claim 11 and a pharmaceutically acceptable carrier.24. A Pharmaceutical composition comprising a compound of claim 12 and a pharmaceutically acceptable carrier.25. The pharmaceutical composition of claim 13, which is formulated to treat the underlying etiology with an effective amount administering the patient in need by oral administration, delayed release or sustained release, transmucosal, syrup, topical, parenteral administration, injection, subdermal, oral solution, rectal administration, buccal administration or transdermal administration.26. The pharmaceutical composition of claim 14, which is formulated to treat the underlying etiology with an effective amount administering the patient in need by oral administration, delayed release or sustained release, transmucosal, syrup, topical, parenteral administration, injection, subdermal, oral solution, rectal administration, buccal administration or transdermal administration.27. The pharmaceutical composition of claim 15, which is formulated to treat the underlying etiology with an effective amount administering the patient in need by oral administration, delayed release or sustained release, transmucosal, syrup, topical, parenteral administration, injection, subdermal, oral solution, rectal administration, buccal administration or transdermal administration.28. The pharmaceutical composition of claim 16, which is formulated to treat the underlying etiology with an effective amount administering the patient in need by oral administration, delayed release or sustained release, transmucosal, syrup, topical, parenteral153 WO 2018/096405 PCT/IB2017/052244 administration, injection, subdermal, oral solution, rectal administration, buccal administration or transdermal administration.29. The pharmaceutical composition of claim 17, which is formulated to treat the underlying etiology with an effective amount administering the patient in need by oral administration, delayed release or sustained release, transmucosal, syrup, topical, parenteral administration, injection, subdermal, oral solution, rectal administration, buccal administration or transdermal administration.30. The pharmaceutical composition of claim 18, which is formulated to treat the underlying etiology with an effective amount administering the patient in need by oral administration, delayed release or sustained release, transmucosal, syrup, topical, parenteral administration, injection, subdermal, oral solution, rectal administration, buccal administration or transdermal administration.31. The pharmaceutical composition of claim 19, which is formulated to treat the underlying etiology with an effective amount administering the patient in need by oral administration, delayed release or sustained release, transmucosal, syrup, topical, parenteral administration, injection, subdermal, oral solution, rectal administration, buccal administration or transdermal administration.32. The pharmaceutical composition of claim 20, which is formulated to treat the underlying etiology with an effective amount administering the patient in need by oral administration, delayed release or sustained release, transmucosal, syrup, topical, parenteral administration, injection, subdermal, oral solution, rectal administration, buccal administration or transdermal administration.33. The pharmaceutical composition of claim 21, which is formulated to treat the underlying etiology with an effective amount administering the patient in need by oral administration, delayed release or sustained release, transmucosal, syrup, topical, parenteral administration, injection, subdermal, oral solution, rectal administration, buccal administration or transdermal administration.34. The pharmaceutical composition of claim 22, which is formulated to treat the underlying etiology with an effective amount administering the patient in need by oral administration,154 WO 2018/096405 PCT/IB2017/052244 delayed release or sustained release, transmucosal, syrup, topical, parenteral administration, injection, subdermal, oral solution, rectal administration, buccal administration or transdermal administration.35. The pharmaceutical composition of claim 23, which is formulated to treat the underlying etiology with an effective amount administering the patient in need by oral administration, delayed release or sustained release, transmucosal, syrup, topical, parenteral administration, injection, subdermal, oral solution, rectal administration, buccal administration or transdermal administration.36. The pharmaceutical composition of claim 24, which is formulated to treat the underlying etiology with an effective amount administering the patient in need by oral administration, delayed release or sustained release, transmucosal, syrup, topical, parenteral administration, injection, subdermal, oral solution, rectal administration, buccal administration or transdermal administration.37. Compounds and compositions of claim 25 are formulated for the treatment of fungal infections, candidiasis and oral infectious diseases.38. Compounds and compositions of claim 26 are formulated for the treatment of fungal infections, candidiasis and oral infectious diseases.39. Compounds and compositions of claim 27 are formulated for the treatment of fungal infections, candidiasis and oral infectious diseases.40. Compounds and compositions of claim 28 are formulated for the treatment of fungal infections, candidiasis and oral infectious diseases.41. Compounds and compositions of claim 29 are formulated for the treatment of fungal infections, candidiasis and oral infectious diseases.42. Compounds and compositions of claim 30 are formulated for the treatment of fungal infections, candidiasis and oral infectious diseases.43. Compounds and compositions of claim 3 1 are formulated for the treatment of fungal infections, candidiasis and oral infectious diseases.155 WO 2018/096405 PCT/IB2017/052244 44. Compounds and compositions of claim 32 are formulated for the treatment of fungal infections, candidiasis and oral infectious diseases.45. Compounds and compositions of claim 33 are formulated for the treatment of fungal infections, candidiasis and oral infectious diseases.46. Compounds and compositions of claim 34 are formulated for the treatment of fungal infections, candidiasis and oral infectious diseases.47. Compounds and compositions of claim 35 are formulated for the treatment of fungal infections, candidiasis and oral infectious diseases.48. Compounds and compositions of claim 36 are formulated for the treatment of fungal infections, candidiasis and oral infectious diseases.49. A compound of claim 1, comprising of formula I:50. A compound of claim 2, comprising of formula II: WO 2018/096405 PCT/IB2017/05224451. A compound of claim 3, comprising of formula III:52. A compound of claim 4, comprising of formula IV:53. A compound of claim 8, comprising of formula VIII:54. A compound of claim 9, comprising of formula IX: | treatment of oral infectious diseases may be formulated for oral buccal rectal topical transdermal transmucosal lozenge spray intravenous oral solution buccal mucosal layer tablet parenteral administration syrup or injection. Such compositions may be used to treatment of oral infectious diseases. |  |
| 215 | **US20190177267** | 2019 |  | A compound of Formula I:    r pharmaceutically acceptable salts, hydrates, solvates, enantiomers, or stereoisomers thereof;  wherein,  R 1, R 3, R 5each independently represents NULL,      A pharmaceutical composition comprising a compound of claim 1 and a pharmaceutically acceptable carrier.  3. A pharmaceutical composition comprising a pharmaceutically acceptable carrier and a compound selected from the group consisting of: | pharmaceutical compositions may be formulated for oral administration, suppository, transdermal, buccal, rectal, topical, transdermal, transmucosal, intravenous, parenteral administration, syrup, or injection. Such compositions may be used to treatment of irritable bowel syndrome (IBS), inflammatory bowel diseases or its associated complications. |  |
|  |  |  |  |  |  |  |
|  |  |  |  |  |  |  |
|  |  |  |  |  |  |  |
|  |  |  |  |  |  |  |
|  |  |  |  |  |  |  |
|  |  |  |  |  |  |  |
|  |  |  |  |  |  |  |
|  |  |  |  |  |  |  |
|  |  |  |  |  |  |  |
|  |  |  |  |  |  |  |
|  |  |  |  |  |  |  |
|  |  |  |  |  |  |  |
|  |  |  |  |  |  |  |
|  |  |  |  |  |  |  |
|  |  |  |  |  |  |  |
|  |  |  |  |  |  |  |
|  |  |  |  |  |  |  |
|  |  |  |  |  |  |  |
|  |  |  |  |  |  |  |
|  |  |  |  |  |  |  |
|  |  |  |  |  |  |  |
|  |  |  |  |  |  |  |
|  |  |  |  |  |  |  |
|  |  |  |  |  |  |  |
|  |  |  |  |  |  |  |
|  |  |  |  |  |  |  |
|  |  |  |  |  |  |  |
|  |  |  |  |  |  |  |
|  |  |  |  |  |  |  |
|  |  |  |  |  |  |  |
|  |  |  |  |  |  |  |
|  |  |  |  |  |  |  |
|  |  |  |  |  |  |  |
|  |  |  |  |  |  |  |
|  |  |  |  |  |  |  |
|  |  |  |  |  |  |  |
|  |  |  |  |  |  |  |
|  |  |  |  |  |  |  |
|  |  |  |  |  |  |  |
|  |  |  |  |  |  |  |
|  |  |  |  |  |  |  |
|  |  |  |  |  |  |  |
|  |  |  |  |  |  |  |
|  |  |  |  |  |  |  |
|  |  |  |  |  |  |  |
|  |  |  |  |  |  |  |
|  |  |  |  |  |  |  |
|  |  |  |  |  |  |  |
|  |  |  |  |  |  |  |